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Summary	  
Background: Modern treatments extend life expectancy in patients with multiple 
myeloma (MM) and a high incidence of chemotherapy-induced peripheral 
neuropathy (CIPN) has evolved. The impact of disease and treatment on health-
related quality of life (HRQoL) in MM is poorly characterised. This work aimed to 
investigate (i) the neuroanatomical functional correlates of pain processing in CIPN 
and (ii) HRQoL and symptom burden in advanced, intensively-treated myeloma. 
Methods: First study: twelve neurophysiologically assessed patients with CIPN and 
12 healthy volunteers underwent fMRI to determine the brain’s haemodynamic 
response to noxious heat stimuli applied to the extremities. Second study: detailed 
HRQoL and neuropathy assessments, serum IL-6 and TNF-α levels were measured 
in 32 patients with MM (median age=61yrs, duration of disease=5.5yrs) who had 
previously undergone 3 lines of treatment. 
Results: First study: Neurophysiological testing in MM patients confirmed peripheral 
neuropathy in the feet. Significant hypo-activation of the right superior frontal gyrus 
and hyper-activation in the precuneus were present in response to foot stimulation in 
the CIPN-myeloma compared to healthy control groups. Significant positive 
correlation existed between neuropathy score and frontal opercula activation, during 
foot stimulation in CIPN-myeloma patients. Second study: Thirty-two MM patients 
(duration of disease=5.5yrs) were recruited. Physical functioning was significantly 
compromised (p<0.001) and associated with progressive work disability and 
concerns regarding loss of independence. Fatigue and pain were the predominant 
symptoms, impacting negatively on physical functioning (p<0.001). Half of the 
patients reported neuropathic pain. This sub-group scored lower measures of 
physical, role and social functioning on EORTC QLQ-C30 and future perspectives 
from the EORTC MY20 assessments compared to patients without neuropathy. 
Average pain and pain interference from the BPI-SF were positively correlated 
(p<0.05 and p<0.005, respectively) with serum IL-6 levels. 
Conclusion: Patients with MM suffer from a high peripheral neuropathy 
symptomatology burden, leading to a worsening functioning and increased pain. 
FMRI data indicates that heat-pain stimuli evoke differential activation of distinct 
cortical regions, suggesting different central pain processing mechanisms in CIPN-
myeloma patients. Despite disease control and supportive care, intensively-treated 
myeloma survivors have significantly compromised HRQoL related to symptom 
burden. 
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Thesis	  Outline	  
 
The objective of this thesis is to determine whether differences exist in central pain 
processing as assessed by functional magnetic resonance imaging during noxious 
thermal stimulation between patients with chemotherapy-induced peripheral 
neuropathy and healthy volunteers and to characterise the HRQoL and late effects 
in patients with advanced but stable myeloma, clinically and in terms of HRQoL. 	  
 
Chapter 1: I will present background knowledge relevant for understanding the 
research presented in this thesis. In the first section, I will discuss multiple myeloma 
followed by pain and chemotherapy-induced peripheral neuropathy and will finish on 
the topic of neuroimaging. I will finish by discussing the objectives of the thesis with 
specific primary and secondary aims for the two studies that I have incorporated in 
this thesis. 
Chapter 2: Investigation of the central pain processing using functional magnetic 
resonance imaging of multiple myeloma patients with chemotherapy-induced 
peripheral neuropathy and compare this to healthy volunteers. 
Chapter 3: Investigation of the late effects of pain, peripheral neuropathy and 
psychosocial issues in intensively treated transplanted multiple myeloma patients. 
Chapter 4: An overall conclusion from both studies. 
Chapter 5: The final conclusion and future work will be discussed in this chapter. 
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Chapter	  1	  
1 Background 
1.1 Multiple myeloma 
Multiple myeloma (MM) accounts for 10-15% of all haematological malignancies and 
is the second most common haematological cancer (Greenlee et al. 2001). The 
male to female ratio is 1.5:1 and the annual incidence of myeloma in the UK is 
approximately 60-70 per million (Cancer Research UK 2010). The prevalence is 
estimated at around 180-270 per million of population, although likely to increase 
due to increased awareness and diagnosis, better treatment options and an ageing 
population (Kumar et al. 2008). Essentially older adults are affected by MM (median 
age at presentation is 70 years); it is uncommon to be diagnosed in those less than 
40 years old and only 15% of patients are aged <60 years (Smith et al. 2006; Bird et 
al. 2011).  
 
Pathophysiology 
Multiple myeloma is a plasma cell disorder originating in the bone marrow with 
subsequent over-abundance of monoclonal paraprotein (M protein). In normal 
physiology, B cells are derived from lymphocytes that matured and differentiated in 
the bone marrow. Once released in the blood, they establish colonies in the 
peripheral lymphoid tissues. When a B-cell receptor binds to an antigen, the B cell 
differentiates into active plasma cells in the germinal centre of lymphoid organs 
whilst others become dormant memory cells. Plasma cells produce antibodies which 
are secreted in the blood; these are known as immunoglobulins (Ig) and are 
grouped in 5 sub-classes: about 80% is IgG, 15% is IgA, 5% is IgM, 0.2% is IgD, 
and a trace is IgE. Antibodies are involved in the humoral arm of the adaptive 
immune system. The memory cells persist in the circulation for long-term protection 
against the same antigen. In MM, there is proliferation of malignant plasma cells and 
a subsequent overabundance of monoclonal paraprotein. The type of MM 
corresponds to the particular type of immunoglobulin that the myeloma cells 
produce. The most common type of myeloma is IgG followed by IgA. The rare 
myelomas include up to 7% of all myelomas and consist of plasma cell leukaemia, 
IgD, IgM, IgE and non-secretory myeloma (Bird et al. 2011). 
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Patients with MM usually present clinically with symptoms of bone disease, 
anaemia, hypercalcaemia impaired renal function, recurrent infections and 
hyperviscosity. Other patients are diagnosed following the incidental finding of a 
raised erythrocyte sedimentation rate, serum protein, serum globulin or plasma 
viscosity. The plasma cell proliferation may interfere with the normal production of 
blood cells, leading to leucopoenia, anaemia, and thrombocytopenia. The plasma 
cells may cause soft-tissue masses, termed plasmacytomas or produce skeletal lytic 
lesions. The monoclonal antibodies produced, lead to impaired humoral immunity 
making patients more susceptible to infections, and the overproduction of these 
antibodies may lead to hyperviscosity, amyloidosis and renal failure. The 
overproduction of monoclonal IgG, IgA, and/or light chains may be identified with 
densitometry of the monoclonal peak on electrophoresis, immunochemical 
measurement of total immunoglobulin isotype level, and urinary total protein and 
light chain excretion. 
No single major causative agent has been identified for MM but risk factors include 
genetic components and race, exposure to radiation and environmental external 
agents, increasing age, diet, obesity (body mass index ≥30kg/m2) and lifestyle 
behaviours. An increased risk of MM and obesity has been reported and a high body 
mass index correlates with a particular genotype that increases interleukin (IL) 6 
production (Kyle et al. 2003). The development of MM is likely to be a stepwise 
process where genetic defects such as translocations accumulate in the malignant 
plasma cell, changes occur in the bone marrow microenvironment that support the 
tumour growth leading to failure of the immune system to control the disease 
(Richardson and Anderson 2004). This interaction between MM cells and bone 
marrow stromal cells leads to enhanced expression and secretion of cytokines and 
chemokines that stimulate proliferation and survival of MM cells. This also leads to 
activation of signal transduction pathways that promote cell proliferation, stimulate 
neoangiogenesis and protection from apoptosis. The best characterised myeloma 
growth factor is the cytokine IL-6 which has been reported to have an important role 
in the pathogenesis and malignant growth of MM (Bommert et al. 2006). Other 
growth and anti-apoptotic factors including vascular endothelial growth factor, 
insulin-like growth factor, tumour necrosis factor alpha (TNF-α) and fibroblast growth 
factors are secreted.  
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Management 
Multiple myeloma is a treatable but incurable disease. Patients with asymptomatic 
MM do not require interventions but need to be closely monitored by a 
haematologist as the overall risk of progression is 10% per year for the first five 
years but declines after this (Kyle et al. 2007). Symptomatic MM is defined by the 
presence of myeloma-related organ or tissue impairment which includes 
hypercalcaemia, renal insufficiency, anaemia or bone lesions (International 
Myeloma Working Group 2003). Disease-directed treatment is only needed for 
symptomatic MM. By delaying treatment, side effects associated with chemotherapy 
can be minimised. Even though treatment directed at MM is postponed in 
asymptomatic patients, supportive care is still given to prevent and manage 
symptoms and complications.  
 
1.1.1 Disease specific treatment 
The choice of treatment modalities in MM has increased over the last several 
decades, and has been associated with significant increases in life expectancy 
(Child et al. 2003; Klepin and Hurd 2006; Smith et al. 2006; Bird et al. 2011). 
Induction therapy followed by high-dose chemotherapy with haemopoietic stem-cell 
transplantation (HSCT) is the standard of care for MM patients who can tolerate this 
treatment (Morgan et al. 2012). However certain patients will be unable to receive 
HSCT because of poor performance status, advanced age, or co-morbidities and 
therefore treatment decisions take into account individual patient factors and patient 
choice. These patients may be offered single-agent or combination chemotherapy, 
which is less intensive. For patients where high-dose chemotherapy is planned, the 
aim of induction treatment is to stimulate high remission rates quickly with minimal 
toxicity and to preserve haemopoietic stem cell function to ensure successful 
mobilsation of peripheral blood stem cells (Bird et al. 2011). Studies have shown 
that stem cell transplantation can result in significantly more disease-free individuals 
and better overall survival than conventional chemotherapy at five-years (overall 
survival 52% versus 12%) (Attal et al. 1996; Barlogie et al. 1999). Delivery of more 
intensive treatment including haematopoietic stem cell transplantation in younger 
patients and introduction of novel agents, has resulted in more profound 
improvements in overall survival, with over half of patients under 50 years old 
predicted to survive beyond a decade following diagnosis of the disease (Pulte et al. 
2011). 
Page | 25  
 
Conventionally, the standard care for patients who were planning to receive high 
dose chemotherapy and HSCT was the induction therapy based on high dose 
dexamethasone, such as vincristine, doxorubicin and dexamethasone (VAD). This 
treatment led to substantial haematological toxicity and the need for central venous 
access thus increasing the incidence of venous catheter-related infections and 
thrombosis. There have been several studies on the use of thalidomide for induction 
and the latest Medical Research Council Myeloma IX trial compared 
cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) with 
cyclophosphamide, thalidomide and dexamethasone (CTD) and the results showed 
higher response rates in the CTD arm (Morgan et al. 2012). Also thalidomide is an 
oral administration and has been shown to have a reduced incidence of infection 
and cytopenia. Thalidomide-containing combination regimens are now widely used 
in the UK following the demonstration that it can be safely and effectively given and 
that stem cell mobilisation and harvesting are not adversely affected by its use (Bird 
et al. 2011). If the patient is unable to tolerate or has contraindications to 
thalidomide then bortezomib in combination with an alkylating agent (melphalan or 
cyclophosphamide) and dexamethasone is recommended as an option for the first-
line treatment of MM if high-dose chemotherapy with stem cell transplantation is 
considered inappropriate (Doss et al. 2011).  
Maximum response to induction therapy usually occurs after four to six cycles. 
Currently, it is recommended to treat to at least partial response, which usually 
occurs within four to six cycles and to substitute to another regimen if there is 
evidence of disease progression after two cycles or partial response after four 
cycles. Peripheral blood stem cell harvesting is usually carried out within four to six 
cycles for all induction regimens following stimulation with growth factors (Bird et al. 
2011). The ideal regimen for mobilising stem cells is not clear but cyclophosphamide 
with granulocyte colony-stimulating factor is commonly used. High dose melphalan 
is the standard conditioning prior to HSCT. Previously, total body irradiation was 
given, which resulted in increased toxicity with no improvement in response rate or 
progression free survival. As well as autologous transplantation as discussed above, 
another form of transplantation is allogeneic stem cell transplantation, which 
involves a healthy donor that has a tissue type that matches the recipient. This can 
result in long-term disease-free survival, however its’ use has been controversial 
because of the significant transplant related morbidity and mortality (Kumar 2009).  
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Patients who do not respond to the induction therapy (no change in M-protein and 
no evidence of clinical progression or progressive disease) are reviewed on a case-
by-case basis to decide whether the patient is still suitable for high dose therapy. 
Patients who are clinically stable (have refractory but non-progressive disease), may 
still benefit from consolidation with high-dose therapy and they might receive 
different chemotherapy regimens or might enter clinical trials.  
When high dose chemotherapy is not planned, the main aim of treatment is to 
stabilise the disease (termed the plateau phase) for as long as possible with minimal 
treatment related toxicity, thereby prolonging survival and maximising quality of life 
(QoL). Previously, the combination of oral melphalan and prednisolone regimens 
were the mainstay of treatment in this group. Nowadays, alternative regimens 
comprising MPT (melphalan, prednisolone and thalidomide) or CTD are used. MPT, 
as first line treatment in elderly patients has shown superior response rates and 
prolongation of progression free survival and overall survival (Dimopoulos and 
Terpos 2010). Attenuated doses of CTDa are given in elderly less fit patients. In the 
non-intensive arm of the Myeloma IX trial, early results demonstrate superior 
response rates for CTDa over melphalan and prednisolone (Morgan et al. 2011). 
Bortezomib and lenalidomide are also effective when used in combination with 
steroids with or without an alkylating agent. However, the National Institute for 
Health and Clinical Excellence (NICE) recommends that lenalidomide in 
combination with dexamethasone is only given to patients who have received two or 
more previous therapies (NICE 2009).  
There is no standard recommended treatment for relapsed patients because of 
disease heterogeneity and variability in patient specific factors including co-
morbidities, age, bone marrow function and the persistence of toxicities related to 
previous therapy (Bird et al. 2011). Data shows that thalidomide, bortezomib and 
lenalidomide based regimens used in treating relapsed patients are usually given in 
combination with corticosteroids and sometimes with an alkylating agent, most 
commonly cyclophosphamide. In patients who had a good response to the initial 
transplant procedure (>18 months to disease progression), a second HSCT may be 
considered (Bird et al. 2011). 
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1.1.2 Neuronal damage and symptoms arising from anti-
myeloma therapies 
Thalidomide, bortezomib, and vincristine have been associated with the 
development of peripheral neuropathy in MM and their mechanisms of action are 
looked at in more detail below. 
 
Thalidomide 
This is a TNF-1α antagonist, which is widely used as an induction treatment, as a 
maintenance treatment and for the management of relapsed-refractory disease, 
usually in combination with steroids and other chemotherapy. Thalidomide is used in 
MM because of its immunomodulatory and anti-angiogenic activity. Other 
mechanisms of action in MM include stimulation of the secretion of alpha-interferon 
and IL-2, induction of apoptosis, and regulation of adhesion molecule expression 
(Hideshima et al. 2000). The most common side effects of thalidomide are deep vein 
thrombosis, peripheral neuropathy, constipation and fatigue, which often restrict 
dose and treatment duration rather than drug effectiveness. The reported incidence 
of thalidomide neuropathy varies in the literature from 25% to 75% (Cavaletti et al. 
2004; Mileshkin et al. 2006; Palumbo et al. 2008). The relationship between the 
development of neuropathy, cumulative dose, dose-intensity of thalidomide and the 
duration of exposure is controversial. In a study by Plasmati et al, 31 newly 
diagnosed MM patients were treated with thalidomide and at the end of treatment, 
83% of the patients had clinical and electrophysiological evidence of a sensory 
axonal, length-dependent polyneuropathy (Plasmati et al. 2007).  
 
Bortezomib 
Bortezomib is a proteasome inhibitor; its mechanism of action targets the 
proteasome and causes the cell cycle to arrest. It has anti-angiogenic properties, 
causes induction of the stress response, apoptosis of MM cells and also targets the 
interaction between the tumour cell and the bone marrow microenvironment (Raab 
et al. 2009). The anti-proliferative, pro-apoptotic, and anti-tumour activities of 
bortezomib result from proteasome inhibition and depend on the altered degradation 
of a host of regulatory proteins. This is the standard treatment for first relapse in the 
UK (based on NICE guidance) and has been studied extensively in large clinical 
trials. The most common side effects reported are peripheral neuropathy, transient 
thrombocytopenia, fatigue, and gastrointestinal disorders (nausea and constipation 
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or diarrhoea). Phase II studies (SUMMIT, CREST) showed that treatment-emergent 
neuropathy was reported in 35% of patients (Richardson et al. 2006) whilst the 
frequency of bortezomib-associated peripheral neuropathy was evaluated in the 
phase III trial (APEX) with 37% of patients having treatment-emergent peripheral 
neuropathy, including 9% ≥ grade 3 (Richardson et al. 2009).  
 
Vincristine 
Vincristine is a vinca alkaloid; it is a mitotic inhibitor and exerts cytotoxicity via 
inhibition of tubulin polymerisation into microtubules, destabilising the mitotic 
spindle. Vincristine is a chemotherapeutic agent, which is part of the conventional 
chemotherapy, VAD. Vincristine is frequently associated with peripheral neuropathy 
(Haim et al. 1994; Verstappen et al. 2005). In rats, there was a high incidence of 
abnormal spontaneous discharge in A-fibre and C-fibres with confirmed vincristine 
evoked neuropathic pain (Xiao and Bennett 2008).  
 
Neuronal consequences of myeloma chemotherpay 
Apart from the sensory disturbances mentioned above, another less common 
complication of chemotherapy is autonomic dysfunction. The autonomic nervous 
system has two subsystems: sympathetic and parasympathetic. The afferent nerves 
from both systems transmit impulses from sensory organs, muscles, the circulatory 
system and all the organs of the body to the controlling centres in the medulla, pons 
and hypothalamus and often these impulses do not reach our consciousness, but 
elicit largely automatic or reflex responses via the parasympathetic and sympathetic 
nerves (Streeten 2012). Autonomic neuropathy is caused by damage to 
unmyelinated nerve fibres, which lead to clinical manifestations including cardiac 
conduction abnormalities, hypotension, impotence, and bowel and bladder 
dysfunction. The autonomic neurons are vulnerable as they are contained in 
ganglia, which lie outside the blood-brain barrier and are supplied by fenestrated 
capillaries that allow free passage of molecules between the extracellular fluid in the 
ganglia and the circulation (Windebank and Grisold 2008).  
A recent immunofluorescence study using punch biopsies taken from the distal leg 
and thigh of three patients with relapsed MM treated with bortezomib alone or 
bortezomib and thalidomide showed marked reduction of both adrenergic and 
cholinergic autonomic fibres, innervating epidermal annexes predominantly at the 
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distal leg site (Giannoccaro et al. 2011). Interestingly, the cell bodies of both the 
autonomic and sensory systems lie outside the blood-brain barrier. It could be 
speculated as the autonomic system functions unconsciously therefore there must 
be sufficient neuronal loss to cause noticeable symptoms such as constipation or 
dizziness (Windebank and Grisold 2008). Nowadays, new anti-myeloma agents 
have increased the options available for patients in the relapse setting. However, the 
side effects of treatment limit the choices available for a number of patients.  
 
1.1.3 Symptom burden in multiple myeloma 
Patients with MM have the highest level of symptoms and the lowest level of QoL 
among patients with haematological cancers (Johnsen et al. 2009). This could be 
because these patients endure more bone pain and pathological fractures, 
increased fatigue and recurrent infections. Chemotherapy-induced peripheral 
neuropathy causes numerous debilitating symptoms, impairs functional capacity, 
and results in dose reductions or possible cessation of chemotherapy (Bhagra and 
Rao 2007). Unfortunately, the neuropathy is usually only partly reversible and in the 
worst cases it is completely irreversible. In addition to physical problems that 
accumulate in patients with MM, psychological and social factors impact on overall 
QoL (Larsen et al. 2003; Gulbrandsen et al. 2004; Sherman et al. 2004; Straus et al. 
2006). A recent qualitative study demonstrated the impact of MM on patients' and 
caregivers' emotional, role, social and work-related areas of life in 20 `survivors` of 
MM (Molassiotis et al. 2011). Psychological problems included those associated 
with cognition and learning, social relationships, compromised education and work 
opportunities, and sexual and family relations. Although QoL has been explored 
previously in relation to specific treatments, including transplantation (Larsen et al. 
2003; Gulbrandsen et al. 2004; Sherman et al. 2004; Straus et al. 2006), there is 
little information relating to the overall impact of modern clinical management 
strategies in patients with MM, particularly in the context of co-morbidities of an 
ageing population (Klepin and Hurd 2006). Furthermore, compared with some other 
cancers with prolonged survival, relatively little is known in MM about psychosocial 
and broader holistic needs, particularly with modern clinical management strategies 
(Mols et al. 2005).  
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1.2 Pain 
‘Pain is an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage’ which is always 
subjective (Merskey 2002). Pain is an essential early warning sign that helps protect 
us from the dangerous environment and that is why the sensation of pain is 
unpleasant so that we cannot ignore it. Acute pain is usually transitory and lasts until 
the noxious stimulus is removed or the principal damage or pathology has healed; it 
usually responds to with analgesic medications and treatment of the precipitating 
cause. However, some painful conditions persist beyond healing time and this leads 
to chronic pain. There is a range of chronic clinical pain conditions and usually they 
are categorised by their site and type of injury. Plastic changes can occur place in 
the periphery, spinal cord and brain following injury and this may increase the 
degree of the perceived pain and may play a role in the development of chronic pain 
(Petersen-Felix and Curatolo 2002). This pain is mediated by high-threshold 
peripheral and central neurons, which respond to noxious stimuli. The transmission 
and modulation of painful stimuli are mediated through the nociceptor neurons (Aβ, 
Aδ and C fibres), the spinal cord and the brain processes.  
There are four elements to the pain process. Initially, transduction occurs when pain 
fibres are activated due to a noxious stimulus, which leads to depolarisation of 
nociceptors. This conversion of membrane potentials to action potentials is called 
transformation. The stimulus is then transmitted via sensory nerve fibres to the 
spinal cord through the dorsal horn and this is known as transmission. This leads to 
direct activation of motor neurons, restricting movement, which is protective. After 
transmission to the second order neuron, the pain stimulus is transmitted via the 
spinothalamic tract to the thalamus. Descending pathways control transmission by 
either inhibiting or enhancing it and this is known as modulation. Pain perception is 
processed in the higher brain cortex and this leads to the knowledge of and reaction 
to pain. 
The somatosensory system consists of the modalities of nociception, 
mechanoreception, proprioception, thermoreception and visceroception providing 
awareness of sensory information from the skin, the viscera and the musculoskeletal 
system (Cruccu et al. 2008). 
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1.2.1 Nociception 
Nociception is described as the neural processes of translating and 
processing noxious stimuli (Loeser and Treede 2008). Nociception protects us to 
prevent injuries by producing a reflex withdrawal from the noxious stimulus and an 
unpleasant sensation resulting in behavioural approaches to evade future interaction 
with such stimuli (Latremoliere and Woolf 2009). Around 90% of all afferent fibres in 
cutaneous nerves are nociceptive. These fibres are termed Aβ, Aδ and C fibres. C 
fibres form the largest group; around 90% of these are found in cutaneous nerves. 
The Aβ fibres are specialised mechanoreceptors for discriminative touch, vibration 
and proprioception. The Aδ and C fibres respond to noxious stimuli which could be 
mechanical, chemical or thermal (usually above approximately 45oC). The diameter 
of axons of sensory neurons is directly correlated to the speed of transmission of 
pain and also whether the neurons are myelinated; C fibres have small diameter 
unmyelinated axons bundled in fascicles surrounded by Schwann cells whist initial 
fast-onset pain is mediated by myelinated A-fibre nociceptors (Djouhri and Lawson 
2004). Peripheral nerves also contain efferent fibres to the sympathetic nervous 
system. The signals from the nociceptors are then transmitted to the spinal cord to 
contribute to motor and sympathetic reflexes. These signals are also processed in 
the brain where the pain related signals are relayed to the cerebral cortex which is 
responsible for the recognition and localisation of pain and also determines the 
motivational-affective components of the pain perception (Lautenbacher and 
Fillingim 2004). Nociceptors have their cell bodies in dorsal root ganglia (DRG) and 
the cell body gives off a single process, which, divide into a peripheral and a central 
branch. The distribution of a peripheral nerve is followed by the peripheral branch of 
each nociceptive DRG cell. The terminals of nociceptors innervate a target organ. 
The central branch enters into the spinal cord and transmits sensory information to 
the central nervous system (CNS) (Bingham et al. 2009) (Figure 1.1). The grey 
matter of the spinal cord is divided into lamina from posterior to anterior (lamina I-
IX). Afferent fibres transmitting cutaneous sensations end principally in laminae I to 
VI. Proprioceptive impulses reach laminae V and VI and these laminae also receive 
fibres from the cerebral cortex (Khurana and Arushi 2009). More specifically, most 
nociceptive Aδ and C fibres terminate superficially in laminae I–II, and a smaller 
number reaches deeper laminae, whereas Aβ fibres predominantly terminate in 
laminae III–VI (D'Mello and Dickenson 2008).  
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Figure 1.1: The pain pathway. 
Nociceptor activation by noxious stimuli produces impulses that travel to the dorsal horn and 
then are transmitted via the ascending pathway to the thalamus and cortex. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Clinical Practice: 
Rheumatology, (Bingham et al. 2009) copyright (2009). 
 
1.2.2 Ascending pathways 
Second-order neurons send their sensory inputs to the brain via the ascending 
pathways (Table 1.1). The dorsal column (medial-lemniscal system) includes the 
fasciculus gracilis, fasciculus cuneatus, and medial lemniscus, which relay fine 
discriminative tactile sense, position sense, and vibratory sense. The anterolateral 
system includes the spinotectal, spinothalamic, spinohypothalamic, spinoreticular 
and spinomesencephalic tracts. These tracts convey chiefly pain and temperature 
sensation, together with pressure, non-discriminative touch, and proprioceptive 
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sensation, which is involved in pain transmission. The somatosensory pathways to 
the cerebellum, which include the anterior, posterior, and rostral spinocerebellar, 
and the cuneocerebellar tracts, transmit mainly proprioceptive (but also some pain 
and pressure) information (Patestas and Gartner 2009) (Figure 1.2) The body’s 
interaction with the environment and the body’s condition are sensed by the 
ascending sensory pathways which relay to the brain.  
 
Table 1.1: Ascending sensory tracts  
Ascending sensory tracts, their anatomical tracts and which modalities of sensation they 
transmit. 
Ascending sensory 
pathways 
Anatomical tracts Functional component 
Dorsal column – medial 
lemniscal 
Fasciculus gracilis 
Fasciculus cuneatus 
Discriminative fine touch, 
vibratory sense, position 
sense 
Anterolateral Spinothalamic 
Spinoreticular 
Spinotectal 
Spinohypothalamic 
Spinomesencephalic 
Pain, temperature, 
nondiscriminative touch, 
pressure, proprioceptive 
sensation 
To cerebellum Anterior, Posterior, and 
Rostral spinocerebellar 
Cuneocerebellar  
Proprioception, some pain 
and pressure 
 
At the level of the spinal cord, sensory incoming nociceptive signals can sometimes 
be prevented from reaching the CNS at the synaptic level of the spinal cord dorsal 
horn. Pain is filtered in the substantia gelatinosa of the dorsal horn grey matter. The 
gate-like mechanism, which inhibits or facilitates afferent impulses into the spinal 
cord before it causes pain awareness and response, is known as the gate control 
theory of pain (Melzack and Wall 1965). Nowadays, the pain experience is known to 
be much more complex and does not only involve noxious stimuli. C fibres and Aδ 
fibres transmit impulses in the substantia gelatinosa thus inhibiting the inhibitory 
interneuron and activating the second order spinothalamic tract neuron that projects 
to the thalamus to keep the gate open. Pain relief is obtained when the inhibitory 
interneuron is activated, e.g by rubbing, therefore stimulating the Aδ/Aβ fibres which 
could lead to inhibition of some nociceptive transmission to the CNS (Wallace 2005).  
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1.2.3 Descending pathways 
Once the pain impulses reaches the brain, descending pathways projecting from 
cerebral structures such as rostral ventromedial medulla (RVM), periaqueductal grey 
(PAG), hypothalamus, dorsal reticular nucleus, in the medulla, to the dorsal horn are 
sent which could either suppress (descending inhibition) or potentiate (descending 
facilitation) passage of nociceptive messages to the brain (Millan 2002) (Figure 1.2). 
Although this is not completely understood, modulation results in descending 
inhibition of nociception by the release of neurotransmitters such as norepinephrine 
and endogenous opioids. Modulatory processes can also increase descending 
facilitation of nociception through multiple chemical mediators including glutamate 
and aspartate and this consequently leads to pain. This results in increased synaptic 
strength and facilitatory output for pain expression and behavioural hyperalgesia. 
Serotonin plays both an inhibitory and facilitatory action. Serotonin is important in 
descending facilitation pathways to the spinal cord, however in certain areas of the 
dorsal horn, it can act via excitatory receptors to facilitate neurotransmitter release 
(Stahl 2008).  
 
Figure 1.2: Transmission and modulation of somatosensory information 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews: Neuroscience, 
(Mantyh 2006) copyright 2006. 
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There is increasing evidence that glial cells, mainly astrocytes and microglia, play an 
important role in chronic pain. Astrocytes are the most abundant glial cells, whilst 
microglia are resident macrophage-like cells in the CNS. In pain free states, these 
glial cells are at rest, however during injury/disease, these cells become active and 
contribute in the pathogenesis of chronic pain by astrocytes forming networks and 
leading to activation of intracellular signalling pathways promoting neuronal-glial 
interactions, which can enhance pain states (Gao and Ji 2010). 
 
1.2.4 Pain processing in higher levels of the CNS 
Once a noxious stimulus reaches the brain, there is activation of a specific network 
of brain regions which is associated with the perception of pain (Tracey et al. 2000). 
The PAG located around the cerebral aqueduct within the tegmentum of the 
midbrain, receives input from ascending spinal pathways and sends projections to 
thalamic nuclei that process nociception. The anatomical and physiological 
organisation of the PAG and its descending projections to the RVM and dorsal horn 
of the spinal cord have been well described in a range of species (Loyd and Murphy 
2009). Some of the functions of the midbrain PAG include pain, analgesia, fear, 
anxiety and vocalisation. With regards to pain, the PAG receives afferents from 
nociceptive neurons in the spinal cord and transmits impulses to thalamic nuclei that 
process nociception (Behbehani 1995). The PAG may be an important area that 
controls peripheral nociceptive perception by descending activity from higher cortical 
regions (Tracey et al. 2002). In a functional magnetic resonance imaging (fMRI) 
study on nine healthy volunteers, heat stimulus was applied to their hand and 
subjects were asked to either focus on or distract themselves from the painful 
stimuli. When the subjects distracted themselves from the pain, the pain intensity 
was significantly lower with a corresponding increased activation in the PAG during 
the distraction condition, suggesting that the PAG is a site for higher cortical control 
of pain modulation in humans (Tracey et al. 2002). 
The thalamus, the largest component of the diencephalon, receives and processes 
all nociceptive information that is relayed to the cortex. Anatomical studies have 
demonstrated that ascending sensory spinal pathways terminate within the thalamus 
before higher order sensory projections are sent to the somatosensory cortex 
(Wilson et al. 1999). Thalamic nuclei contain many inhibitory interneurons that can 
modulate the transmission of signals through the thalamus, making filtering an 
important thalamic function (Swenson 2006). The thalamus is not only a sensory 
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relay station but also regulates and processes the information that is presented to 
the cortex (McCormick and Bal 1994). The brain stem, the cortex, and the thalamic 
reticular nucleus influence the modulation of the thalamus, allowing it to modulate 
transmission to the cortex in accord with current attentional needs (Sherman and 
Guillery 2002). The representation of body surface in the form of somatotopic maps 
is a fundamental feature of somatosensory organisation. Such maps have been 
demonstrated at all levels of the somatosensory system including the thalamus in 
many mammalian species.  
The basal ganglia consist of the striatum (putamen, caudate nucleus and nucleus 
accumbens), the globus pallidus, the subthalamic nucleus, and the substantia nigra. 
They are involved in neuronal pathways involving motivational, associative, 
emotional and cognitive functions and are a major site for adaptive plasticity in the 
brain, affecting a broad range of normal behaviours, neurological and psychiatric 
conditions (Borsook et al. 2010). Basal ganglia lesions have helped us to 
understand the possible role of basal ganglia in pain and analgesia. In patients who 
develop infarction of the putamen and globus pallidus, this could result in sensory 
deficits including pain (Russmann et al. 2003). Efferent pathways from the basal 
ganglia project to frontal lobe areas including prefrontal, premotor and 
supplementary motor areas. The basal ganglia have influences on cortical regions 
involved in motor responses, in performances relating to predicting events, and also 
play a part in learning and attention (Herrero et al. 2002).  
 
1.2.5 Sensitisation: Peripheral & Central 
Following an injury, whether due to inflammation or a nerve injury, hyperalgesia can 
occur due to an increase in the sensitivity of primary afferent nociceptors in the 
vicinity of the injury (peripheral sensitisation), and from an increase in the excitability 
of neurons in the spinal cord (central sensitisation) (Woolf and Thompson 1991). 
Once an injury has occurred, the Aδ and C fibres become sensitised and have a 
lower threshold for being activated. The injury also causes a release of inflammatory 
mediators like prostaglandin, bradykinin, serotonin which lowers the threshold for 
nociceptive stimuli. The depolarized nociceptive sensory endings release substance 
P and calcitonin gene related peptide (CGRP), thus contributing to the spread of 
oedema by producing vasodilatation, an increase in vascular permeability, and the 
spread of hyperalgesia by leading to the release of histamine from mast cells. The 
reaction produced by the noxious stimulus may outlast the stimulus (as in chronic 
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pain) and this can lead to alterations in cytokine and neurotrophin production, and 
receptor channels. Changes also occur in the dorsal horn due to sustained neuronal 
activation producing wind-up, early gene induction, neurotrophin production, and the 
induction of neurotransmitter and receptor synthesis (Hill 2001).  
In central sensitisation, there is increased neuronal activation caused by increased 
membrane excitability and reduced inhibition. This is a demonstration of the 
plasticity of the somatosensory nervous system in response to inflammation and 
neural injury (Latremoliere and Woolf 2009). During central sensitisation, neurons in 
the dorsal horn display changes such as spontaneous activity, a decrease in the 
threshold for activation by peripheral stimuli, and an increase in their receptive fields 
(Latremoliere and Woolf 2009). At the synaptic level, glutamate, an excitatory 
neurotransmitter of primary afferent neurons, binds to several receptors on 
postsynaptic neurons in the dorsal horn, including ionotropic amino-3-hydroxy-5-
methyl-4-isoxazole propionate (AMPA), N-methyl-D-aspartate (NMDA), and kainate 
receptors and metabotropic (G-protein coupled) glutamate receptor subtypes 
(Latremoliere and Woolf 2009). Normally, the NMDA receptor is blocked by a 
magnesium ion in its pore. When activated nociceptors release glutamate and the 
neuropeptides Substance P and CGRP that, leads to membrane depolarisation that 
forces magnesium to leave the NMDA receptor pore, allowing glutamate to bind to 
the receptor. This generates an inward current and allows entry of calcium in the 
neuron, leading to activation of intracellular pathways, which contributes to the 
maintenance of central sensitisation (Figure 1.3). Substance P, which is co-released 
with glutamate at the nociceptor pre-synaptic terminus, also plays a part in the 
generation of central sensitisation. It binds to the neurokinin-1 G-protein–coupled 
receptor and causes a prolonged membrane depolarisation, thus contributing to the 
temporal summation of C fibre–evoked synaptic potentials as well as to intracellular 
signalling. CGRP potentiates the effects of substance P and participates in central 
sensitisation through postsynaptic CGRP1 receptors, which activate protein kinase 
A and C. Calcium influx leads to activation of intracellular kinases which 
phosphorylate ionotropic NMDA and AMPA glutamate receptors increasing their 
activity and producing the changes that manifest as central sensitisation. This effect 
is further potentiated by nitric oxide synthesised by either neuronal or inducible nitric 
oxide synthases in the dorsal horn (Latremoliere and Woolf 2009).  
Normally, inhibitory interneurons continuously release GABA and glycine to 
decrease the excitability of the output neurons and modulate pain transmission. 
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However, in central sensitisation, this inhibition can be lost, further increasing the 
potentiation of the nociceptor signal. 
 
Figure 1.3: Central Sensitisation - Glutamate/NMDA receptor-mediated 
After injury, activated C and Aδ nociceptors release a variety of neurotransmitters into the 
synapse, thus activating NMDA receptors, which release Mg2+ leading to increase 
intracellular calcium. This activates calcium-dependent signalling pathways and second 
messengers causing an increase in the excitability of the output neuron and facilitating the 
transmission of pain messages to the brain. 
Glu - glutamate, SP - substance P, CGRP - calcitonin-gene related peptide, ATP – 
adenosine triphosphate, PKC - protein kinase C, PKA - protein kinase A, GABA - Gamma-
Aminobutyric acid, Gly - Glycine  
Reprinted and adapted from Cell, Vol 139(2), Basbaum, A. I., et al, "Cellular and molecular 
mechanisms of pain." Pages 267-284, Copyright (2009), with permission from Elsevier  
 
1.2.5.1 Central sensitisation in pathological states of the CNS 
Central sensitisation contributes to the longer-lasting, and sometimes persistent, 
pain hypersensitivity present in pathological damage to the nervous system. In 
chronic pain, due to either peripheral nerve or CNS damage, there can be recruiting 
of central hypersensitivity pathways, even in the absence of peripheral contributions. 
Large Aδ sensory fibre damage may lead to allodynia where gentle touch may be 
perceived as painful. Furthermore, prolonged sensory input to the dorsal horn of the 
spinal cord may cause excitotoxic death of inhibitory interneurons, thus further 
increasing the excitability of nociceptive transmission (Hill 2001). Sensory neurons 
in the DRG and dorsal horn undergo changes in transcription that alter their growth, 
membrane properties and transmitter function (Figure 1.4). Peripheral nerve injury 
leads to a degeneration of C fibre terminals in lamina II causing loss of presynaptic 
input and triggering intrinsic axonal growth capacity as part of the regenerative 
response thus providing a chance for myelinated Aβ fibres to sprout from laminae 
III-IV into laminae I-II and make contact with nociceptive specific neurons 
(Latremoliere and Woolf 2009). There is a reduction in the release, activity and 
synthesis of the inhibitory transmitters which leads to a state of disinhibition (Sivilotti 
Page | 39  
 
and Woolf 1994). In neuropathic pain, after peripheral nerve injury, damaged and 
non-damaged A and C fibres begin to generate spontaneous action potentials. In 
neuropathy, apoptosis of inhibitory interneurons could be attributed to the 
disinhibition in the superficial dorsal horn with loss of GABA and a reduction in 
glycinergic inhibitory currents (Moore et al. 2002). The decending pathways also 
exacerbate this dorsal horn excitation after peripheral nerve injury as there is an 
increase in descending excitatory activity from the brainstem, as well as a reduction 
of descending inhibitory controls (D'Mello and Dickenson 2008).  
Changes in the brain also occur. This has been demonstrated in rodents after partial 
peripheral nerve injury where sensitised neurons are detected in the thalamus and 
primary somatosensory cortex (Guilbaud et al. 1992). Activation of the brain during 
neuropathic pain compared to nociceptive pain can be classified by two fundamental 
phenomena. Firstly, there is increased activity in primary nociceptive areas, classical 
areas of the pain matrix (more details of the pain matrix in section 1.4.7.2), and 
secondly, there is recruitment of cortical areas beyond the classical pain matrix 
(Seifert and Maihofner 2009). In chronic pain, there are also changes occurring in 
the brain volume, mainly being reported in anterior cingulate cortex, orbitofrontal 
cortex, insular cortex and dorsal pons which appears to be partially reversible when 
the pain is treated (Kuner 2010). Neuroimaging has demonstrated changes in the 
somatosensory cortical representation and excitability in patients with phantom limb 
pain (Flor et al. 1995; Willoch et al. 2000) and in complex regional pain syndrome 
(Maihofner et al. 2005).  
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Figure 1.4: Mechanisms during physiological and pathological state in the 
spinal cord dorsal horn. 
In the pathological state, changes occur including suppression of inhibition, potentiation of 
presynaptic release and postsynaptic excitability, gene transcription, release of 
neuromodulators from activated microglia and astrocytes and a net increase in nociceptive 
input onto higher brain structures. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Medicine, (Kuner 2010) 
copyright 2010. 
 
Activation of the glia in the spinal cord has been suggested to lead to pathological 
pain such as neuropathy. This occurs by the release of neuronal signaling 
molecules such as cytokines and chemokines thus causing neurotoxicity, neuronal 
hyperexcitability and chronic inflammation (Milligan and Watkins 2009). 
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1.2.6 Neuropathic pain 
Neuropathic pain has been described by the special interest group on neuropathic 
pain of the International Association for the Study of Pain as ‘pain arising as a direct 
consequence of a lesion or disease affecting the somatosensory system’ (Treede et 
al. 2008). Neuropathic pain is a syndrome caused by a variety of different lesions 
and diseases, which manifests as a range of signs and symptoms and there are 
multiple underlying mechanisms of these different conditions (Jensen et al. 2011). 
The clinical key findings in neuropathic types of pain are spontaneous, continuous 
and paroxysmal pains with allodynia or hyperalgesia (Figure 1.5). Patients with 
chronic pain may express different combinations of these symptoms. Since 
neuropathic pain arises due to a disease or a lesion affecting the somatosensory 
system, its diagnosis is based on the demonstration of abnormal function in such 
systems, including negative (hypoesthesia and hypoalgesia) and positive sensory 
phenomena (allodynia and hyperalgesia) (Moisset and Bouhassira 2007).  
 
 
Figure 1.5: Symptoms in neuropathic pain  
Reprinted from NeuroImage, Vol 37, Suppl 1, Xavier Moisset and Didier Bouhassira, Brain 
imaging of neuropathic pain, S80-88, Copyright (2007), with permission from Elsevier.  
(Moisset and Bouhassira 2007). 
 
 
Epidemiological surveys indicate that 6-8% of the general population report chronic 
pain with neuropathic characteristics and these patients usually report poorer 
physical and mental health compared with patients with other types of chronic pain, 
even when adjusting for pain intensity (Freynhagen and Bennett 2009). In a large 
European study, it was shown that moderate to severe chronic pain occurs in 19% 
Page | 42  
 
of adults; nearly half do not receive proper pain management and their pain is very 
detrimental to their social functioning and working abilities (Breivik et al. 2006). In a 
postal survey of the general population carried in France, the reported prevalence of 
neuropathic characteristics in chronic pain respondents was 6.9% (95%CI: 6.6–7.2), 
which was moderate to severe in 5.1% (95%CI: 4.8–5.4) (Bouhassira et al. 2008). In 
a similar postal survey of the general population in the UK, the prevalence of pain, 
which was predominantly neuropathic in origin, was 8% and these people had 
significantly greater pain intensity, higher levels of expressed need, and a longer 
duration of pain (Torrance et al. 2006). In both UK and French surveys, the results 
demonstrated that the people who had chronic pain of neuropathic origin showed 
impairments relating to QoL and sleep and had higher anxiety and depression 
scores as assessed by the SF36 and SF12 (Smith et al. 2007; Attal et al. 2011). A 
recent systematic review showed that that the prevalence of cancer patients with 
neuropathic pain varied from about 20% to approximately 40% when mixed pain as 
well as pure neuropathic pain were included (Bennett et al. 2011). Neuropathic pain 
is often not diagnosed and when it is it often inadequately treated, and is 
accompanied by disability, poor QoL, distress and increased cost to the healthcare 
system (Haanpää and Treede 2010).  
To diagnose neuropathic pain, assessment of the pain is required by undertaking a 
detailed history taking and clinical examination (and including bedside tests of 
somatosensory functions: touch, vibration, cold, warmth and pain sensibility as well 
as motor and autonomic signs). It is also important to localise the lesion by 
performing a neurological examination. The International Association for the Study 
of Pain developed a grading system for a clinical diagnosis of neuropathic pain 
(Haanpaa et al. 2011) (Figure 1.6).  
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Hypothesis: Is it likely that the pain is neuropathic in nature? 
(Does the distribution of the pain relate to an anatomical site; does the history propose an 
appropriate disease or lesion?) 
â 
 Tests to assess and confirm 
 
A: Sensory signs (negative or positive), in the region of the 
damaged nervous structure (either in bedside sensory 
examination or in quantitative sensory testing) 
 
B: Diagnostic test confirming a lesion or disease explaining 
neuropathic pain (peripheral and central nervous system) 
 
 
à 
 
 
Absence of A and B 
Unconfirmed as  
neuropathic pain 
   
     A & B  â      A or B â 
Confirmed neuropathic pain          Probable neuropathic pain 
Figure 1.6: Flow chart of a grading system for neuropathic pain 
Adapted from (Haanpaa et al. 2011) 
 
Screening tools are used to identify patients with possible neuropathic pain, 
particularly when used by non-specialists. They are easy to use both by the patients 
and the health care professionals in clinics or via the telephone. These provide 
immediate information. About 10–20% of patients with a clinical diagnosis made by 
a physician of neuropathic pain are not identified when screening tools are used and 
therefore, screening tools may offer guidance for further diagnostic evaluation and 
pain management but cannot replace clinical judgment (Haanpaa et al. 2011). 
Screening tools will be discussed later in section 1.3.6.  
Neuropathic pain is usually long lasting; however, some patients recover from this 
pain completely, and others may learn coping skills and might find relief with 
medications. This next section will now focus specifically on neuropathy caused by 
chemotherapy.  
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1.3 Chemotherapy-induced peripheral neuropathy 
Chemotherapy-induced peripheral neuropathy (CIPN) constitutes major dose-
limiting side effects of chemotherapy and is one of the most severe and 
unpredictable side effects of modern anticancer treatment. The incidence of CIPN 
varies considerably from 10 to 100% and the characteristics of CIPN are related to 
the type of chemotherapy used, the treatment schedules, dose intensity and 
cumulative dose (Balayssac et al. 2011). Another reason for such variability in the 
incidence is the way data is collected in studies when looking for neurotoxicity, as 
there is no standard measurement with regards to tools or sensory testing for CIPN 
(Dunlap and Paice 2006). Studies using detailed neurophysiological testing, or 
scoring systems report higher incidence of CIPN compared to studies that only use 
routine evaluation (Delforge et al. 2010). 
With the use of haematopoietic factors that limit haematotoxicity, higher doses of 
anticancer drugs can be given in combination therapy, which increases the risk of 
further neurotoxicity (Chaudhry et al. 1994). Different chemotherapy classes target 
different components of the peripheral nervous system (PNS) including neuronal cell 
bodies in the DRG, mitochondria, axonal transport pathways, axonal membrane ion 
channels and calcium regulation (Park et al. 2008) and can cause pure sensory, 
mixed sensory motor or autonomic neuropathies. The difference of the anti-cancer 
drug sensitivity between the central and the peripheral nervous system relates to the 
CNS having a less permeable blood brain barrier compared to the blood-nerve 
barrier protecting the PNS.(Balayssac et al. 2005). The PNS is therefore more likely 
than the CNS to be affected by drug neurotoxicity. The incidence of neuropathy 
increases if certain co-morbidities such as diabetes, vitamin deficiencies or 
excessive alcohol intake already exist. 
Chemotherapy-induced peripheral neuropathy may occur either early in the course 
of chemotherapy or after repeated courses. Sometimes, CIPN severity can progress 
months after the discontinuation of anti-myeloma therapy, a phenomenon known as 
coasting (Cavaletti et al. 2011); up to 8% of MM patients exhibit coasting when 
treated with bortezomib (Farquhar-Smith and Wigmore 2011).  
In the next section, specific classes of anticancer drugs specifically related to MM 
will be discussed and the aforementioned three common drugs that are used: 
thalidomide, bortezomib and vincristine (figures 1.7 – 1.9). 
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Figure 1.7: Schematic diagram 
showing the chemical structure of 
thalidomide  
Thalidomide is an immunomodulatory agent. 
The empirical formula for thalidomide is 
C13H10N2O4 and the gram molecular 
weight is 258.2. 
Image from Pub Chem (NIH) 
 
 
Figure 1.8: Schematic diagram 
showing the chemical structure of 
bortezomib 
Bortezomib is an anti-neoplastic agent. The 
molecular formula is C19H25BN4O4 and the 
molecular weight is 384.24.  
Image from Pub Chem (NIH) 
 
 
 
Figure 1.9: Schematic diagram 
showing the chemical structure of 
vincrisitine 
Vincrisitine is the salt of an alkaloid obtained 
from a common flowering herb, the 
periwinkle plant. The molecular formula is 
C46H56N4O10•H2SO4 with a molecular 
weight of 923.04 
Image from Pub Chem (NIH) 
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1.3.1 CIPN in multiple myeloma 
Peripheral neuropathy at the time of presentation in patients with MM is relatively 
infrequent, however those who present with established amyloidosis, POEMS 
syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal 
gammopathy and skin changes) or following a nerve compression might present 
with neuropathy (Smith et al. 2006). Following the administration of modern anti-
myeloma therapies, including thalidomide and bortezomib, an accumulating burden 
of peripheral neuropathy has been recognised (Smith et al. 2006; Richardson et al. 
2009) and large clinical trials of novel agents using grading tools for screening CIPN 
have recognised peripheral neuropathy as a dose-limiting toxicity .  
It has been shown that 70% of patients treated with thalidomide for 12 months will 
develop neuropathy (Mohty et al. 2010). By 14 months, 50% of patients who were 
receiving low doses of thalidomide (25-50mg daily) developed sensory neuropathy 
(Schiff et al. 2009). Clinically this usually presents as bilateral symmetrical sensory 
disorders and rarely as motor disorders. The sensory symptoms that patients 
experience includes stinging sensations or numbness that initially affect the toes, 
occasionally the fingers, and may also extend proximally. Later, the deep vibration 
sensitivity and proprioception may be affected, leading to progressive ataxia, 
difficulty in walking and trembling when posture is maintained. Whether there is a 
relationship between cumulative dose (Chaudhry et al. 2002; Cavaletti et al. 2004; 
Glasmacher et al. 2006) and duration of treatment with thalidomide (Tosi et al. 2005; 
Mileshkin et al. 2006) remains controversial and there are conflicting studies in the 
literature (Mohty et al. 2010).  
With regards to bortezomib-induced peripheral neuropathy, the overall incidence 
ranges between 30% and 47%, with approximately 15% of cases having severe 
neuropathy (grade 3 to 4) (Bang et al. 2006). If CIPN occurs, this is usually by the 
fifth cycle of bortezomib treatment, and it tends to plateau by the eighth cycle (Schiff 
et al. 2009) however it can occur within the first treatment cycle. 
CIPN is thus a common, potentially severe and dose-limiting side effect of 
treatment. Although some reversibility may be possible after dose reduction or 
cessation of specific agents, there is increasing recognition of the chronicity of 
peripheral neuropathy in many patients, not only compromising the administration of 
further anti-myeloma therapies but also generating long term and irreversible pain 
and disability. In addition, this frequently leads to the need for long-term 
administration of analgesic drugs with their associated side effect profiles. Overall 
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the result of developing peripheral neuropathy is reduced QoL, which significantly 
counters the recent achievements of improved life expectancy in this disease.  
 
1.3.1.1 Current understanding of the pathophysiology of CIPN in 
multiple myeloma 
The pathophysiology of CIPN is incompletely understood but might be caused by 
drug-induced damage to the dorsal nerve root ganglia neurons, axons, and/or 
Schwann cells of the peripheral nervous system. Structural damage to the 
peripheral nervous system results in abnormal somatosensory processing in the 
peripheral or central nervous system (Bhagra and Rao 2007). The concepts 
regarding the pathophysiology of neuropathic pain derived from experimental work 
in animal models and extrapolation to humans will be dependent upon model 
suitability. C and Aδ primary afferent neurons become abnormally sensitive and 
develop pathological spontaneous activity following a nerve injury, which leads to 
peripheral sensitisation. This triggers expression of sodium channels, the release of 
various receptor proteins, and growth factors from degenerating nerve fibres. This 
activity provokes secondary changes in central sensory processing, leading to spinal 
cord hyper-excitability and central sensitisation (Baron 2006).  
Pain impulses, beyond the peripheral nociceptor and dorsal horn, ascends in the 
contralateral spinothalamic tract; there are connections to the medulla and brain 
stem via the spinoreticular and spinomesencephalic tracts and to the hypothalamus 
via the spinohypothalamic tract (Brooks and Tracey 2005). The spinal and 
intracranial pathways have so far not been thoroughly investigated in CIPN.  
Chemotherapy-induced peripheral neuropathy arising from thalidomide is believed 
to be the result of axonal injury with progressive loss of large diameter myelinated 
fibres (Figure 1.10). In nerve electrophysiological studies (NES), the fundamental 
sign is a 50% decrease in the sensory nerve action potential (SNAP) amplitude, with 
relative conservation of nerve conduction velocities (Table 1.2) and this was shown 
in a study by Mileshkin et al who screened patients with relapsed/refractory MM in a 
trial of dose-escalating thalidomide with or without interferon and showed that 
patients had motor NES changes and often developed concurrent sensory changes, 
suggesting that thalidomide frequently causes a sensorimotor axonal neuropathy 
(Mileshkin et al. 2006). There is evidence to demonstrate that wallerian 
degeneration of the nerve fibres contributes to the development of neuropathic pain 
via production of cytokines like TNF-α and nerve growth factors (Xu et al. 2006). 
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Other mechanisms may be involved that include a decrease in nerve blood supply 
due to the anti-angiogeneic properties of thalidomide, direct toxic effects of 
thalidomide on neurons of the posterior root ganglia or dysregulation of neurotrophin 
activity through effects of thalidomide on nuclear factor-kappa B transcription factor 
(Mohty et al. 2010). Genetic variations in genes involved in drugs neurotoxicity have 
been shown to have a likely impact on whether the patient develops neuropathy 
(Johnson et al. 2008). 
 
 
Figure 1.10: Chemotherapy-induced toxicity in the peripheral nervous system. 
These are the specific sites where chemotherapy causes injury leading to neuropathy. 
Reprinted and adapted from Cytokine, Vol 59, Issue 1. Wang X. M., T. J. Lehky, et al, 
Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy, 
Pages No. 3-9, Copyright (2012), with permission from Elsevier 
 
Bortezomib, a highly selective reversible inhibitor of the 26S proteasome, shows 
antineoplastic effects against a variety of lymphoid disorders, including MM. It 
causes more sensory rather than a motor peripheral neuropathy (numbness, 
paresthesia, burning sensation, sensory loss, dysesthesia and pain) and affects the 
feet more than the hands (Mohty et al. 2010). A quantitative sensory study in 
patients with bortezomib-induced pain has shown these patients have significantly 
elevated touch detection threshold, impaired sharpness detection, and elevated 
thresholds for the detection of skin warming and heat pain; patients also had 
increased reports of cold pain. (Cata et al. 2007). This study also gives us insight to 
the refractory nature of chronic bortezomib-related neuropathic pain in that many of 
these patients had only partial pain relief despite different analgesics such as 
opioids and calcium channel blockers (Cata et al. 2007). Bortezomib-induced 
neuropathy is therefore associated with deficits in Aβ, Aδ and C primary afferent 
fibres. The present knowledge of the pathological features of bortezomib-induced 
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peripheral neurotoxicity is very limited. In a study by Cavaletti et al 2007, the effect 
of chronic bortezomib administration on the peripheral nervous system and on the 
spinal cord of rats was evaluated. Sciatic nerve examination and morphometric 
determinations demonstrated mild to moderate pathological changes, involving 
predominantly the Schwann cells and myelin, although axonal degeneration was 
also observed. Bortezomib-induced changes were also observed in DRG (Figure 
1.10). Spinal cord was morphologically normal (Cavaletti et al. 2007). Another 
mechanism proposed is that there could potentially be a dysregulation of the 
neurotrophic factors since bortezomib inhibits the activation of the transcription 
factor, nuclear factor-kappa B and blocks the transcription of the trophic nerve 
growth factor (Mohty et al. 2010).  
 
Vincristine acts by binding on intracellular tubulin, which interferes with axonal 
transport. It does not cross the blood brain barrier. It is thought that it induces 
alterations in the cellular microtubule structure in the peripheral nervous system 
(Figure 1.10) and this might be a mechanism for neuropathy (Polomano and Bennett 
2001; Quasthoff and Hartung 2002). In an attempt to understand the potential 
mechanism of vincristine-induced pain in humans undergoing chemotherapy Aley et 
al, established a model of vincristine-induced hyperalgesia in rat. They injected rats 
with different doses of vincristine (20, 100 or 200µg/kg intravenous into a tail vein) 
and found that vincristine produced both acute and chronic effects on pain sensitivity 
(Aley et al. 1996). A study of patients receiving vincristine (two different dose 
intensities) for lymphoma (n=114) showed neuropathic changes in both groups; 
symptoms can begin two weeks after the first dose of vincristine, and the cumulative 
risk of long-term therapy was >75% (Verstappen et al. 2005). 
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Table 1.2: Electrophysiological findings following anti-myeloma therapy 
Drug Nerve conduction Autonomic function tests 
Thalidomide SNAP & CMAP reduced; 
Sensory & motor NCV distally 
slowed (mild) 
Rare autonomic involvement 
 
Bortezomib SNAP & CMAP reduced; 
Sensory & motor NCV distally 
slowed (mild) 
Rare autonomic involvement 
 
Vincristine SNAP & CMAP reduced; 
Sensory & motor NCV distally 
slowed 
Postganglionic sympathetic & 
parasympathetic loss of 
function with gastrointestinal 
dysmotility & orthostatic 
hypotension, urogenital 
dysfunction 
SNAP, sensory nerve action potential; CMAP, compound muscle action potential; NCV, 
nerve conduction velocity 
 
1.3.2 Predisposing factors for CIPN 
It is not clear what the predisposing factors for developing neuropathy in patients 
receiving neurotoxic agents are and studies have shown contradictory results partly 
because the toxicity was measured using different assessment scales. In trials using 
bortezomib, the consistent risk factor for development of neuropathy was a previous 
history of peripheral neuropathy. On the other hand, age, history of diabetes, 
disease stage and creatinine clearance did not affect the incidence whilst in the 
relapsed patients, prior treatment with agents known to cause neuropathy did not 
appear to affect the incidence of neuropathy (Richardson et al. 2009; Dimopoulos et 
al. 2011). The myeloma itself may be an important causative factor as patients with 
newly diagnosed MM may have signs and symptoms of neuropathy and these 
patients may develop more severe neuropathy with neurotoxic agents (Richardson 
et al. 2006; Badros et al. 2007; Richardson et al. 2009). In the SUMMIT and CREST 
trials, prolonged exposure to bortezomib did not increase the incidence or severity of 
the neuropathy (Richardson et al. 2006). With thalidomide, in the Total Therapy 2 
study, the incidence of neuropathy was higher in patients over the age of 65 (41% 
vs. 17%, p<0.001) (Barlogie et al. 2006). In other studies, the risk was not 
influenced by age, sex and prior therapy including the use of vincristine (Tosi et al. 
2005; Mileshkin et al. 2006). Factors that seem to increase the incidence and 
degree of neuropathy with vincristine include large and frequent doses of the drug, 
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age (infants and adults appear to be mostly affected), patients with obstructive liver 
disease (might be potentiated by delayed biliary excretion as this is the main route 
of vincristine elimination) together with underlying neuropathy and malnutrition 
(Gidding et al. 1999). 
 
1.3.3 Reversibility of CIPN 
When bortezomib induced peripheral neuropathy develops, it is at least partially 
reversible in >50% of patients, particularly if the dose adjustment recommendations 
are adhered to (Mohty et al. 2010). In the VISTA trial, 60% of neuropathy due to 
bortezomib was completely resolved within a median of 5.7 months whilst in the 
APEX trial, 64% of patients with grade ≥2 bortezomib induced peripheral neuropathy 
experienced improvement or resolution within a median of 3.6 months (Richardson 
et al. 2011). There are mixed reports for the reversibility of thalidomide induced 
peripheral neuropathy. If sensory neuropathy develops with thalidomide, it is 
suggested that thalidomide is either stopped or there is a dose reduction as the 
symptoms can often worsen and become irreversible (Mohty et al. 2010). Neurotoxic 
symptoms and signs disappear weeks to months after vincristine therapy has been 
discontinued however reports that in one third of retrospectively studied adult 
patients, sensory neuropathy was found up to 77 months after therapy was stopped 
and subjective complaints existed for up to 40 months [100].  
 
1.3.4 Current diagnosis and assessment of CIPN in myeloma 
Currently the diagnosis of CIPN in MM patients is largely clinically based on history 
and physical examination. Blood tests are aimed largely at excluding other causes 
of neuropathy. Diagnosis of neuropathic pain is made when the distribution of pain 
and the associated sensory abnormalities, together with a history of chemotherapy 
known to cause neuropathy are all present. 
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1.3.5 Quantitative measures of CIPN: Laboratory testing 
Laboratory testing mainly includes quantitative sensory testing (QST): a 
psychophysical technique requiring co-operation from the patient measuring: 
• warmth: a C fibre–mediated sensation,  
• cooling: an Aδ-mediated sensation,  
• vibration: a sensation mediated by large, myelinated Aβ afferents.  
The sensory stimulus is constant and the same stimulus is delivered to all subjects, 
however the response is subjective. If the result is abnormal, it may imply that there 
is a signal dysfunction along the sensory pathways anywhere between the 
receptors, the sensory or associated cortices (Shy et al. 2003). Individual modalities 
tested will provide clues to the type of nerve fibres affected. For example impairment 
of vibration perception (128Hz tuning fork) and joint position sense reflect large fibre 
neuropathy whereas defective warm and cold thermal discrimination is in keeping 
with small nerve fibre involvement.  
Another test includes nerve conduction studies (NCS): measure the latency, velocity 
and amplitude of impulses travelling along a nerve. These tests focus on 
establishing that symptoms and signs are due to peripheral neuropathy and that the 
anatomical characteristics of the neuropathy are compatible with the known toxicity 
of the agent being used (Table 1.3).  
 
Table 1.3: Quantitative evaluation of CIPN 
History & Questionnaires Symptoms and distribution 
Physical examination Sensory – tactile, pinprick, thermal, 
vibration, joint position sense 
Motor including tendon reflexes 
Laboratory testing  Glycosylated haemoglobin, thyroid testing, 
Vitamin B12 & folate level 
Nerve conduction studies Sensory and motor nerve latency, velocity 
& amplitude 
Electromyography Distinguish neuropathies 
Quantitative sensory testing Detection threshold of accurately calibrated 
sensory stimuli (vibratory, thermal and 
cooling) 
Page | 53  
 
However, no adequate controlled studies have been published using quantitative 
measurements as the primary endpoint for CIPN. Also a correlation between 
quantitative measurements and clinical symptoms has not yet been established 
(Cleeland et al. 2010). Several limiting factors exist in the use of these tests 
including availability of instruments, their cost, and the variability in results obtained 
with different devices. These methods depend on the patient’s co-operation and 
compliance and on the standard neurologic examination, which could be a major 
potential pitfall in the assessment of sensory threshold. 
Physician based assessments are usually performed to grade CIPN with common 
toxicity scales, such as the National Cancer Institute-Common Toxicity Criteria, but 
several non-validated composite (i.e., clinical and instrumental) scales have also 
been used. The reason composites are used is to provide a more detailed analysis 
and also provides different aspects of CIPN that can be frequently missed by simple 
common toxicity scales (Cavaletti et al. 2007). Moreover, the common toxicity scales 
combine signs and symptoms of peripheral nerve impairment with subjective 
function limitations and QoL impairment. The Total Neuropathy Score in its complete 
version was originally developed and validated for diabetic neuropathy (Cornblath et 
al. 1999). The Total Neuropathy Score and its reduced versions appear to be the 
most effective of such scales and have been repeatedly tested in patients receiving 
chemotherapy. Highly significant correlation have been found between versions of 
the Total Neuropathy Score in patients with CIPN and several common terminology 
criteria scales, but the evaluation of CIPN has been deemed more accurate using 
the Total Neuropathy Score (Cavaletti et al. 2006; Cavaletti et al. 2007).  
 
1.3.6 Qualitative measures of CIPN: Questionnaires  
A variety of assessment tools exist that are based on the patient’s perception and 
self-report of pain. To ensure accurate and reliable reporting of the HRQoL and 
pain, several assessments should be used. At the bedside a simple way of 
assessing pain is by using the verbal rating scale (mild, moderate, severe) (Jensen 
et al. 1986) or a numeric rating scale where the patient grades their pain on a 0–10 
scale (0 = no pain, 10 = worst pain imaginable) (Paice and Cohen 1997). For 
neuropathic pain, several tools exist to identify pain of predominantly neuropathic 
origin, as distinct from nociceptive pain, without the need for clinical examination 
(Bennett et al. 2005). When a more comprehensive pain evaluation is needed, a 
multidimensional pain assessment is utilised. One widely used assessment tool is 
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the Brief Pain Inventory (Cleeland and Ryan 1994) which is a simple and easy to 
use tool which has been translated into many different languages. These are more 
commonly used in research settings. Pain is a multidimensional phenomenon with 
sensory-discriminative, affective-motivational, motor, and autonomic components. 
Therefore, these aspects are important to consider when looking at a patient’s pain 
experience. Quality of life questionnaires refer to an individual’s emotional, social, 
and physical wellbeing together with their functional ability. These are useful 
measures for evaluating progress in health goals and measuring the effectiveness of 
a clinical intervention as an important outcome is the change in the patient’s own 
perceived state of health. Overall, these assessments are subjective and therefore 
these scales are based on the individual’s perception.  
Both in research and in clinics, patients are often asked to fill in questionnaires, 
however, it is important that the patients are able to understand and complete these 
assessments. Therefore the choice of the assessment tool to be given to the patient 
to complete has relevance as studies have shown that poor compliance, visual 
impairments, poor physical condition, and illiteracy are influencing factors in patients 
not completing these assessment tools (Stahl et al. 2003). No matter which 
assessment tool is used, the ultimate goals are in making the right diagnosis, giving 
the appropriate treatment, and following-up the patient. It is thus important that the 
physician checks the questionnaires as otherwise these will not impact on the pain 
control (Trowbridge et al. 1997). 
 
1.3.7 Current management of CIPN 
As the exact pathophysiology of CIPN is not completely understood, this has limited 
tge development of evidence-based neuroprotective strategies. Studies have been 
carried out to prevent and treat neuropathy secondary to chemotherapy using 
antioxidants, neurotrophic growth factors and detoxicants; unfortunately none of 
these were successful and management of CIPN patients is still an unmet clinical 
need (Cavaletti et al. 2011). To date, the dose modification of the chemotherapy is 
the only way to limit the neuropathy in most patients and this should be considered 
as soon as symptoms and signs develop and affect the patient’s activities of daily 
living. It has been recommended that if peripheral neuropathy, grade 1 with pain or 
grade 2 neuropathy interfering with function but not with daily activities, develops 
(evaluated according to the National Cancer Institute’s Common Terminology 
Criteria for Adverse Events), then the dose of bortezomib is reduced to 1.0mg/m2 
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from 1.5mg/m2 and thalidomide reduced to 50% or suspended until disappearance 
of toxicity and then re-initiated at 50% dose. If patients were to develop grade 2 with 
pain or grade 3 neuropathy interfering with daily activities then both bortezomib and 
thalidomide will be suspended until disappearance of toxicity and re-initiated at a 
lower dose with bortezomib administered once weekly and if grade 4 develops then 
bortezomib and thalidomide will be discontinued (Mohty et al. 2010; Bird et al. 
2011). 
The possibility of a delayed worsening of CIPN after treatment withdrawal (coasting) 
should always be considered. Standard analgesic regimes are not very effective in 
treating neuropathic pain and there has been very little research specifically in the 
management of painful CIPN. A multimodal practice with the use of opioids together 
with other pain modulating drugs is now recommended (Ossipov and Porreca 2005; 
Raphael et al. 2010; Bird et al. 2011). A systematic approach for evaluating pain 
includes a thorough history followed by a pain assessment tool, physical 
examination, and any relevant investigations. 
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1.4 Neuroimaging 
Neuroimaging has revolutionised the way we understand how the brain works. 
Nowadays, the main techniques available for imaging of brain function include: 
fMRI, magnetoencephalography and positron emission tomography (PET). These 
techniques markedly differ in their invasiveness and technical properties. Functional 
MRI and PET measure the effect of neuronal activity (metabolic and vascular 
changes) rather than assess the activity of neurons directly. Neuronal and synaptic 
activity leads to increased regional cerebral blood flow and this link in known as 
neurovascular coupling. 
 
1.4.1 Functional Magnetic Resonance Imaging 
Functional MRI is one of the most recently developed forms of neuroimaging and is 
used to determine the haemodynamic response related to neural activity in the 
brain. First discovered in the 1990 by Seiji Ogawa and Ken Kwong, the importance 
of the blood oxygen level dependent (BOLD) technique is the MRI contrast, which is 
used to infer brain activity. Functional MRI has become a popular tool for studying 
brain function especially since it has several advantages: there is no need to inject 
radioactive isotopes as it is non-invasive and uses non-ionising electromagnetic 
radiation; it produces good spatial resolution (2-4mm); scanning time can be short 
(depending on the paradigm) and due to overall diagnostic efficacy of MRI, it 
potentially has relatively wide availability. Magnetic field strengths are measured in 
units of Tesla (T). One Tesla is about to 20,000 times the strength of the earth's 
magnetic field. A typical magnet is created by a large electric current flowing through 
wires that are formed into a loop in the magnet structure. Static magnetic fields of 
the order of 1.5T-7T are used for in-vivo fMRI. To create such a large static 
magnetic field requires a high current-density and this is achieved by the use of 
superconducting magnet windings. In a high field-strength clinical research system 
operating at 3T, the wires need to be superconducting and immersed in liquid 
helium as a cryogenic liquid to keep it near absolute zero and in the 
superconducting state. 
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1.4.1.1 Brain navigation 
The cerebrum is divided into two hemispheres each consisting of four lobes: frontal, 
parietal, occipital and temporal. The brain consists of grey matter containing closely 
packed neuron cell bodies and white matter mostly constituted by myelinated axons. 
The brain’s structure is usually most aptly visualised in three dimensions however, 
conventionally, for MRI the brain is projected in isometric planes; sagittal plane: 
obtained by a vertical cut parallel to the ears, a coronal plane: parallel to the face 
and, a transversal plane: obtained by a horizontal cut as illustrated in Figure 1.11. 
 
Figure 1.11: Visualisation of the brain showing MRI images of coronal, sagittal 
and transverse (axial) planes 
 
1.4.1.2 Basic MR Physics 
MRI is a ‘spin’–phenomenon, where the spinning momentum of a nuclear charge 
produces a small magnetic field (like a tiny magnet with north and south poles). This 
behaves like a spinning top, which spins about its axis. Atomic nuclei consist of 
unpaired positively charged protons and uncharged neutrons. MRI uses in particular 
the properties of hydrogen atoms in water molecules, as water is the biggest source 
of protons in the body, followed by fat. This allows discrimination between white and 
grey matter, and cerebral spinal fluid in structural images of the brain. Under normal 
circumstances these nuclei have no fixed orientation so there is no overall magnetic 
field (Liney 2005). However, when nuclei are placed in an external magnetic field, 
this causes the nuclei to precess about the magnetic field direction, at a precession 
frequency equal to what is termed the Larmor frequency and they begin to align in 
given directions dictated by the laws of quantum physics (Figure 1.12). For a 
hydrogen nucleus, this can be in one of 2 directions: either parallel or anti-parallel to 
the applied static magnetic field (Bo). Those that are parallel to Bo are in a lower 
energy state than those that are anti-parallel are in a higher energy state. Above 
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absolute zero (-273°C), there is a slight overall difference between the populations 
in these 2 states. This difference depends on temperature and the magnitude of Bo. 
Even at body temperature (37°C) and at 3T, the difference is small and this is why 
sensitive equipment is required for a MRI scanner. 
 
     No external magnetic     External 
magnetic 
      field    
 field 
             spin 
Figure 1.12: External magnetic field, Bo (in red) applied produces a small net 
magnetisation due to the net number of spins which align in the direction of 
the applied field 
z axis = longitudinal direction often aligned with the main magnetic field.  
y, x axis = transverse plane, perpendicular to the direction. 
 
This net magnetisation (Mo) becomes the source of the MR signal - once it has been 
perturbed away from its equilibrium state. This process is how a signal is produced. 
For a patient who is lying supine with their head first in a superconducting magnet, 
the x direction is often chosen to be the left-right direction of the patient and the y 
direction is often chosen to be the anterior-posterior direction (Pooley 2005). A 
radiofrequency (RF) pulse is required to perturb Mo and change the net alignment of 
the nuclei. This is delivered via a RF transmitter coil. When the RF pulse is applied, 
the net magnetisation rotates through what is termed a flip angle. The angle that Mo 
has been ‘flipped through’ depends on the strength and the duration of the RF pulse. 
Immediately after the RF pulse, the protons begin to return to their equilibrium state 
and in so-doing the net magnetization alters mainly due to two effects: 
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• The hydrogen nuclei that are ‘excited’ gradually transfer their energy to the 
surrounding environment or lattice. As this happens, Mo returns towards Bo. 
This is termed longitudinal recovery or the spin-lattice interaction which is 
governed by a time-constant T1. Liquids have a long T1 whereas solids have 
a short T1. 
 
• The excited hydrogen nuclei also exchange energy with each other and as 
this happens, their net magnetization spreads out or dephases and this is 
termed spin-spin interaction. The rate of dephasing is governed by a time-
constant T2. T2 time constant describes the decay of the component of the 
net magnetisation. As with T1, the more mobile the sample, the longer the 
T2. 
Once the energy has been dissipated to the lattice it has gone and thus T1 is always 
longer than (or equal to) T2.  
The quality or homogeneity of the magnetic field plays an important role in the final 
image. Due to inhomogeneity in the main magnetic field, protons resonate at slightly 
different frequencies and therefore get out of phase and lose their transverse 
magnetization coherence. This is termed T2* decay. The T2* time constant governs 
the overall signal decay in the transverse plane and comprises both spin-spin 
interactions (T2 decay) and additional loss of phase due to imperfections in the 
external magnetic field, and magnetic susceptibility effects. Therefore, a magnet 
with good field homogeneity will allow T2* values to be closer to the true T2 values 
of tissues. Alterations from the ‘true’ T2 depend on local inhomogeneities. T2* is 
always shorter than T2. Thus, following a 90o RF pulse, a signal is produced by the 
rotating transverse magnetization and this is termed free induction decay (FID) 
which rapidly dephases due to T2* effects. 
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1.4.1.3 Pulse Sequence 
An MR image is produced using a pulse sequence which contains such a RF pulse 
and a gradient pulse to spatially encode the resultant signal, which has controlled 
timings and durations. There are 2 principle types of pulse sequence: spin echo 
(SE) and gradient echo (GE). Spin echo sequences generally use 2 RF pulses (90o 
and 180o) to create an echo which is spatially encoded to form an image (Figure 
1.13). The purpose of the 180o pulse after the 90o pulse is to refocus the protons by 
rotating the magnetization through 180o about the X axis, causing the magnetization 
to partially rephase, producing a signal. This eliminates the effects of the external 
causes of dephasing and the size of the echo signal depends only on the intrinsic T2 
of the tissue and its molecular characteristics. Application of a 180° RF pulse will 
allow formation of an echo at a time TE (echo time).  
 
 
Figure 1.13: Spin Echo 
Echo time (TE) is the time between the 90° RF pulse and MR signal sampling, 
corresponding to maximum of echo. The 180° RF pulse is applied at time TE/2. Repetition 
time (TR) is the time between two 90° excitations pulses 
 
A GE sequences uses a single RF pulse followed by a gradient pulse to create the 
echo (Figure 1.14). The gradient echo sequence differs from the spin echo 
sequence in that there is no 180° RF rephasing pulse. It is also worth noting that the 
excitation flip angle is usually below 90° (partial flip angle). This effects signal 
contrast and the minimum TE that can be attained. 
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Figure 1.14: Differences between spin echo and gradient echo.  
T2* weighted scans use a GE sequence. Gradient echo is subject to additional losses above 
the intrinsic T2 decay and makes it more prone to susceptibility losses at air/tissue 
boundaries, but can increase contrast for certain types of tissue, such as venous blood 
 
Gradients alter the magnetic field resulting in a change in resonance frequency or a 
change in phase. Gradient fields are located in the x, y, and z directions. Gradient 
coils located within the magnet are designed to produce a desired gradient magnetic 
field and are used for overall spatial localistion (building an image).  
There are many different types of pulse sequence, and by altering the TR and TE 
this can produce many different image contrasts. Contrast in needed in order to 
distinguish between different tissues. Contrast is due to differences in the MR signal, 
which depend on the T1, T2 and proton density of the tissues and sequence 
parameters used. The higher the signal is, the brighter it will appear on the MR 
image. 
Each tissue has a specific proton density, T1 and T2 relaxation time. MR images 
display tissue contrasts that depend on proton density, T1 and T2. By setting the TR 
to short values, tissue contrast will depend on differences in longitudinal 
magnetization recovery (T1) (Hoa 2009). If TE is long enough, differences in 
transverse relaxation will alter tissue contrast (the T2 effect). However, the signal 
will disappear if TE is too long. In other words, a short TR and short TE sequence is 
usually called T1-weighted, a long TR and long TE sequence is usually called T2-
weighted and a long TR and short TE sequence is usually called proton density –
weighted. Cerebro-spinal fluid (CSF) is dark in a T1-weighted image (long T1 and 
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T2) whilst it is bright in a T2-weighted image. However, when the CSF is forced out 
in the periventricular matter as oedema T1 is shorter and this is due to the fact that 
in the CSF the protons are freer to move around whilst are more tightly packed in 
oedema. On the other hand, fat is bright in a T1-weighted image and grey in the T2-
weighted image (short T1 and long T2). 
It is possible to measure many echoes after each excitation pulse as long as the 
intrinsic spin-spin interaction (given by T2) in the xy plane has not decayed away. 
Echo planar imaging (EPI) can be imagined as an "add on" to a pulse sequence, to 
acquire more signals from each excitation pulse. Echo planar imaging is a unique 
imaging method because it can collect an MR image, from a single FID, in about 40-
100ms. The advantages of this rapid imaging technique are that it helps to reduce 
motion-related artifacts and gives us a unique insight into the dynamic processes of 
the brain and this is very good for BOLD studies. The disadvantages are that EPI is 
very demanding on the imaging hardware because large field gradients have to be 
generated and switched rapidly and also the formation of artifacts due to factors 
related to the imaging sample (physical characteristics and nuclear magnetic 
resonance properties and the chemical shift components in tissue samples generate 
a chemical shift artifact), the hardware (gradient coils and amplifiers and field 
inhomogeneity) and the type of experiment. To overcome some of these limitations, 
modifications of the EPI pulse sequence and per-subject implementation can be 
implemented (eg. volume-selective shimming and the use of fat-suppression 
pulses). 
 
1.4.1.4 Quality of the MR image 
The quality of an MR image depends on the spatial resolution, the image contrast, 
the signal to noise ratio (SNR) and contrast to noise ratio and the presence of any 
artifacts. An MR experiment is a compromise between scan time and image quality 
and this is optimized according to the function of the organs and pathology. Spatial 
resolution corresponds to the size of the smallest detectable information. The 
smaller the voxels are, the higher the potential spatial resolution will be. In the 
context of BOLD fMRI this means that the voxels with BOLD-related signal changes 
can be closer to active neuronal areas. The matrix size determines the voxel volume 
and different sizes exist (e.g: 128 x 128 or 256 x 256 or 512 x 512) (Figure 1.15). 
Also the field of view and slice thickness play a role in the voxel volume. 
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Matrix size:  512 pixels        256 pixels 
Figure 1.15: Different sizes of the matrix 
Varying the matrix size, varies the details of the images scanned (NB: not the actual matrix 
sizes are depicted, rather a visual representation). 
 
In a MR image, the voxels that make up the image contain a mixture of contrast 
(different signals) and noise. The SNR is a measure of signal strength relative to 
background noise. The signal is the voxel brightness. Incoherent noise appears on 
the image as irregular grainy patterns, which can degrade image details. The 
sources of noise in the image are from the MR coils and the patient’s body due to 
thermal motion. The operator can control factors that produce noise, such as which 
RF coil is used (the smaller the sensitive volume of a coil, the lower the noise from 
the adjacent structures which it can detect, and the better the SNR will be), using 
the narrowest possible receiver bandwidth and also deciding on the voxel size. Low 
SNR may result in missing small levels of information or the obscuring of subtle 
contrast. The relative differences in signal from different tissues compared to the 
amount of noise present are termed contrast to noise ratio (CNR).  
Changing acquisition parameters result in changes in the SNR, CNR and spatial 
resolution, which affect the final outcome or quality of the MR image. It is advised 
that to produce a good image, the contrast is first set by choosing the appropriate 
pulse sequence and timings, followed by the smallest field of view that fits the 
anatomy scanned and finally the matrix for the spatial resolution. However, the 
choice of these parameters together with how many times a signal is averaged, all 
affect how ‘noisy’ the image appears and thus what can be reliably detected. 
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1.4.1.4.1 Artifacts	  	  
Artifacts are features in an image that are not present in the subject (object) being 
scanned and which may lead to false interpretation. Artifacts are often due to 
subject motion. These could relate to random movements such as coughing, 
swallowing or eye movements. Also a periodic motion associated with respiration, 
cardiac beats, arterial or CSF pulsation can lead to the formation of artifacts, most 
notably ghosting. These ghost images could be reduced by synchronising the TR 
and the periodic motion, so that the measurements are always performed with the 
subject in the same spatial position. Reducing the patient's movements sometimes 
requires the use of physical restraint, sedation or general anesthetic. Flowing blood 
or CSF causes flow artifacts in the body. When blood flows through a slice it can 
receive the RF pulse, but flows out of the slice by the time the signal is recorded. 
Therefore, by the time the echo is recorded the slice has only blood in it, which has 
not experienced the 90o or the 180o pulse thus resulting in no signal in the blood 
vessel. To overcome this, a multi-slice sequence is used so that the slices could be 
positioned such that blood experiencing a 90o pulse in one slice can flow into 
another slice and experience 180o rotation and into a third and contribute to the 
echo (Hornak 1996). Therefore, the vessel will have high signal intensity. Another 
source of artifact can be due to the magnetic susceptibility of a material (which is the 
tendency for that material to alter the magnetic flux density when placed in a 
magnetic field). This can create local disturbances (eg. from dental work or tattoos) 
in the applied magnetic field resulting in image distortion and phase disruption / 
signal changes. In the context of this thesis, the acquisition sequence (T2*-weighted 
EPI), which is used to monitor BOLD fMRI contrast, can also be hampered by 
dropout of signal in the orbitofrontal and parietal brain regions due to the close 
proximity of magnetic field gradients near air-tissue interfaces (eg: sinuses). 
Chemical shift is apparent as a mis-registration between water and fat. The protons 
on water and fat molecules resonate at slightly different frequencies and this can 
interfere with the frequency-encoding process, leading to the formation of bright or 
dark bands. Performing imaging at low magnetic field strength, by decreasing voxel 
size and by increasing receiver bandwidth, can reduce this effect. Another kind of 
chemical shift artifact (phase cancellation artifact) occurs with gradient echo 
sequences as the absence of a 180° RF pulse causes a phase shift between 
protons of fat and water when the echo is formed. This phase shift depends on their 
resonance frequency shift. When fat and water spins, there will be Tes and this will 
be totally in phase and totally out of phase. If the selected TE is when the spins are 
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out of phase, then a black boundary will be seen around organs surrounded by fat. 
There are specific TEs in GE imaging which give the phase cancellation artifact. 
Therefore, choosing the right TE is very important to avoid this artifact. Partial 
volume artifacts occur whenever a voxel contains a mixture of tissue types and this 
can easily happen when scanning the body. This is resolved by using a smaller 
voxel, however this may result in poorer SNRs in the image. A wraparound artifact is 
the appearance of a part of the imaged anatomy, which is located outside of the field 
of view, inside of the field of view (Hornak 1996). An example is if the head is being 
scanned, the nose might be outside the field of view. However, the nose appears at 
the back of the head in the image, and this happens because objects located 
outside the field of view appear at the opposite side of the image. This occurs when 
the selected field of view is smaller than the size of the imaged object. Overall, 
artifacts are common in MRI and primarily lead to image degradation, although they 
can occasionally mimic pathological lesions. However, artifacts have helped to 
develop new technologies. In early reports of the development of MRI, flowing blood 
was simply a nuisance, producing artifacts. However, nowadays sequences are 
used to visualise rather than suppress flowing blood in the clinically useful technique 
of MR angiography. Of great importance to this work, a difference in magnetic 
susceptibility that, as outlined above, can lead to the production of signal distortions 
and dropout artifacts, can also be used in the form of the BOLD contrast effect, to 
yield differences in signal resulting from changes in the relative amounts of oxy- and 
de-oxyhaemoglobin which change on neuronal / synaptic activity (Ogawa and Lee 
1990).  
 
1.4.2 Neurovascular coupling 
This refers to the relationship between local neural activity and subsequent changes 
in cerebral blood flow (CBF), that is, constriction/dilation of blood vessels to 
decrease/increase of cerebral blood flow to the brain region. The magnitude and 
spatial location of blood flow changes are assumed to be tightly linked to changes in 
neural activity through a complex sequence of coordinated events involving 
neurons, glia, and vascular cells that collectively adjust delivery of energy substrates 
to meet the local adenosine triphosphate demand (Riera et al. 2008). Brain 
activation is accompanied by a complex sequence of cellular, metabolic, and 
vascular processes. Neuronal activity is metabolically demanding. Increases in 
neuronal activity cause an increase in oxygen and glucose consumption (Hyder et 
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al. 1997), and timely delivery of energy substrates from blood to support neural 
activity is essential (Paulson et al. 2010). Whereas the fractional increases in CBF 
and glucose consumption are similar in magnitude, oxygen consumption increases 
much less than CBF, leading to a net increase in the amount of oxygen present in 
the blood and tissue that are local to the neuronal / synaptic activity. This oversupply 
of oxygen due to the mismatch between CBF and oxygen consumption is the basis 
of BOLD fMRI, which detects alterations in levels of deoxygenated haemoglobin and 
cerebral blood volume (Pasley and Freeman 2008). 
 
1.4.3 Blood oxygen level dependent fMRI 
The technique BOLD fMRI assesses neural activity. In the normal resting state, a 
high concentration of de-oxyhaemoglobin diminishes the MR signal due to its 
paramagnetic nature. When an area of the brain is being activated, there is 
increased blood flow and increased oxygen consumption. The surrounding neurons 
convert oxygenated haemoglobin, which is diamagnetic to deoxygenated 
haemoglobin. This overall difference in magnetic susceptibility (due to some oxygen 
consumption leading to an overall increase in oxygenated blood-delivery) results in 
BOLD signal changes on T2*-weighted imaging. Therefore changes in the BOLD 
signal can be used to detect changes in neural activity. 
In a typical experiment the subject completes a series of task and rest intervals 
during which T2*-weighted MR images are acquired repeatedly. The signal changes 
during this time course are examined on a voxel-by-voxel basis to test how well they 
correlate with a model of the haemodynamic response to the task. In order to 
visualise the resultant functional anatomy, voxels that demonstrate a statistically 
significant correlation between measured signal and model can be highlighted and 
over-layed onto a greyscale anatomical image to create a BOLD-response or 
‘activation’ map of the brain. The location and extent of activation is linked to the 
type of task or stimulus performed, for example a simple finger movement task will 
produce activation in the primary motor cortex (Liney 2005).  
With neural activation, assuming a constant rate of blood flow to the functional area, 
the oxygenated haemoglobin level would be expected to decrease. Indeed, after 
brain activity there is a brief drop in blood oxygenation in the haemodynamic 
response (initial dip). However, there is a subsequent reactive increase in blood flow 
to the area, causing a net increase in the level of oxygenated haemoglobin (Figure 
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1.16). Once neural activity has returned to ‘resting’ baseline, localised arterial blood 
flow, volume and relative oxy-/deoxy-haemoglobin ratio also return to pre-activation 
(and hence T2*-weighted MR signal) levels. A post-stimulus undershoot (Fransson 
et al. 1998; Attwell and Iadecola 2002) is known to often precede the return to the 
baseline state.   
  
 
Figure 1.16: Typical haemodynamic response to neural activity and its effect 
on fMRI signal intensity.  
Following stimulus: the BOLD response shows a small post-stimulus dip, then reaches a 
peak activation at 4–6 seconds, and often undershoots the baseline slightly before returning 
to prestimulus (10 seconds or more following the stimulus) (Mohamed et al. 2000).  
 
A temporal resolution on the order of 100 milliseconds and a spatial resolution of 1-2 
millimeters for fMRI is much greater than that of PET scanning (Posse et al. 1996). 
This allows for neuroanatomical structures to be readily visible and for transient 
cognitive events to potentially be imaged. The temporal resolution is determined by 
how often ‘single-shot’ images can be acquired (given by the repetition time) which 
is often limited by scanner gradient specifications and how large the volume to be 
measured is (field of view (FOV) and number of 2-D slices). The BOLD signal 
changes seen in fMRI are relatively small and depend on the field strength of the 
scanner (~ 2-3% at 1.5T and 4-6% at 3T 3T for typical motor or visual activation).  
Due to MRI’s non-ionising nature, each subject cab be scanned several times during 
one imaging session (ie. different ‘runs’) and on different occasions. Within one run 
a lot of images are acquired, due to the small contrast-to-noise ratio of the BOLD 
response, scanning the volume of the brain over and over. This volume consists of 
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several slices. Each slice consists of small volume elements, called voxels, which 
are three-dimensional pixels (Figure 1.17). The anatomical prescriptiuon of slice 
position and orientation can be varied for a ‘run’, depending which areas are of 
interest. A slice has a certain thickness and the in-plane resolution is given by the 
extent of the image (FOV) and the acquisition matrix size. Thus for a FOV=25.6cm 
and a matrix of 256 x 256, the in-plane spatial resolution would be 1mm. 
 
 
Figure 1.17: MRI process of what happens during a visit for a scan.  
A subject attends for an MRI scan where fMRI data is acquired whilst scanning the subject. 
From each run, slices are obtained and each and the MRI signal is represented as a voxel, a 
small volume of tissue within the patient’s body. 
 
 
1.4.4 fMRI experimental designs 
BOLD fMRI does not measure absolute neural activity and study designs are of 
paramount importance in order to statistically contrast the neuronal activity of 
interest with a suitable rest or background condition. Over recent years, different 
presentation schemes or ‘paradigms’ have been employed to assess the 
haemodynamic response to many types of stimuli. Stimulus paradigms have been 
block, event-related or of mixed designs. Normally, one stimulus would evoke a 
BOLD response as seen in figure 1.18.  
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Figure 1.18: The haemodynamic response in relation to a stimulus 
Blue = stimulus; Black = BOLD signal responding to a single stimulus. This demonstrates a 
delay between the stimulus and the brain’s haemodynamic response.  
 
1.4.4.1 Block design 
Epoch-based design uses blocks of stimulation (boxcar designs with alternating 
activation and rest yielding on and off conditions, Figure 1.19). When the subject is 
given a series of categorically similar stimuli one after another then the BOLD 
response can increase to a measurable level; the chances of measurement when 
the subject is being scanned increases. The BOLD signal is made up of individual 
haemodynamic responses from each stimulus. 
 
Figure 1.19: Block design  
Alternate between stimuli of tasks and controls and measures fMRI response to each block. 
(Blue = on and off stimulus, Red = BOLD haemodynamic brain response). 
 
The advantages of a block design are that this allows considerable experimental 
flexibility and is statistically powerful and (relatively) straightforward to analyse. 
However, this design has its own limitations. Potential confounds can be present 
such as habituation and anticipation and the BOLD signal may not remain constant 
across the epoch of interest. Within a block, the underlying haemodynamic response 
can change from the first trial in the block to the last trial within the block.  
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1.4.4.2 Event-related design 
This paradigm allows detection of the brain’s response to brief events or stimuli. 
This allows randomly intermixed events of different types and thus means that the 
response to any one event is not systematically influenced by prior events (Figure 
1.20). This type of design is useful for behavioural studies. 
 
Figure 1.20: Event-related design  
Measures brain’s responses to brief events/stimuli repeated many times. The blue line 
represents the stimulus and the black ‘wave’ repesents the brain’s haemodynamic response. 
 
Event related designs allow for stimulus events from various experiment conditions 
to be presented randomly in one run therefore more randomisation is possible and 
this leads to a less predictable experimental nature. For each event there is a single 
haemodynamic response function which can be identified. The disadvantages 
related to event related design are that it is more complex both in the design and in 
the statistical analysis and afforded statistical power. 
 
1.4.4.3 Mixed designs  
A combination of block and event-related designs is a mixture of the characteristic 
block design measurement of repetitive sets of stimuli and the transient responses 
detected by event-related designs (Amaro and Barker 2006). 
 
1.4.5 Analysis of functional neuroimaging data 
The analysis of imaging data in this work was carried out using statistical parametric 
mapping software designed in University College London (SPM5) – see Methods 
Chapter. A commonly used method for detection of neural activity and the variability 
in the data of experimental and confounding effects in fMRI is using the general 
linear modelling together with the Gaussian random field theory (GRF). A model is 
set-up according to the stimulus applied and this model will be fitted to the data 
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obtained, and therefore a good fit between this model and the data means that the 
data has a high probability that it resulted from the specified stimulation. General 
linear model (GLM) estimates parameters by analysing each voxel using any 
statistical parametric test and the resulting statistics are assembled into an image 
(Friston et al. 1994). The GRF is important as it allows detection of an effect or 
activation at an unknown spatial location. Data from individual subjects can be pre-
processed independently. Analysis of functional neuroimaging data involves several 
steps (figure 1.21): 
Spatial pre-processing: the aim is to reduce unwanted variance components in the 
voxel time-series that are induced by movement or shape differences among a 
series of scans. The process involves realignment, spatial normalisation and spatial 
smoothing. A Gaussian model was used to eliminate type 1 and type 2 errors. SPM5 
combines the GLM and GRF and allows statistical inference to be made in reference 
to deviations in the BOLD response from the null hypothesis.  
Realignment: The aim is to remove movement artifact in fMRI time-series. The SPM 
programme does this by realigning a time-series of images to the first image in the 
series, acquired from the same subject using a least squares approach and a six 
parameter (rigid body) spatial transformation (Friston et al. 1996). The six 
translational and rotational corrections are displayed as a function of scan number 
providing an indicator of subject spatial stability. 
Normalisation: This module spatially (stereotactically) normalises images into a 
standard space defined by a template image thus making the results from different 
studies and individualscomparable by aligning them to a standard space. The 
template images supplied with SPM conform to the space described by the atlas of 
Talairach and Tournoux (Talairach and Tournoux 1988). Generally these algorithms 
work by minimizing the sum of squares differences between the acquired image and 
the template. 
Smoothing: This is for smoothing or convolving image volumes with a Gaussian 
kernel of a specified width (Friston et al. 2000). It is used as a preprocessing step to 
suppress noise and effects due to residual differences in functional and gyral 
anatomy during inter-subject averaging.  
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Anatomical localisation: The anatomical location presented in this thesis has been 
identified in two ways. All images are normalised to a standardised anatomic space 
(Talairach and Tournoux 1988) using the Montreal Neurological Institute (MNI) 
template.  
 
 
 
Figure 1.21: Overview of SPM analysis 
Negative x coordinates denote the left side of the brain; and positive x coordinates give 
regions in the right side of the brain. The SPM5 display utility displays images in neurological 
convention, which means that the left side of the image corresponds to the left side of the 
brain. 
 
1.4.6 Statistical analysis of data 
Statistical parametric mapping refers to the construction of spatially extended 
statistical processes to test hypotheses about regionally specific effects. Statistical 
parametric maps (SPMs) are image processes with voxel values that have, under 
the null hypothesis, a known distributional approximation (usually Gaussian) 
(Frackowiak 1997). SPMs show the location, spatial extent, and relative magnitude 
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of statistically significant activations to an experiment. When SPM estimates a 
model, the software analyse the data obtained across the experiment and sees if it 
fits the hypothesis, which would have been described in the design matrix. The 
design matrix specified how factors of the model change over time. The SPM 
automatically convolves the effects of the hemodynamic response function with the 
stimulus vectors, as well as filtering changes in the data that are not relevant to the 
conditions. The design matrix contains the explanatory variables. Each column of 
the design matrix corresponds to a condition associated with the experiment. The 
formulation of a design matrix appropriate to the study is important and inferences 
are sought. After completion of the model estimation, a set of data is obtained 
showing the effect each condition of the experiment had at each voxel. The 
importance to know is if one condition made a significantly greater contribution than 
another condition and this is specifically done by contrast analysis. Each voxel is 
assigned with a T-statistic and SPM could be programmed at a certain p-threshold 
to find only the voxels whose t-statistics fit above that probability threshold.  
Experimental designs in functional neuroimaging can be broadly divided into 
subtractive, parametric and factorial. In designing the experiment, the task might be 
designed to be identical, however the brain is likely to show changes in activity 
between tasks due to confounding factors as the brain is involved in other parallel 
physiological processes unrelated to the experimental task. Therefore, to highlight 
areas of the brain related to the task, statistics are employed to look for the most 
significant difference above the background brain activity and this is known as the 
general linear model. 
Subtractive designs apply the idea of subtracting images acquired when the subject 
was performing the active condition from images when the subject was performing a 
control condition. Here, there is the assumption that the two conditions can be 
cognitively added, a principle known as pure insertion, implying no interactions 
among the cognitive components of a task. The images would be analysed 
assuming that any BOLD signal difference, above the statistical level chosen, would 
represent all brain regions involved in the performance of that task. This design is 
used for cognitive or sensorimotor activation studies (Friston et al. 1996). However 
the assumption of pure insertion in subtraction logic is often false.  
Parametric designs include studies where some physiological, clinical, cognitive or 
sensorimotor parameter is correlated with physiology to produce a SPM of the 
significance of the correlation or regression. In this design, a range of different levels 
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of parameters are introduced and then the relationships are identified between the 
imaging signal and the values that the parameter assumes (Moonen et al. 1999).  
Factorial designs provide for interactions between each component. An interaction 
represents a change in a change and is associated with factorial designs where two 
or more factors are combined in the same experiment (Frackowiak 1997). The effect 
of one factor, on the effect of the other, is assessed by the interaction term. Factorial 
designs have a wide range of applications and are important for clinical studies. The 
effect of a disease process on sensorimotor or cognitive activation is simply an 
interaction and involves replicating a subtraction experiment in subjects with and 
without the pathophysiology studied (Friston et al. 1996). The parameters used in 
the study detailed in Chapter 2 were included as a flexible factorial model and will be 
discussed later.  
 
1.4.7 Brain activation  
1.4.7.1 Finger movement task 
Finger tapping is a simple motor control task and it involves the control of 
movements in the spatial domain and movement timing. In functional neuroimaging 
studies, finger-tapping tasks are commonly used to study the human motor system. 
In such tasks, subjects are asked to tap their fingers in synchrony either at their own 
pace or with a series of pacing tones separated by a constant interval. Pacing 
stimuli are used to make sure that all subjects perform uniformly the finger tapping 
task uniformly at a predetermined rate. The stimuli are usually in the form of 
regularly paced, repetitive auditory or visual cues. Complex finger tapping tasks 
such as bimanual tapping tasks or multi-finger sequential are often used together 
with pacing stimuli and are employed to elicit neural activation that is more 
representative of what would be observed in an typical manual movement. A meta-
analysis on finger-tapping tasks showed that clusters of concordance in regions 
commonly associated with the performance of motor tasks including the primary 
sensorimotor cortex, supplementary motor area (SMA) located in the medial part of 
the superior frontal gyrus, basal ganglia and cerebellum (Witt et al. 2008). Areas of 
the cerebral cortex are involved in the planning, control and execution of voluntary 
motor tasks. There are different areas in the motor cortex, which have different 
functional roles (Figure 1.22). The primary motor cortex has a somatotropic 
representation, known as the motor homunculus, where the surface area devoted to 
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control a particular movement of each body part varies in direct proportion to the 
accuracy of the movements that can be made by that part. The hand and arm motor 
area is the largest.  
a)
 
b)
 
Figure 1.22: a) Motor cortex typically divided in primary motor cortex, pre-motor 
area and supplementary motor area; b) Somatotropic representation on the 
primary motor cortex. 
Reproduced with permission from www.thebrain.mcgill.ca 
 
The primary sensorimotor cortex activation has been associated with simple 
voluntary movements and also involved in the processing of complex sequential 
tapping tasks as well as the processing of bimanual movements. The SMA 
processes simple voluntary movements together with higher motor processing 
functions (movement initiation, motor planning, programming and learning, bimanual 
coordination, responsiveness to cueing of movement and selection of movement). 
Basal ganglia play a part with the performance of simple repetitive and complex 
sequential movements. The cerebellum is activated during preparation, execution, 
and timing of both simple and complex movements (Witt et al. 2008). The 
cerebellum stores learned sequences of movements; it contributes to fine-tuning 
and co-ordination of movements and sustains close communications with the cortex. 
The primary motor cortex, SMA, basal ganglia and cerebellum are not the only parts 
of the cortex that are involved in generating voluntary movements. The posterior 
parietal cortex also plays a crucial role in relation to motor planning and the 
prefrontal cortex is important for executive function, judgement and higher level 
processing (Leff et al. 2011). 
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1.4.7.2 Experimental pain stimulation in healthy volunteers 
Changes in brain activity in response to painful stimuli have been studied using 
fMRI. Over the last twenty years, imaging studies have examined the perception and 
modulation of experimental stimuli including pain. This has led to the 
characterisation of a network of brain areas that consistently activate in response to 
pain, which has been designated as the “pain matrix” (Melzack 1999). These brain 
areas are primarily responsible for discriminating location and intensity of painful 
stimuli together with affective pain processing (Rainville et al. 1997; Bushnell et al. 
1999; Kanda et al. 2000; Vogt et al. 2003). Disruption of the pain matrix and the 
associated pathways are thought to have implications for the pathogenesis and 
persistence of neuropathic pain (Tracey 2005). Mainly these studies have been 
carried out on healthy volunteers following acute pain stimulation and so largely 
remain to be tested in the context of pathological neuropathies. In a meta-analysis 
by Apkarian et al, haemodynamic studies of acute pain in normal subjects using 
PET and fMRI showed the six most commonly reported areas: anterior cingulate 
gyrus, primary and secondary somatosensory cortex, insular cortex, thalamus and 
prefrontal cortex (Apkarian et al. 2005) (Figure 1.23). These authors then compared 
incidences of significant activation of several brain areas across chronic clinical 
conditions (where the brain activity was specifically related to the condition) and 
acute pain. The comparison showed that chronic clinical pain conditions (like 
migraine, complex regional pain syndrome, fibromyalgia, irritable bowel syndrome, 
cardiac pain) more frequently involve prefrontal cortex, whilst in normal subjects, 
perception of experimental pain more frequently involves somatosensory cortex S1 
and S2, thalamus and anterior cingulate gyrus (Apkarian et al. 2005). 
 
Page | 77  
 
 
Figure 1.23: The ‘pain matrix’ showing areas where there is brain activation 
with painful stimuli 
 
The ACC is part of the forebrain and plays a pivotal role in controlling the sensory, 
attentional, motivational and emotional elements of pain (Mohr et al. 2005). The 
insular cortex is folded deep within the lateral fissure between the temporal lobe and 
the frontal lobe and regulates emotion, self-awareness, cognitive functioning and 
interpersonal experience (Jaggi and Singh 2011). The prefrontal cortex is important 
for the social, emotional and executive functioning in humans (Teffer and 
Semendeferi 2012) and has extensive neural connections in the brain. The primary 
and secondary somatosensory cortices receive noxious and innocuous input from 
the thalamus and processes temporal and spatial aspects of somatosensory stimuli 
(Hofbauer et al. 2001). The thalamus forms part of the lateral wall of the third 
ventricle and is composed of multiple nuclei, which receive input from many cortical 
and subcortical structures; it is the sensory relay station to the cortex and is also 
part of the limbic system (McCormick and Bal 1994). Other brain areas, including 
the cerebellum, amygdale, basal ganglia, and hippocampus can also be activated 
depending on individual factors (Tracey and Mantyh 2007).  
Pain is a subjective experience, and influenced by the individual’s personality and 
complex multi-factorial networks involving emotions, memory and cognition, 
pathological and genetic factors. Also the response to pain is based on the particular 
situation and the appropriate response. In one study using fMRI (Ploner et al. 2010), 
16 healthy human subjects were recruited and received brief radiant heat pulses to 
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the dorsal aspect of the subject’s right foot (adjusted to pain threshold). Stimulus 
intensity was adjusted to pain threshold so that about half of the stimuli were 
perceived as painful and half were not. Stronger activation of the cerebral pain 
network including thalamus and somatosensory, mid-cingulate, and insular cortices 
resulted from stimuli perceived as pain compared to activation that resulted from 
identical stimuli that were not perceived as painful. There was also activation in 
dorsolateral prefrontal cortex and putamen (probably related to perceptual decision 
and motor processes). Neural activity in brain areas related to pain and pain 
modulation three seconds before pain and no pain stimuli was reported to be in the 
left anterior insular cortex where stronger activity was present not only in response 
to but before pain and no pain stimuli. This likely reflects the susceptibility to a 
sensory event that then determines the subsequent perception of pain. When 
cerebral connectivity before pain and no pain stimuli was compared, the anterior 
insular cortex exhibited the strongest response indicating that this brain region is 
particularly linked to the subjective perception of pain. The pre-stimulus functional 
connectivity of the bilateral anterior insular cortex to the brainstem in the PAG (an 
area of importance in the pain modulatory system), reflected the susceptibility to 
pain and affected subsequent stimulus perception. The authors concluded that 
variations in functional connectivity underlie personality-related differences in 
individual susceptibility to pain (Ploner et al. 2010). 
 
1.4.7.3 Experimental pain stimulation in chronic conditions 
Abnormalities in pain processing, rather than just damage or inflammation to the 
peripheral nerves, seem to play a part in chronic painful conditions like fibromyalgia 
syndrome, chronic low back pain and irritable bowel syndrome (Verne et al. 2003; 
Giesecke et al. 2004). Chronic neuropathic pain and changes in the brain have been 
less thoroughly investigated (Moisset and Bouhassira 2007). However, recent 
studies in another, much more common cause of peripheral neuropathy like 
diabetes, may identify a means of systematically investigating CIPN in MM. 
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1.4.7.3.1 Extrapolation	  of	  MRI	  studies	  from	  diabetic	  peripheral	  neuropathic	  
pain	  
The Sheffield Diabetes/Radiology team reported evidence for the involvement of the 
CNS in diabetic peripheral neuropathy (DPN). Eaton et al, using non-invasive in-vivo 
MR imaging, measured the spinal cord cross-sectional area three different levels 
(lower cervical, upper and lower thoracic regions) of nineteen patients with DPN, ten 
diabetic patients with no DPN and ten healthy volunteers. They demonstrated a 
lower cross-sectional spinal cord area in the cervical and upper thoracic regions in 
patients with DPN compared to healthy volunteers, indicating extensive disease 
(Eaton et al. 2001). The theories postulated by this result are that the peripheral 
nerve damage causes secondary shrinkage of the spinal cord due to degeneration 
or atrophy or that the primary insult may be to the CNS, with the peripheral changes 
occurring as secondary phenomena and it is also plausible that both CNS and 
peripheral involvement occur concomitantly (Selvarajah et al. 2011). In another 
study, 98 subjects with type 1 diabetes were subdivided into three subgroups (no 
DPN, subclinical DPN, and established DPN) and Selvarajah et al were able to 
demonstrate decreased cross-sectional spinal cord area in patients with early 
subclinical DPN and also a significant trend of lower cord cross-sectional area with 
more severe neuropathy occurred across diabetic groups, indicating a continuing 
loss of cord area as the disease progresses (Selvarajah and Tesfaye 2006). Brain 
neurochemical and blood flow abnormalities are also reported within the thalamus, 
known to be a principle gateway to the brain’s sensory cortex. Eighteen male 
subjects with type 1 diabetes (eight no DPN, ten established DPN) and six age and 
sex-matched non diabetic healthy controls underwent proton magnetic resonance 
spectroscopy of the thalamus and the main finding was a significantly thalamic 
neuronal dysfunction in the group of patients with DPN compared to patients with no 
DPN and healthy volunteer controls (Selvarajah et al. 2008). One possible 
explanation for thalamic neuronal dysfunction in DPN may be that the damage to the 
peripheral nerves led to loss of afferent input thus leading to changes occurring at 
progressively higher levels in the CNS. In another study, eighteen subjects with type 
1 diabetes (no DPN=6, painful DPN=5, painless DPN=7) and five healthy volunteers 
had MR perfusion imaging at 1.5T; exogenous perfusion contrast (intravenous bolus 
of gadolinium chelate) was used to examine the microvascular perfusion 
characteristics of both the thalamus and caudate nucleus (control region). Group 
comparisons showed that painless DPN had lower thalamic regional cerebral blood 
volume compared with healthy volunteers and no DPN, whereas painful DPN had 
higher thalamic regional cerebral blood volume (p=0.04). Thus, in painful DPN there 
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was increased thalamic vascularity, whereas in painless DPN, greater thalamic 
microvascular impairment was present. Similar changes were not demonstrated in 
the caudate nucleus, which was a control area (not involved in somatosensory 
perception) (Selvarajah et al. 2011). In a preliminary study, 18 type 1 diabetic 
subjects (6 with no DPN, 6 with painful DPN, and 6 with painless DPN) were studied 
to test the feasibility of monitoring the brain’s response to the presentation of heat-
pain in the context of DPN; all participants had fMRI at 3T and a thermode device to 
the dorsum of the right foot delivered heat pain stimulation. This analysis showed 
that subjects with no DPN had greater BOLD response than those with painless 
DPN. Subjects with painful DPN showed significantly greater response than those 
with painless DPN. The neuro-anatomical areas involved in the BOLD response to 
heat pain include the primary somatosensory cortex, lateral frontal and cerebellar 
regions (Figure 2.24) (Wilkinson et al. 2007). This may be explained by reduced 
ascending nociceptive input as a result of diabetic neuropathy. 
 
 
Figure 1.24: Statistical Parametric Map 
a) (neurological co-ordinates) showing sagittal, coronal and axial projections of anatomical 
areas of significantly greater BOLD response (P<0.05 corrected for multiple comparisons) in 
type 1 diabetic subjects with DPNP than those with painless DPN; b, c & d) differences 
overlaid on the base EPI images within the b) somatosensory cortex, c) middle gyrus of the 
frontal lobe and d) cerebellum.  
Adapted from (Wilkinson et al 2007). 
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1.4.7.3.2 Extrapolation	   of	   MRI	   studies	   from	   other	   chronic	   painful	  
neuropathic	  conditions	  	  
Abnormalities in pain processing as shown on neuroimaging rather that just damage 
or inflammation to the peripheral nerves seem to play an important part in chronic 
painful conditions like trigeminal neuralgia, post-herpetic neuralgia and chronic low 
back pain (Giesecke et al. 2004; Geha et al. 2007; Moisset et al. 2011). Post-
herpetic neuralgia is an example of a human chronic neuropathic condition, since 
patients display multiple central and peripheral signs of neuropathy. Changes that 
occur include loss of cells in the DRG and of myelin and axons in the dorsal horn, 
decreased innervation by nociceptive afferents, as well as brainstem and spinal cord 
lesions on MRI (Geha et al. 2007). In a fMRI study by Geha et al, the ratings of 
fluctuations of spontaneous pain during fMRI were analysed against the ratings of 
fluctuations of a bar observed during scanning, the overall brain activity for 
spontaneous pain of post-herpetic neuralgia involved affective and sensory-
discriminative areas mainly including the primary and secondary somatosensory, 
thalamus, insula and anterior cingulate cortices. Areas that play a part in emotion, 
hedonics, reward, and punishment were also activated including the ventral 
striatum, orbital frontal cortex, amygdala, and ventral tegmental area. Trigeminal 
neuralgia is a unique neuropathic pain syndrome combining paroxysmal pain and 
evoked pain. An fMRI study in fifteen patients with classic trigeminal neuralgia in the 
second or third division of the nerve were studied, painful stimuli of the cutaneous 
trigger zone were associated with significantly increased activity in the spinal 
trigeminal nucleus, thalamus, primary and secondary somatosensory cortices, 
anterior cingulate cortex, insula, premotor/motor cortex, prefrontal areas, putamen, 
hippocampus and brainstem whilst non painful stimuli activated the same areas 
except the spinal trigeminal nucleus, brainstem and anterior cingulate cortex 
(Moisset et al. 2011). In this study, a large number of areas of the ‘pain matrix’ were 
activated during non-painful stimulation of the trigger zone and this could reflect the 
state of maintained sensitisation of the trigeminal nociceptive systems in trigeminal 
neuralgia.  
Another area of interest that activates to painful stimuli is the cerebellum. Noxious 
thermal heat and brush stimuli were applied to the right side of the face in a group of 
patients with neuropathic pain involving the maxillary region of the trigeminal nerve 
and in a group of healthy subjects and this showed that different cerebellar regions 
were activated in acute and chronic pain processing (Borsook et al. 2008). Painful 
stimuli trigger cerebellar lobules activation which are believed to be involved in 
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cognitive and emotional processing both in patients with neuropathic pain and 
healthy subjects whilst the cerebellar sensorimotor regions are activated by touch 
and thus it is proposed that the cerebellum modulates the cognitive and emotional 
experience that differentiates the pain awareness from the appreciation of 
innocuous stimulation (Moulton et al. 2010). In a study looking at patients with 
chronic back pain, there were significant differences in the CNS grey matter 
(decrease of grey matter in the brainstem and the somatosensory cortex and 
increase in grey matter bilaterally in the basal ganglia and the left thalamus) 
between chronic back pain patients and healthy controls using voxel-based 
morphometry suggesting a cortical and subcortical reorganisation on a structural 
level (Schmidt-Wilcke et al. 2006).  
Chronic neuropathic pain and possible changes in the brain have been less 
thoroughly investigated (Moisset and Bouhassira 2007). Our understanding of the 
pathological mechanisms underlying CIPN and possible future treatment target 
areas for this debilitating complication may be significantly enhanced by applying the 
fMRI techniques. To our knowledge, there have been no fMRI studies in MM 
patients who have developed treatment emergent CIPN. 
 
1.4.8 Opioids use and the effect on the CNS 
It is well known from preclinical studies that chronic opioid exposure has an effect on 
the nervous system and that clinical changes in the brain structure and function 
seem to occur (Robinson and Kolb 1999; Cunha-Oliveira et al. 2007). Studies 
administering acute opioid in opioid-naive volunteers revealed changes in BOLD 
signal in several areas of the CNS; mainly morphine and remifentanil decreased the 
brain activity in the somatosensory cortex and nucleus accumbens which is contrary 
to what happens after a painful stimulus and increased signal change in areas rich 
in opioid receptors mainly anterior and posterior cingulate cortex and frontal gyri 
(Becerra et al. 2006; Leppa et al. 2006). An fMRI study on ten chronic opioid-
dependent patients showed changes in the structure and the function areas of the 
brain associated with affect and impulse control and motivation and reward including 
volumetric changes in amygdala, white matter tract abnormalities in the internal and 
external capsules and alterations in functional connectivity involving the nucleus 
accumbens, anterior insula and amygdala (Upadhyay et al. 2010). In another study, 
ten chronic low back pain patients were administered oral morphine daily for one 
month and MRI showed reduced grey matter in the right amygdala and dosage-
Page | 83  
 
correlated volumetric increase in the right hypothalamus, left inferior frontal gyrus, 
right posterior cingulate, and right caudal pons which are known to have high mu-
opioid receptor density and binding capacity (Younger et al. 2011). After an average 
of 4.7 months of stopping the opioids, an MRI was performed and demonstrated that 
many of the morphine-induced brain changes were still present (Younger et al. 
2011).  
  
1.4.9 Thermal stimulation in fMRI studies 
Noxious thermal stimulation has been delivered by a thermode in different studies 
(Disbrow et al. 1998; Peyron et al. 1999; Tracey et al. 2002; Valet et al. 2004; 
Apkarian et al. 2005; Freund et al. 2009) or by a laser (Bornhovd et al. 2002; Garcia-
Larrea et al. 2003) Babiloni et al.2007). Noxious stimulation selectively activate 
nociceptive-specific transduction mechanisms in afferents located in the superficial 
layers of the skin (Julius and Basbaum 2001). Aδ and C nociceptors are activated 
with thermal stimulation. Thermal stimuli can be applied via a contact heat evoked 
potential device (CHEPS), which delivers heat pulses rapidly with adjustable peak 
temperatures. The advantages over laser evoked potentials (LEPs) is that C fibre 
afferents (which confer the slow, long-lasting aspect of pain) are consistently 
activated; it stimulates a larger area than LEPs thus evoking brain responses of a 
higher signal-to noise ratio (Granovsky et al. 2008) and is generally much safer in 
that repetitive use does not cause erythema (Chen et al. 2001). Also LEPs usually 
have a very short stimulus duration, which may be a disadvantage in a clinical study 
where the stimulus is somewhat unnatural in comparison to the general real life 
experience of thermal pain. However, contact thermodes unavoidably activate non-
nociceptive Aβ fibre afferents, because contact with the skin activates slowly 
adapting mechanoreceptors. In a study by Warbrick et al, event-related brain 
potentials using electroencephalography (EEG) were measured in response to 
contact heat stimuli applied to the arm and leg in ten healthy subjects (Warbrick et 
al. 2009). They used a single trial analysis using a multiple linear regression 
approach and found that single trial averaging resulted in larger amplitude 
measurements for fixed location stimulation. In a study, 16 healthy volunteers had a 
contact thermode applied to the right forearm either at a fixed location or at variable 
locations after each pulse with an inter-stimulus intervals 8–10seconds. The results 
showed that with fixed stimulus location, perceived pain intensity and contact-heat 
evoked potentials exhibited signs of rapid habituation reflecting fatigue of peripheral 
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nociceptive neurons and in such conditions, nociceptive input to the spinal cord 
progressively diminishes due to peripheral fatigue of Aδ and C fibre nociceptors 
(Greffrath et al. 2007). In my study, the effect of coupling neuronal activation and the 
BOLD response had to be taken in account and that the modelled BOLD response 
is applicable to the general linear model.  
Another way of selectively activating nociceptive fibres is by intra-epidermal 
electrical needle electrodes where the free nerve endings of Aδ and C fibres lie in 
the epidermal layer of the skin. Although this is more accurate, it has the 
disadvantage of being invasive (Mulert and Lemieux 2010).  
There have been various design studies using noxious heat stimulation with varying 
temperatures, stimuli and durations. A study conducted in the Academic Unit of 
Radiology in Sheffield, measured the brain’s response to heat pain stimulation in 
diabetic peripheral neuropathy and the heat pain stimulation was 30 seconds with 
an inter-stimulus duration of 150 seconds (Wilkinson et al. 2007). This showed clear 
group differences in neuronal activity between painful and painless neuropathy. An 
fMRI study conducted by Tracey et al. utilised a shorter stimulus duration of 12 
seconds to investigate the attention modulation of pain, eliciting significant PAG 
activation with this design (Tracey et al. 2002). In another BOLD fMRI study to 
evaluate attention in pain, a short 5 seconds stimulus with a 40 second inter-
stimulus duration was applied (Bantick et al. 2002). A 10 second design to evoke 
heat-pain stimulation was assessed by Upadhyay et al and demonstrated the 
presence of distinct temporal profiles in BOLD fMRI responses in healthy subjects 
(Upadhyay et al. 2010). A study using noxious heat (46°C for 29 seconds alternating 
with a baseline temperature of 35°C for 36 seconds) showed activation in the 
somatosensory pathways involved in pain discrimination (somatosensory cortex and 
thalamus); in motivational and affective areas (cingulate gyrus); in motor control 
(cingulate gyrus, precentral gyrus, and cerebellum); in the memory of pain (insula); 
and in regions implicated in the modulation of pain (PAG) (Becerra et al. 1999). 
This stimulus diversity suggests that the optimum duration of heat-pain stimulation 
and the inter-stimulus interval duration are not known; therefore a protocol for the 
CIPN pilot study was developed to estimate the most effective duration and inter-
stimulus interval to evoke stimulation and BOLD fMRI response (See chapter 2). 
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1.4.9.1 Habituation to thermal stimulation 
Habituation, a decrease in pain and pain-related responses with continuous or 
repetitive thermal painful stimulation has been demonstrated in the neuroimaging 
literature. In a fMRI study, six male healthy volunteers were given four noxious 
(46°C) stimuli lasting 29 seconds and when all four stimuli were analysed together, 
a decrement of statistical significance was observed relative to the combination of 
the first two stimuli and in fact no significant activation was seen for the last two 
stimuli in any anatomical region in both averaged and individual data sets (Becerra 
et al. 1999; Greffrath et al. 2006).  
In one session single trial event related design, using six painful laser stimulation on 
the left hand in 32 healthy subjects, fMRI BOLD habituation was assessed by 
comparing the first half of the experiment against the second half; the site of the 
stimulation was manually moved after each trial and the interval between stimuli was 
pseudo-randomised between eight and twelve seconds (Mobascher et al. 2010). 
Areas of the brain that showed habituation were found in primary and secondary 
somatosensory cortices, the insula and the anterior cingulate cortex (ACC). Also in 
those subjects with faster habituation, there was increased activation in the rostral 
ACC and the PAG and these subjects provided lower pain ratings (Mobascher et al. 
2010).  
In another fMRI study investigating habituation to pain in twenty healthy volunteers, 
repeated painful stimulation over several days with a 20 minute pain paradigm to the 
left volar forearm (10 blocks of thermode stimuli with each block containing a series 
of six 48°C stimuli, each lasting six seconds), for eight consecutive days was 
delivered, and fMRI performed on days 1, 8 and 22. This resulted in significantly 
decreased pain ratings to identical painful stimuli and this was also reflected in the 
MRI results where over time, there was a decrease in the BOLD response to the 
painful stimuli in the pain matrix. On the other hand, there was increased activation 
in the subgenual ACC over time where this region plays an important role in 
endogenous pain control thus suggesting that habituation to pain may be centrally 
mediated by increased antinociceptive activity (Bingel et al. 2007).  
However, in another study, 24 healthy volunteers were exposed to a 20-minute 
session of painful stimulation once a day to the left volar forearm over eight days. 
Half of the participants received the opioid-receptor antagonist naloxone on days 
one and eight (Rennefeld et al. 2010). The results demonstrated that the naloxone 
administration did not affect the development of pain habituation and that painful 
Page | 86  
 
stimulation repetitively over several days resulted in a significant habituation to pain 
at the site of stimulation and also significant pain attenuation at the non-stimulated 
limbs. This could indicate that there is a contribution of a central mechanism 
involving the supraspinal CNS which could involve a change in cognitive or affective 
processing of pain (Rennefeld et al. 2010).  
 
1.4.10 Reproducibility of fMRI data 
The test-retest reliability of fMRI BOLD signal changes has been investigated 
especially over the last few years. Motor tasks such as finger tapping and other 
paradigms such as learning tasks have been used for reproducibility studies 
(Wagner et al. 2005; Gountouna et al. 2010). In the literature, studies have shown 
that areas of activation are qualitatively repeatable when using the same scanner 
but are quantitatively of high inter and intra subject variability (McGonigle et al. 
2000; Marshall et al. 2004; Gountouna et al. 2010).  
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1.5 Summary 
Cancer care recognises that, as well as reducing tumour size and prolonging life, it 
is important to take into account the burden of treatment side effects (both acute and 
long-term), co-morbidities and the large range of associated psychological and 
social issues affecting patients and families (Ahmedzai and Walsh 2000). In 
addition, oncology has focused latterly on the problem faced by those in long-term 
remission; i.e. survivors. This interest has been focused on survivors of childhood 
cancer, but increasingly is being extended to the follow-up of adults, including those 
long-term survivors with controllable but incurable cancers such as MM (Demark-
Wahnefried et al. 2006; Baker et al. 2007; Eiser et al. 2007; Greenfield et al. 2007). 
Multiple myeloma is an incurable disease, but treatment of active symptomatic 
disease may result in repeated phases of control. Delivery of more intensive 
treatment, including haematopoietic stem cell transplantation and introduction of 
novel agents, has resulted in significant improvements in life expectancy. Despite 
enhanced disease control, none of the current novel agents are free of significant 
toxicity, which frequently persists after completing treatment. Myeloma is thus 
increasingly being considered as a chronic disease state in which progressive 
damage from MM is potentially compounded by cumulative treatment related 
toxicities.(Brenner et al. 2009; Johnsen et al. 2009; Bird et al. 2011; Snowden et al. 
2011). However, compared with some other cancers with protracted survival, (Mols 
et al. 2005) relatively little is known in MM about patients’ psychosocial and broader 
holistic needs, particularly with modern clinical management strategies.  
Pain is described as an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage and is subjective. Whilst the experience of 
acute pain has a protective role, chronic persistent pain has no biological advantage 
and causes suffering and misery. Chronic pain creates physical, emotional and 
financial issues to patients, their families and society (Breivik et al. 2006). The 
incidence of chemotherapy-induced neuropathy can be variable with different 
chemotherapeutic regimes. Neurotoxicity can be so severe that it can limit the dose 
of chemotherapy and even potentially stop curative cancer treatment thus having an 
impact on survival. More cancer patients are experiencing better outcomes with 
chemotherapy and prolonged survival. Long-term management of CIPN is therefore, 
becoming one of the most challenging aspects of treatment in this disease. There is 
still no prophylactic treatment to deal with it and current neuropathy treatments are 
poor, owing to a lack of knowledge regarding pathological mechanisms.  
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Thus, there is an urgent need for better understanding of the mechanisms of CIPN 
to prevent or treat this adverse event so that more patients are treated with the 
therapeutic full dose and for the correct length of time. Neuroimaging methods can 
potentially play an important part in this and have made a huge impact within brain 
research. A significant amount of research has been conducted with pain models in 
healthy volunteers and the non-invasive identification of pain mechanisms has led 
scientists and clinicians to reconsider issues related to the pathophysiology and 
diagnosis of certain painful diseases. Neuroimaging is becoming an increasingly 
important tool in the study of clinical painful scenarios; both in the acute and chronic 
conditions.  
This thesis is divided into two studies.  
The aims of first study are: 
-  To determine whether differences exist in central pain processing pathways 
as assessed by fMRI during noxious thermal stimulation between MM patients with 
chemotherapy-induced peripheral neuropathy and healthy volunteers.  
- To determine the degree to which quantitative sensory testing predicts 
presence and severity of CIPN. 
- To describe HRQoL in MM patients with CIPN, using qualitative 
assessments (questionnaires).  
 
The aims of the second study are: 
- To characterise the late effects in patients with advanced but stable MM, 
clinically and in terms of HRQoL 
- To investigate the relationship between symptoms and functioning and 
cytokine levels relevant to MM. 
- To compare HRQoL in MM patients with neuropathy and those without 
according to s-LANSS.  
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Chapter	  2	  
Central	  pain	  processing	   in	  multiple	  myeloma	  patients	  
with	  chemotherapy-­‐induced	  peripheral	  neuropathy	  
 
2 Introduction 
A high incidence of CIPN has evolved due to modern cancer treatments. One such 
cancer is MM, a haematological malignancy, which is characterised by abnormal 
proliferation of plasma cells primarily found in the bone marrow. Following the 
administration of modern anti-myeloma therapies, an accumulating burden of 
peripheral neuropathy has been recognised (Richardson et al. 2009; Bird et al. 
2011). Chemotherapy-induced peripheral neuropathy is thus a common, potentially 
severe and dose limiting side effect of treatment. Mohty et al reported that the 
incidence of CIPN is very common, >70% in certain trials of thalidomide and around 
40% with bortezomib (Mohty et al. 2010). Although some reversibility may be 
possible after dose reduction or cessation of the causative agents, there is 
increasing recognition of the developing chronicity of peripheral neuropathy in many 
patients. This chronic nature not only potentially compromises the administration of 
further anti-myeloma therapies but can also generate long term and irreversible pain 
and disability. In addition, this frequently leads to the need for long-term 
administration of analgesic drugs with their attendant side effect profiles. In the latter 
scenario, therapeutic response is often very poor. Overall, the result can be one of 
reduced QoL and survival, which significantly counters the recent achievements of 
improved life expectancy in this disease. 
Peripheral neuropathy is often considered a disease of the peripheral nervous 
system, however early studies also report pathology within the spinal cord (i.e. the 
CNS). Although peripheral abnormalities are often reported, no great advancements 
in treatment have emerged. Studies using MRI have shown abnormalities in spinal 
cord in diabetic peripheral neuropathy (Eaton et al. 2001; Selvarajah et al. 2006) 
even at a sub-clinical stage (Selvarajah et al. 2008). Brain neurochemical and blood 
flow abnormalities are also reported within the thalamus (Selvarajah et al. 2008; 
Selvarajah et al. 2011) known to be a principle gateway to the brain’s sensory 
cortex. In diabetic peripheral neuropathy, both peripheral and CNS dysfunction are 
implicated.  
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Changes in brain haemodynamic response to painful stimuli have been studied 
using fMRI. Abnormalities in pain processing as shown on neuroimaging rather than 
just damage or inflammation to the peripheral nerves, seem to play an important 
part in chronic painful conditions such as trigeminal neuralgia, post-herpetic 
neuralgia and chronic low back pain (Giesecke et al. 2004; Geha et al. 2007; 
Moisset et al. 2011). Our understanding of the pathological mechanisms underlying 
CIPN and identification of possible future treatment target areas for this debilitating 
complication may be significantly enhanced by applying fMRI in this context. To our 
knowledge, there have been no reported fMRI studies in patients with MM who have 
developed treatment emergent CIPN.  
In this study, we sought to determine whether differences exist in central pain 
processing as assessed by BOLD fMRI, during noxious thermal stimulation between 
MM patients who develop CIPN and health volunteers. We hypothesised that nerve 
damage caused by chemotherapy results in the alteration of the cortical and sub-
cortical pain matrix, and that in turn contributes to altered pain perception in CIPN-
myeloma patients. 
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2.1 Methods and materials 
2.1.1 Pilot Study for the fMRI design 
Before proceeding to the main study, a pilot study was performed with healthy 
volunteers to design and test an fMRI protocol during heat-pain stimulus delivered 
by a contact heat evoked potential thermode device. Ethics approval was obtained 
(see section 2.4). 
Five healthy volunteers (2 male, 3 female; mean age 36 ± 15 years) were studied to 
investigate the fMRI technique used for the main study. The volunteers were 
identified by members of the team (mainly members of staff) and given a healthy 
volunteer information sheet. Potential volunteers were screened and if willing to 
undergo this study a written consent form and MRI screening forms were signed 
prior to scanning.  
 
Inclusion Criteria  
• Subjects above the age of 18 
• Able to provide informed written consent 
• Able and willing to comply to study requirements 
 
Exclusion Criteria  
• The presence of any major psychiatric or neurological disorder on examination 
or medical history 
• Claustrophobia 
• Pre-existing neuropathy due to other aetiology 
• Medications that could affect pain perception, e.g. non-steroidal anti-
inflammatory drugs 
• Standard MRI exclusion criteria: heart pacemaker, electrical implants. 
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2.1.1.1 Thermal Stimuli 
A contact heat evoked potential device (CHEPS) (Medoc Ltd, Ramat Yishai, Israel) 
was used for contact thermal stimulation (Figure 2.1). It has a contact diameter of 
27mm and uses heating foil technology in combination with a Peltier element. The 
CHEPS heating rate was set to its maximum 70°C/s, the cooling rate was set to 
40°C/s and the baseline temperature was fixed at 32°C. The pathway unit was PC-
controlled, enabling the programming of specific thermal stimulation protocols which 
were delivered by the MR-compatible CHEPS thermode. 
 
Figure 2.1: Medoc Pathway unit (left) and CHEPS thermode used for thermal 
stimulation (right). 
 
Two experimental protocols for thermal stimulation were tested (Figures 2.2a and 2.2b) and 
the CHEPS thermode was applied to the dorsum of the right foot. 
 
Figure 2.2a: Protocol 1 - Heat-pain stimulation for 5 seconds 
A 5-second thermal stimulus (47°C) was applied to the right foot with a random pain-free 
interval (32°C) of 40,45 and 50 seconds 
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Starting with 10 seconds at baseline temperature of 32°C, a five second thermal 
stimulation was delivered at 47°C. This was then followed by a pseudo-randomised 
inter-stimulus interval of 40, 45 or 50 seconds where the temperature returned to 
32°C. This sequence was repeated 15 times. The timings of onset for the heat pain 
stimuli for this protocol were 10, 55, 105, 160, 205, 260, 310, 355, 405, 460, 505, 
555, 600, 655 and 705 seconds. 
 
Figure 2.2b: Protocol 2 – Heat-pain stimulation for 30 seconds  
A warm stimulation (42°C) for 30 seconds followed by a thermal stimulation (45-48°C) for 30 
seconds was delivered with a random pain-free interval (35°C) of 150, 155 or 160 seconds 
 
The protocol 2 sequences started with 30 seconds at a baseline of 35°C and were 
followed by a warm stimulation sequence of 42°C for 30 seconds and a noxious 
sequence at the pre-determined temperature (45-48°C) for 30 seconds. The inter-
stimulus interval was pseudo-randomised to 150, 155 or 160 seconds where the 
temperature returned back to 35°C. This sequence was repeated 3 times. The 
timings of the onset of the heat pain stimuli (noxious) for this protocol were at 60, 
300 and 540 seconds. 
 
2.1.1.2 Heat-Pain stimulation 
To determine the threshold of thermal stimulation to be delivered during scanning, 
volunteers received a five second duration stimulation starting at 47°C. They were 
asked to verbally rate the intensity of the pain on a numerical rating scale (NRS) 
from zero (no pain) to ten (maximum imaginable pain).  
In this pilot study we wanted to achieve a pain rating of ≥ 7/10. The stimulation 
threshold was increased or decreased accordingly by steps of 1°C, until the verbal 
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pain rating was ≥ 7 and the volunteers could tolerate this painful stimulus when used 
inside the scanner. The maximum temperature used was 48°C and the minimum 
temperature was 45°C. 
After the fMRI scan, volunteers were asked to verbally rate the overall intensity of 
pain experienced inside the scanner on the same NRS and also asked if they were 
able to anticipate the onsets of the thermal stimulus in the two protocols to give an 
appreciation which inter-stimulus interval could best remove anticipation.  
 
2.1.1.3 fMRI Acquisition 
Data was acquired using a 3.0 Tesla (Achieva 3.0T, Philips Medical Systems, 
Holland) MRI scanner. The scanning protocol included a standard T1-Wighted, 3-
Dimesional and T2-Weighted, 2-dimensionsal anatomical imaging scans prior to 
functional imaging sequences. The fMRI data sets comprised of single-shot T2* 
weighted gradient-recalled, echo planar imaging sequence. For each data set 35 
slices of 4mm thickness, with an in-lane resolution of 1.8mm x 1.8mm at each 
imaging time-point or dynamic were captured. 
Time to echo (TE) = 35ms; Time to repeat (TR) = 3000 ms; SENSE encoding factor 
= 1.5. T2* weighted functional imaging runs were carried out at rest (baseline scan), 
during an auditory-motor finger tapping task and during application of both 
stimulation protocols using CHEPS to the dorsum of right foot.  
Synchronisation between the CHEPS protocol and fMRI acquisition was verified by 
the scanning operator (physicist) and a member of the team operating the CHEPS 
thermode.  
 
2.1.1.4 Finger–tapping sequence 
Inter-individual variation in non-pain related BOLD response was measured using a 
motor task sequence, which assessed brain regions known to have no association 
with the pain matrix. This allowed the assessment of neurovascular-coupling. A 180 
second (60 dynamics) scanning sequence was used. A 30 second rest period (ten 
dynamics) was followed by finger tapping for 30 seconds. This was repeated three 
times. 
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The finger task movement consisted of the volunteers touching their thumbs to the 
index, ring, middle, and little fingers consecutively on both hands at the subjects’ 
own pace at a steady rate. During the rest period, the subjects were asked to relax 
their hands at their sides. The scanning operator prompted the volunteers to start 
and stop using the intercom system via headphones. The successful initiation and 
ending of the finger-tapping sequence according to the auditory cue (start/stop) was 
monitored and recoded by a member of our team. The volunteers were taught the 
task and practised it before the fMRI scanning in order to make sure they 
understood the procedure.  
 
2.1.1.5 fMRI data Analysis 
The analysis of imaging data was carried out using statistical parametric mapping 
software (SPM5). Analysis of functional neuroimaging data involves several steps. 
Spatial pre-processing was performed and the aim was to reduce unwanted 
variance components in the voxel time-series that were induced by movement or 
shape differences among a series of scans.  
The process involved realignment, spatial normalisation and spatial smoothing prior 
to the statistical analysis of the data. This was done for all the images obtained per 
subject.  
The first step was slice time correction, which corrects differences in image 
acquisition time between slices and this was necessary to make the data on each 
slice correspond to the same point in time. Afterwards, the individual brains were 
displayed and reoriented to the anterior commissure as this area is approximately 
located in the centre of the brain and this alignment was chosen to minimise the 
influence of inter-individual anatomical differences (Figure 2.3).  
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Figure 2.3: Alignment process in SPM displaying an image being aligned to 
the anterior commissure.  
The top-left image is coronal with the top (superior) of the head displayed at the top and the 
left shown on the left, (as if the subject is viewed from behind). 
The bottom-left image is axial with the front (anterior) of the head at the top and the left 
shown on the left, (as if the subject is viewed from above). 
The top-right image is sagittal with the front (anterior) of the head at the left and the top of 
the head shown at the top, (as if the subject is viewed from the left). 
The panel on the left gives information about the position of the cross-hair and the intensity 
of the image. The positions are reported in both mm and voxels. The coordinates in mm 
represent the orientation the MNI space. The vx coordinates indicate which voxel is being 
displayed. Below this are a number of boxes that allow the image to be re-oriented and 
shifted.  
The panel on the right shows various details about the image being displayed including 
positional and voxel size information. 
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Realignment (estimate and reslice), also known as motion correction, was then 
carried out and this realigned a time-series of images acquired from the same 
subject and used an image (in this case, first slice was used in descending order) as 
a reference to which all subsequent scans were realigned. The reference scan was 
chosen as a representative scan. The aim was primarily to remove movement 
artefact in fMRI time-series. Normalising the images of the study afterwards was 
performed so that inter-individual averaging becomes a more reasonable statistical 
application and also so that activation sites can be reported according to their co-
ordinates within a standard space and therefore have a precise characterisation of 
functional anatomy. This module spatially normalised the MRI images into a 
standard space defined by the template image (standard reference image) supplied 
by SPM. Spatial smoothing of the realigned and normalised images followed and the 
purpose of this was to deal with the functional anatomical variability that is not 
compensated by spatial normalisation and thus improving the ability of a statistical 
technique to detect true activations. When each image is spatially smoothed, this 
improves the SNR, but also reduces the resolution, thus a balance must be found 
between improving the SNR and maintaining the resolution of the functional image. 
A good estimate of the extent of such a smoothing was given by the full width at half 
maximum in mm of the Gaussian kernel (8 8 8 as the default in SPM). After finishing 
this process, the data could be analysed for statistics.  
At this point, a statistical model for the data was designed. Firstly, statistics 
indicating evidence against a null hypothesis of no effect at each voxel were 
computed and an image was produced. Secondly, the image was then assessed, 
locating voxels where an effect was shown whilst limiting the possibility of false 
positives. A statistical model was designed to obtain model parameters which were 
then used to look for an effect of interest, in this study, the difference between pain-
heat stimuli and baseline and to do this a statistic for each brain voxel that tests for 
the effect of interest in that voxel was calculated and this result was shown as a 
volume of statistic values. The next step was to decide if the volume showed any 
evidence of the effect. As it was not known beforehand where to look for an effect, 
we searched the whole brain and the question was detecting an effect or activation 
at an unknown spatial location. This presented statistical problems related to the 
problem of multiple comparisons as functional analyses involve a number of 
statistical comparisons (Nichols et al. 2005). However, by applying the random field 
theory, a threshold in a set of data was found and the Gaussian model was used to 
eliminate type 1 and type 2 errors (Figure 2.4). The SPM5 combines the GLM and 
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random field theory and allows statistical inference to be made in reference to 
deviations in the BOLD response from the null hypothesis. Estimation using the 
GLM of the condition-specific effects was created by convolving a boxcar sequence 
with the hemodynamic response function.  
 
 
Figure 2.4: Modelling in SPM 
The reason for modelling is to make inferences about effects of interest and to decompose 
data into effects and error and form statistic using estimates of effects and error. 
 
In our experiment we used a block design, as this was adequate for our study since 
this was an early, exploratory research project and it allowed us to use multi-factorial 
designs. The parameters used in this study were included as a flexible factorial 
model. 1st level analysis specified the design matrix, the fMRI data files and filtering 
estimation of GLM parameters and finally was able to analyse the results using 
contrast vectors to produce statistical parametric maps of individual brains for each 
subject. In this step, the conditions were specified and these were different 
according to the protocol used.  
A functional anatomical mask of voxels activated in response to all heat-pain stimuli 
(compared with baseline) in both groups of subjects (CIPN-myeloma and healthy 
volunteers) was created at a voxel-level statistical threshold p<0.001, uncorrected. 
This mask was used as a volume-of-interest for correction for multiple comparisons 
in subsequent between-group contrasts. 
In protocol 1, the conditions specified where: 
The onset (seconds) of timing for the heat-pain stimuli were:  
10 55 105 160 205 260 310 355 405 460 505 555 600 655 705  
The duration of the heat-pain stimuli was 5 seconds. 
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The onset (seconds) of the timing at baseline (temperature set at 32oC) were: 
0 15 60 110 165 210 265 315 360 410 465 510 560 605 660 710  
And the duration (seconds) of the baseline were: 
40 45 50 40 50 45 45 45 50 40 45 40 50 45 50 
 
In protocol 2, there were 3 conditions specified: 
The onset (seconds) of timing for the warm stimuli were:  
30 240 480 
The duration of the heat-pain stimuli was 30 seconds. 
 
The onset (seconds) of the timing at baseline after the heat-pain stimuli 
(temperature set at 35oC) were: 
90 330 570 
The duration (seconds) of the baseline was 150 seconds. 
 
The onset (seconds) of timing for the heat-pain stimuli were:  
60 300 540 
The duration of the heat-pain stimuli was 30 seconds. 
 
For finger tapping, 
The onset for each finger tapping (scans): 
10 30 50 
The duration was 10 scans. 
The design matrix was then produced for each subject.  
2nd level analysis was used for group analysis and the flexible factorial design matrix 
was produced for protocol 1 and 2 (Figure 2.5a and 2.5b). 
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b) 
Figure 2.5: Design matrix after 1st level analysis 
a) For Protocol 1: 5 subjects with duration of heat-pain stimuli for 5 seconds 
b) For protocol 2: 5 subjects with duration of heat-pain stimuli for 30 seconds 
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The results were evaluated using contrast analysis where a contrast was specified 
in terms of weights for each condition. In the pilot study it was decided to use spatial 
extent thresholding (voxel threshold = 55) to exclude isolated or small groups, 
leaving significant clusters of brain activation behind. In view of such small numbers, 
the results were not corrected for multiple comparisons and significantly activated 
regions (p< 0.001, uncorrected) were superimposed onto a T1 average brain. A 
flexible factorial design was implemented to compare brain activation between 
groups.  
For finger tapping, second level analysis was performed using one sample t-test as 
the five healthy volunteers data was grouped together and analysed. 
All activation results were displayed in the anatomical space as defined by the MNI; 
however the convention in the neuroscience community is to report brain locations 
in the standard space of the Talairach and Tournoux atlas (Talairach and Tournoux 
1988). The location of regions with BOLD activity was determined by converting MNI 
(x,y,z) co-ordinates as provided by SPM5 into Talairach co-ordinates, which were 
then interpreted using the Talairach and Tournoux atlas (Talairach and Tournoux 
1988). 
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2.2 Results of pilot study 
Five healthy volunteers were recruited for this pilot study. They all underwent an 
fMRI scan during which two different protocols were tested on the dorsum of the 
right foot. Average group activation results for each protocol were calculated and 
relative activation of the protocol measured.  
 
2.2.1 Pain rating 
Ratings for pain intensity were taken before and after MRI scans. The mean and 
standard deviation (SD) pre-scan rating was 7.6 ± SD 0.9; the mean post-scan 
rating was 7.8 ± SD 1.3. The mean temperature used for both the thermal 
stimulation protocols was 47.4 ± SD 1.8°C. 
After the MRI scans, volunteers were asked about their pain experience. All 
volunteers felt that the stimulation during protocol 2 was more painful than for 
protocol 1 due to a greater unpleasantness associated with the longer stimulus 
duration.  
 
2.2.2 Group analyses of experimental protocols 
The group analysis of the two protocols revealed substantially more regions of 
activation within areas of the pain matrix with protocol 2 compared to protocol 1 
(Figure 2.6). In particular there was extensive activation in the prefrontal cortex 
(PFC), ACC, insular and thalamic areas with protocol 2 at p <0.001 (cluster 
threshold) (Table 2.1). On comparison to protocol 2, protocol 1 did not significantly 
activate any brain regions.  
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Table 2.1: Areas of BOLD fMRI activation after thermal stimulation for protocol 
1 and 2 
Group average data for experimental thermal stimulation protocols are presented. Statistical 
thresholds were P < 0.001, uncorrected for both protocols. 
 
 
 
Neuroimaging Data Talairach co-ordinates 
(x,y,z) 
 t Statistic 
Group analysis for Protocol 1 
No significant brain areas activated 
 
 
Group analysis for Protocol 2 
Rt anterior cingulate 
Lt superior frontal gyrus  
Lt paracentral lobule in SMA 
Rt Medial frontal gyrus  
Rt Middle Frontal Gyrus 
Rt sub-lobar Insula 
Lt inferior frontal gyrus  
Lt anterior cingulate  
Rt Sub-lobar thalamus 
 
 4, 18, 18 
-34, 46, 26 
-2, -30, 66 
20, 44, 12 
36, 40, 12 
26, 28, 6 
-24, 32, -2 
-16, 40, 8 
4, -4, 4 
 
30.99 
24.09 
22.26 
19.93 
19.16 
19.16 
16.82 
16.55 
14.39 
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a) 
 
 
b) 
Figure 2.6: Brain activation in ‘pain matrix’ regions in protocol 2.  
Functional image data is displayed against sections through a canonical single subject T1-
weighted image showing a) coronal view of the right anterior cingulate gyrus and b) sagittal 
view of the left prefrontal cortex. For display purposes, the cluster-level threshold is p<0.001, 
uncorrected, at threshold level (kE) of 369 and 67 respectively. 
 
 
2.2.3 Finger-tapping 
There was significant activation in the motor areas when the finger tapping data was 
analysed (Table 2.2). Although the primary motor cortex was only minimally 
activated, the premotor cortex and SMA were activated bilaterally and there was 
substantial activity in the cerebellum (Figure 2.7). Bilateral somatosensory cortex 
activation was present which reflects the sensory input from the feeling of fingers 
tapping. 
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Table 2.2: Areas of BOLD fMRI activation for finger tapping (group analysis) 
Neuroimaging Data Talairach  
co-ordinates (x,y,z) 
 t Statistic  Z Score 
Lt post central gyrus 
Rt posterior cerebellum 
Rt inferior parietal lobule  
Lt superior temporal gyrus 
Rt post central gyrus 
 
Rt inferior frontal gyrus  
Lt, sub-lobar insula  
Rt medial frontal gyrus  
Lt medial frontal gyrus  
Rt primary motor cortex  
-42, -24, 52 
 
4, -70, -14 
52, -36, 44 
-52, -2, -4 
40, -24, 52 
 
 
48, 44, 10 
 
 
-46, 6, 4 
10, 8, 50 
 
-10, -8,58 
16 -26 56 
301.34 
118.63 
60.63 
56.49 
52.85 
44.89 
27.45 
21.91 
 
20.00 
8.56 
6.16 
5.54 
5.05 
5.00 
4.94 
4.81 
4.41 
4.21 
 
4.13 
3.28 
Group average data for the finger-tapping protocol are presented. The statistical threshold 
was set to P < 0.001, uncorrected. 
 
 
Figure 2.7: Group analysis of activation for finger tapping 
Brain activation highlighted on functional image data displayed against sections through a 
canonical single subject T1-weighted image showing: (a) coronal view of bilateral S1 and 
pre-motor cortex activation and (b) sagittal view activation of cerebellar areas of activation.  
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2.3 Discussion of pilot study 
In this pilot study, our aim was to test the feasibility and efficacy of the designs for 
fMRI related protocols. We have shown that it is feasible to capture brain activation 
in response to noxious thermal stimulation with a CHEPS device using BOLD fMRI. 
Similarly our finger tapping experiment successfully produced functional brain BOLD 
responses of the motor areas.  
 
Pain rating 
A verbally delivered 11-point numerical rating scale was used for pain rating in the 
pilot study. The reason for this choice is that the validity of NRS has been well 
documented and it is extremely easy to administer and score compared to the visual 
analogue scale as this has more practical difficulties (Rebollo 2008). For the main 
study, we decided to use the graphically 11-point numeric rating scale.  
 
Noxious thermal stimulation paradigms 
Group analysis of fMRI data for five volunteers during CHEPS thermal stimulation 
with protocols 1 and 2 showed distinct areas of activation that varied between the 
two protocols. Protocol 1, (5 second thermal pain stimulation durations) revealed no 
significant areas of BOLD activation in regions associated with pain processing. In 
contrast, protocol 2 (30 second thermal pain stimulation) produced significant 
(p<0.001) BOLD activation in many of the regions thought to be involved in the 
processing of painful stimuli. These brain areas included: ACC, PFC regions, the 
SMA and the right insula.  
We concluded that the difference in mean activation between the two protocols was 
due to the duration of stimulation; the 5 second stimulation might be too short 
duration to evoke fMRI response. This pilot data suggested that the greater 
activation was observed with protocol 2; this could also be due to the consequence 
of a more unpleasant pain experience associated with a longer duration of pain 
stimulation. This was supported by the greater pain unpleasantness reported by the 
patients post-scan for protocol 2. 
When we analysed the fMRI images, inter-group comparisons could not be 
effectively accomplished due to our small population size and no significant 
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activation with protocol 1. Based on the overall group neuronal activation produced 
in pain networks with protocol 2, we chose to base the final stimulation design on 
this protocol. It was decided that when our main study was conducted, a protocol 
with more stimulation epochs would be more advantageous in producing a more 
defined neural activation to painful stimulation. We settled on seven separate 
stimulation epochs, which is shown later on in figure 2.17.  
 
Inter-stimulus Interval 
In protocol 1, the inter-stimulus interval was pseudo-randomised to 40, 45 or 50 
seconds, while in protocol 2 it varied between 150, 155 or 160 seconds. The 
purpose of testing varying durations was to try and minimise the ability of patients to 
anticipate pain. None of the volunteers were able to accurately anticipate the 
stimulus onsets in both protocols. We therefore decided to choose a shorter 
duration, which in-turn enabled us to carry out more stimulation epochs in the time 
available.  
 
Finger tapping 
Non-pain related BOLD activation was assessed in this pilot study using finger 
tapping. In the literature, areas of greatest activation, which have motor involvement, 
were shown to be bilateral in S1, cerebellum, bilateral in SMA, prefrontal cortex and 
pre-motor cortices. Similar results for brain activation were obtained in the five 
volunteers. This demonstrated the feasibility of performing a motor task to assess 
non-pain related BOLD activation. Instead of the radiographers telling the subject to 
start and stop finger tapping, we introduced an auditory beep for the main study 
protocol, to which subjects would tap their fingers in time with, stopping and starting 
with the audio cue. The aim was to ensure a more consistent rate and rhythm of 
finger tapping during the main study. 
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2.4 Overview of the main study 
 
2.4.1 Hypothesis 
Peripheral nerve damage caused by chemotherapy in MM results in the alteration of 
the cortical and sub-cortical pain matrix, and this in turn contributes to altered pain 
perception in CIPN.  
 
2.4.2 Primary Aim 
To determine whether differences exist in central pain processing pathways as 
assessed by fMRI during noxious thermal stimulation between MM patients with 
chemotherapy-induced peripheral neuropathy and healthy volunteers.  
 
2.4.3 Secondary Aims 
1) To determine the degree to which quantitative sensory testing predicts 
presence and severity of CIPN. 
2) To describe the QoL of patients with MM and chemotherapy-induced 
peripheral neuropathy, using questionnaires.  
 
The study was conducted in compliance with the EU GCP directive and the ICH 
Good Clinical Practice, and formally approved by Sheffield Teaching Hospitals NHS 
Foundation Trust R&D Department following local research ethics committee review. 
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2.5 Methods and Materials 
The study sample comprised of patients with MM who developed CIPN (n=12) and 
healthy volunteers (n=12). Patients were identified from the haematology clinics and 
the haematologist explained this study. Afterwards, patient information sheets 
(Appendix 1) were sent to all subjects. This was followed up a week later where I 
called the patient to answer any questions and if willing to participate, arrange their 
study visit. On the day they attended, subjects completed written consent forms. 
Healthy volunteers were recruited by having posters across the Royal Hallamshire 
Hospital and on contact a healthy volunteer information sheet was sent out 
(Appendix 2). A week later this was followed by a phone call by myself to check if 
they were willing to participate and arrange their study visit.  No incentive was given 
to patients or healthy volunteers except that travel expenses were paid for.  
 
Criteria for subject inclusion for patients with MM 
• Age less than 70 years 
• Treated with one of the anti-myeloma therapies 
o Thalidomide 
o Bortezomib 
o Vincrisitine 
• Neuropathic pain for at least six months duration 
• Pain of ≥7/10 on a graphical numerical rating scale 
• Willing to discontinue analgesics and co-analgesic (anti-depressants and 
anti-epileptics) medication 48 hours before fMRI if possible 
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Criteria for subject exclusion  
• Presence of any major psychiatric disorder 
• Standard MR exclusion criteria 
• Claustrophobia 
• Neuropathy caused by other medical conditions 
 
2.5.1 Study visit for neuropathy assessment 
 
2.5.1.1 Quantitative measures 
All subjects underwent standard assessments of neuropathy. This included 
completion of a case report (Appendix 3) form encompassing a detailed clinical 
history and examination followed by comprehensive neurophysiological testing.   
 
2.5.1.1.1 Neurophysiological	  testing	  
Quantitative sensory testing 
Quantitative sensory testing refers to a set of methods that extend the traditional 
neurological examination of somatosensory function and the aim of QST is to 
provide parameters for sensory loss (small and large fibre functions) and sensory 
gain (hyperalgesia, allodynia, hyperpathia) (Rolke et al. 2006). The main 
advantages of QST over standard bedside examination would be greater precision 
in assessing the functionality of the somatosensory systems. The limitations of QST 
are that firstly there is no general agreement on standard procedures and every 
sensory function may be assessed in a variety of ways and even the same test 
instrument may give different outcomes due to a variation of stimulation parameters. 
Variability was limited/improved by standardising the technique Secondly, to perform 
all these tests take a long time and would not be possible to perform in a routine 
clinic. 
The QST assembles a comprehensive list of robust and validated short form tests 
representing measures of all relevant sub-modalities of the somatosensory system, 
namely: 
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cold and warm detection thresholds; mechanical detection threshold; mechanical 
pain threshold and mechanical pain sensitivity; dynamic mechanical allodynia and 
vibration detection threshold.  
The Aβ-fibre function is represented by the mechanical detection thresholds (MDT) 
and vibration detection thresholds (VDT). The Aδ-fibre function is represented by the 
cold detection threshold (CDT) and the mechanical pain threshold for pinprick 
stimuli. The C-fibre function is represented by the warm detection threshold (Rolke 
et al. 2006). 
The thermal tests and vibration detection threshold were performed using Computer 
Assisted Sensory Evaluation IV (CASE IV) (W.R. Electronics, Stillwater, MN, USA) 
(Figure 2.8). Cold and warm detection thresholds were measured. Heat pain 
detection thresholds were assessed using a porcelain block device, through which 
pre-defined temperature stimuli were applied to the dorsum of the right foot. The 
thermal stimulator uses a 4-degree-per-second ramp up and down, and is typically 
operated in a range from 9 to 49°C, with accuracy of ± 0.25°C. Patients were 
instructed to rate the randomised heat pain intensities using a numeric rating scale. 
The NRS is a linear 11 point scale (0-10) which was used consistently in this study. 
The CDT of right foot was also assessed. Participants were asked to respond to 
whether randomised temperatures below baseline skin temperature were felt using 
a yes/no response buttons. Results were entered and recoded by the system.  
 
 
Figure 2.8: Computer Assisted Sensory Evaluation (CASE) IV system 
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With the CASE IV system, a statistically validated set of age adjusted normative 
data is provided. Several factors affect the length of testing: the time required to 
explain the test to the patient, the speed in which the patient makes decisions, the 
alertness of the patient and the number of stimuli needed to find the threshold (WR 
Medical Electronics Co 2005). For thermal testing the time also depends on the level 
of sensitivity because larger stimulus magnitudes (longer times) are needed for 
insensitive patients. 
With regards to vibration detection threshold, an algorithm known as one time period 
with 4, 2, 1 stepping system was used. This was performed using a 30g preloading 
weight at the location of the vibrating stylus. This algorithm starts at a baseline level, 
which then increases in stimulus level if patients are insensitive. The VDT of the 
dorsum of right big toe proximal to the nail bed was assessed. Participants’ 
responses to vibration frequencies were again recoded using yes/no response 
buttons. 
The QST measurements using the CASE IV System were expressed in the form of 
percentiles. Values were expressed as percentiles, where >99th percentile was 
considered to be abnormal. The CASE IV system works by using 25 standardised 
stimulation levels, which are known as just noticeable differences (JND) for patient 
testing and analysis. The model of JND steps is based on the fact that a sensitive 
person can detect fine differences between two levels of stimulation, whereas an 
insensitive person cannot. These differences of <1 JND steps are difficult to 
distinguish, thus one JND step is the smallest difference presented to patients. For 
the vibration and cooling detection thresholds an algorithm known as one time 
period with 4, 2, 1 stepping is used by the system. This algorithm starts at a baseline 
level, which then increases in stimulus level if patients are insensitive. The 
increase/decrease in stimuli level alters, beginning with JND of 4, decreasing by 
JND of 2 and increasing by a step value of 1, until the individual’s cooling and 
vibration thresholds are determined. Because the 4, 2, 1 rule eliminates additional 
trials at unnecessary steps, the test is accurate, reliable, and time-efficient. The test 
is started at a baseline level: for vibration stimuli, the baseline is 0 micrometres of 
displacement; for cooling stimuli, the baseline is set to 30°C; for heat-pain the 
baseline is set to 34oC. For warming stimuli, the maximum temperature is limited to 
50°C. For cooling stimuli, the minimum temperature was 8°C. (WR Medical 
Electronics Co 2005).  
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2.5.1.1.2 Clinical	  Neuropathy	  Assessments	  
When testing with the monofilament, cotton wool and vibration fork, the first test was 
performed at the subject's chest (over sternum) so the subject could compare the 
quality of the sensation evoked by each test stimulus as the site of neuropathy was 
expected to have altered sensation.  
The mechanical detection threshold was measured at the plantar surface of the big 
toe and the pad of the index finger using a standardised nylon Semmes-Weinstein 
monofilament. It delivers a 10-gram force when it applied perpendicularly to the 
skin’s surface and buckles. The contact area with the skin is uniform to avoid sharp 
edges that would facilitate nociceptor activation. Each subject was instructed to 
close their eyes during this test and were asked if they could feel the stimulus and to 
identify the location of the filament (Ruppert M et al. 2004; Felix and Widerstrom-
Noga 2009).  
Mechanical pain sensitivity was assessed using a pinprick stimulus to obtain a 
stimulus response function for pinprick-evoked pain. Subjects were asked if they felt 
the pinprick and whether it was painful. This test was designed to detect pinprick 
hyperalgesia. Dynamic mechanical allodynia was assessed using a light tactile 
stimulator (innocuous stimulus), a cotton wool tip fixed to an elastic strip. The tactile 
stimulus was applied with a single stroke of approximately 2 cm in length over the 
skin.  
The Neuropathy Impairment Score – Lower Limbs plus 7 tests (NIS (LL) +7), 
provides a composite measure of the neuropathic impairments of lower limbs. This 
was used and is discussed later under section 2.5.1.1.5. 
 
2.5.1.1.3 Nerve	  Conduction	  Studies	  (NCS)	  
The use of NCS is to help localise the site or level of the lesion; determining if the 
pathology involves the peripheral nerve, neuromuscular junction, plexus, nerve root 
or anterior horn cells; help identify the pathophysiology, in particular distinguishing 
axonal loss from demyelination; diagnose mononeuropathies and diagnose more 
diffuse processes. Nerve conduction studies are also used to monitor nerve function 
over time to determine disease progression and to assess the complications of 
treatment (eg. chemotherapy). Nerve conduction studies correlate well with the 
morphological changes seen in nerve biopsies (Veves et al. 1991) and with clinical 
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testing and examination (Redmond et al. 1992; Feki and Lefaucheur 2001). These 
tests measure sensory and motor nerve function transmitted by impulses from large 
(myelinated) fibres that make up only 25% of the total nerve fibre population. 
Electrophysiological tests are therefore not sensitive to small fibre damage (Dyck et 
al. 2003). Therefore, NCS cannot be used as the only tests in the investigation of 
CIPN (Cleeland et al. 2010). 
The parameters most commonly tested in NCS are peripheral nerve conduction 
velocity (NCV), summated amplitude, conduction latency and motor nerve F-Wave 
latency. In the upper limb, the median and ulnar nerves; sensory and motor are 
usually tested. In nerve fibre demyelination, there is a decreased latency and NCV 
whilst in nerve fibre loss there is a reduction in peripheral nerve summated 
amplitudes.  
Several factors alter the rate of nerve conduction. Most important in a clinical 
laboratory are temperature of the tested nerve, normal variations among nerves and 
nerve segments, and patient age (Kimura 1984). It is best to conduct studies in a 
warm room with the temperature maintained between 21 and 23°C. If the skin 
temperature falls below 34°C, the limbs should be warmed. Sensory and motor 
conduction velocities are substantially slower in the legs than in the arms. Longer 
nerves may generally conduct more slowly than shorter nerves and conduction 
velocity is generally faster in the proximal than in the distal segments of a nerve.  
Common sources of errors include the spread of the stimulating current to a nerve 
not under study, eliciting an unwanted potential from distant muscles; the presence 
of an anatomises between the nerves or anomalous innervations and errors inherent 
in the measurement of nerve length and conduction time (Kimura 1984). 
I attended training sessions and performed all the nerve conduction studies. 
Training sessions included a regular attachment with a clinical consultant 
neurophysiologist at the Royal Hallamshire hospital and also an attachment to the 
Diabetes centre where nerve conduction studies were being carried out with a 
Consultant Diabetiologist (with neuropathy assessment expertise). Competency was 
established prior to assessing study subjects by performing repeat nerve conduction 
measurements on 20 normal controls to ensure reproducibility of methods precision 
of results and minimise intra-examiner variability had been achieved. 
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Nerve conduction equipment 
The nerve conduction study was performed using the Medelec, Synergy Oxford 
Instruments, Oxford UK. The temperature was maintained to at least 31±1°C during 
the entire nerve conduction study. Room temperature was around 24±2°C. Skin 
preparation (cleaning the skin with alcohol and then abrading the skin with a mild dry 
abrasive material) was performed prior to starting nerve conduction studies to 
minimise shock artefact and improve the quality of the study. The ground electrode 
was placed between the active recording electrode and the stimulating electrode. 
The strength of the stimulus was increased in steps until a maximum response was 
obtained. When maximum response was obtained the stimulator was increased by 
5-10% more to make sure the response was supramaximal.  
Measurements 
All distances were measured to the nearest 1.0mm. Extreme care was taken to use 
the same distance for each subsequent test. All waveform measurements were 
made at the sweep speed and display sensitivity at which the waveform was 
acquired.  
Sensory NCS were performed by electrical stimulation of a peripheral nerve and 
recording from a purely sensory portion of the nerve. Sensory latencies were 
calculated in milliseconds (ms). Sensory amplitudes were much smaller than the 
motor amplitudes, usually in the microvolt (µV) range. The sensory NCV was 
calculated based upon the latency and the distance between the stimulating and 
recording electrode (Figure 2.9). 
 
Figure 2.9: Sensory Wave Form 
S= Stimulus point, T = Take off point, P = Peak. The time latency from S to T is typically 
about 3 milliseconds. 
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Motor NCS were performed by electrical stimulation of a peripheral nerve and 
recording from the muscle supplied by the stimulated nerve. The electrical impulse 
was measured from the time it travelled from the stimulation to the recording site; 
this is latency and was measured in ms. The amplitude (size of the response) was 
also measured in millivolts (mV). By stimulating two different locations along the 
same nerve, the NCV across different segments was determined. The distance 
between the different stimulating electrodes and the difference in latencies was 
calculated. 
 
Sural Nerve Sensory Nerve Conduction Study 
The sural nerve innervates the lateral and the posterior third of leg; the lateral 
aspect of foot & heel, and the lateral portion of the ankle. This nerve, formed by the 
junction of the medial sural cutaneous with the peroneal anastomotic branch, 
passes downward near the lateral margin of the tendo calcaneus, lying close to the 
small saphenous vein, to the interval between the lateral malleolus and the 
calcaneus. The sural nerve passes down to the posterolateral side of leg and onto 
the dorsal aspect of lateral side of foot, giving rise to lateral calcaneal branches 
(Gray and Standring 2005). 
The right sural nerve was examined in the left side-lying position. The active 
recording electrode was placed immediately behind the lateral malleolus. The 
ground electrode was placed between the stimulating and recording electrodes. The 
sural nerve was stimulated 14.0cm from the active recording electrode in the midline 
of the posterior lower leg (Figure 2.10). 
 
 
Figure 2.10: Stimulation of the right sural nerve  
 
This shows the active recording electrode placed behind the 
lateral malleolus and the nerve was stimulated in the midline of 
the posterior lower leg 
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The sweep speed was set at 1.0ms/division. The amplifier gain/display sensitivity 
was set at 10µV/division. When a supramaximal response was obtained, this 
marked with the cursors. The distance between the active electrode and the site of 
the cathode stimulating electrode were measured and recorded. 
 
Peroneal Motor Nerve conduction Study 
The deep peroneal nerve begins at the bifurcation of the common peroneal nerve, 
courses anteriorly around fibula and passes obliquely forward beneath the extensor 
digitorum longus. It comes into relation with the anterior tibial artery and supplies 
anterior compartment muscles where it then descends to the front of the ankle joint 
and divides into a lateral and a medial terminal branch. The terminal lateral branch 
curves laterally and supplies the extensor digitorum brevis, extensor hallucis brevis, 
the adjacent tarsal and tarsometatarsal joints and occasionally, the second and third 
dorsal interosseous muscles. The medial terminal branch divides into two sensory 
nerves that supply the adjacent sides of the great and second toes with sensation 
(Gray and Standring 2005). 
The nerve was stimulated at the ankle and the fibula head at the knee. The active 
electrode was placed over the centre of the palpable portion of the extensor 
digitorum brevis muscle on the lateral aspect of the dorsum of the foot. The 
reference electrode was placed over the fifth metatarsal-phalangeal joint. For the 
ankle stimulation site, the cathode was placed on the anterior aspect of the ankle, 
lateral to the tendon of the tibialis anterior muscle (8cm from the active electrode). 
For the fibular head stimulation site, the cathode was placed slightly posterior and 
inferior to the fibula. The distance between the active recording electrode and the 
cathode of the stimulator was measured. The distance between: 1) the active 
electrode at the ankle and the site of the stimulating cathode electrode; 2) the ankle 
and fibula head. 
 
 Tibial motor nerve conduction study 
The tibial nerve is the larger of the two divisions that form the sciatic nerve. It 
originates from L4 through S3 roots and travels as part of the sciatic through the 
posterior thigh under the long head of the bicep femoris. The tibial nerve passes 
through the popliteal fossa to pass below the arch of soleus. It supplies the motor 
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innervation of the posterior compartment of the leg and all foot muscles (except the 
extensor digitorum brevis). Its motor distribution in the leg includes the 
gastrocnemius, plantaris, soleus, popliteus, tibialis posterior, flexor digitorum langus 
and flexor hallucis longus. The nerve is superficial as it passes vertically down the 
middle of the popliteal fossa. It lies lateral then crosses superficially to lie medial to 
the popliteal artery. As it leaves the fossa, it gives off the sural nerve supplying the 
posterior leg. Its course then becomes deep as it passes between the 
gastrocnemius and soleus muscles, under the tendinous arch formed by the soleus, 
lying on the posterior surface of the tibialis posterior muscle and then on the tibia. It 
again becomes superficial at the upper end of the medial malleolus where it passes 
behind it and in front of the calcaneous tendon. Its terminal course takes it under the 
flexor retinaculum (posterior tarsal tunnel). The medial calcaneous branches 
perforate the flexor retinaculum and supply the skin of the heel and medial side of 
the sole of the foot. Under the retinaculum the nerve divides into medial and lateral 
plantar branches and innervates the plantar aspect of the foot (Gray and Standring 
2005). 
The active electrode was placed over the centre of the abductor hallucis muscle 
anterior and inferior to the navicular tubercle. For the distal stimulation site at the 
ankle, the cathode was placed on the medial aspect of the ankle 8.0cm proximal to 
the active recording electrode. For the proximal stimulation site, the cathode was 
placed in the middle of the popliteal fossa. The distance between the active 
recording electrode at the ankle and the site of the stimulating electrode were 
measured. The distance between the ankle and the knee were also measured. 
 
2.5.1.1.4 Autonomic	  testing	  
There is a variety of tests performed for specific autonomic testing mainly including 
cardiovagal or parasympathetic test, adrenergic or sympathetic tests and sudomotor 
tests (Biaggioni 2011). Computer assisted autonomic function tests were performed 
in this study to assess if autonomic neuropathy was present in patients with CIPN. 
The simplest way to measure autonomic function is by studying the cardiovascular 
system. A 3–lead electrocardiogram (ECG) was recorded after the subject had 
rested supine for five minutes (Burdick Eclipse LE Electrocardiograph, Burdick Inc., 
Milton, Wisconsin USA) and the ECG leads were connected to an ATARI 360S 
microprocessor on a computer. Both were equipped with analogue to digital signal 
converters and QRS algorithm recognition software sampling at 600Hz. 
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Assessment of the parasympathetic and sympathetic autonomic function was 
conducted by measuring the heart rate variability (HRV). This involved measuring 
the beat-to-beat variation in heart rate and was accomplished by measuring the R-R 
interval variation (Figure 2.11): 
  
Figure 2.11: The R-R intervals on an ECG trace  
 
i) At rest, heart rate was obtained after the subject had rested supine for five 
minutes, 
ii) During deep breathing where patients were asked to take slow deep breaths 
at a rate of six cycles/min. Results were expressed as the ratio of the peak 
inspiratory heart rate to the lowest expiratory heart rate during a single cycle 
(O'Brien et al. 1986), 
iii)  During valsalva manoeuvre where patients were asked to exhale into a tube 
connected to a mercury sphygmomanometer and maintain a pressure of 
40mmHg for 15 seconds. On relaxation, ECG recording continued for a 
further 45 seconds. The valsalva ratio was calculated as the ratio of the 
highest heart rate achieved during the manoeuvre to the lowest heart rate 
during the relaxation period (Ewing and Clarke 1982). 
iv) Lying-standing. The peak heart rate (due to sympathetic activation) occurs at 
approximately the 15th beat after standing; as vasoconstriction occurs and 
blood pressure rises towards baseline, heart rate falls, reaching a nadir at 
approximately the 30th beat (Ewing and Clarke 1982). Therefore, the 
maximum and minimum R-R ratio is defined as the longest R-R interval 
during beats 20-40 divided by the shortest R-R interval during beats 5-25. 
Orthostatic hypotension was assessed by measuring the postural fall in blood 
pressure using a mercury sphygmomanometer 60 seconds after standing and 
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sympathetic autonomic failure was diagnosed when the level fell by at least 20 
mmHg. 
Physiologically, heart rate variations should be present at rest. In parasympathetic 
denervation, these variations are lost. Normally, heart rate changes according to 
breathing, standing from the lying/sitting position, increased intra-thoracic pressure 
and sympathetic activation. O’Brien et al. have standardised a number of simple 
tests to evaluate autonomic nerve function (O'Brien et al. 1986) and age-related 
normative values have been established. 
Autonomic neuropathy may also affect small fibres in the periphery, specifically 
those innervating blood vessels and sweat glands. Quantitative sudomotor axon 
reflex testing is a recognised test in the evaluation of small fibre neuropathy 
(England et al. 2009); however this was not performed in this study.  
 
2.5.1.1.5 Assessment	  Tools	  
Total Neuropathy Score (reduced version) 
The Total Neuropathy Score (reduced version) TNSr, has been used to stage 
neuropathy in MM patients and this was used in this study (Table 2.3) (Cavaletti et 
al. 2007). A composite score (0-32) is used and it evaluates motor and sensory 
symptoms and signs, quantitative determination of the pinprick and vibration 
perception threshold, and the neurophysiological examination of one motor and one 
sensory nerve in the leg. 
The presence of neuropathy was defined as TNSr >2. A higher score indicates 
worse peripheral neuropathy. 
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Table 2.3: Total Neuropathy Score (reduced version) 
Parameter 0 1 2 3 4 
Sensory 
symptoms 
None Symptoms 
limited to 
finger & toes 
Symptoms 
extend to 
ankle & wrist 
Symptoms 
extend to 
knee & 
elbow 
Symptoms 
above knee & 
elbow, 
functionally 
disabling 
Motor 
symptoms 
None Slightly 
difficult 
Moderately 
difficult 
Require 
help/ 
assistance 
Paralysis 
Pin 
sensibility 
Normal Reduced in 
fingers & 
toes 
Reduced in 
ankle & wrist 
Reduced in 
knee & 
elbow 
Reduced to 
above elbow & 
knee 
Vibration 
sensibility 
Normal Reduced in 
fingers & 
toes 
Reduced in 
ankle & wrist 
Reduced in 
knee & 
elbow 
Reduced to 
above elbow & 
knee 
Strength Normal Mild 
weakness 
Moderate 
weakness 
Severe 
weakness 
Paralysis 
Tendon 
reflexes 
Normal Ankle reflex 
reduced 
Ankle reflex 
absent 
Ankle reflex 
absent, 
others 
reduced 
All reflexes 
absent 
Sural Nerve 
amplitude 
Normal/ 
reduced 
to <5% 
LLN 
76 to 95% of 
LLN 
51 to 75% of 
LLN  
26 to 50% of 
LLN 
0 to 25% of LLN 
Peroneal 
Nerve 
amplitude 
Normal/ 
reduced 
to <5% 
LLN 
76 to 95% of 
LLN 
51 to 75% of 
LLN  
26 to 50% of 
LLN 
0 to 25% of LLN 
ULN = Upper limit of normal; LLN = Lower limit of normal 
 
Neuropathy Impairment Score (NIS) 
A group of muscles both right and left sides were evaluated for weakness:  
1 - 25% weak; 2 - 50% weak; 3 - 75% weak; 3.25 - movement against gravity; 3.5 - 
movement with gravity eliminated; 3.75 - muscle flicker without movement; and 4 - 
paralysis.  
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Muscle stretch reflexes were graded as: 
normal, 0; decreased, 1; or absent, 2.  
Touch-pressure, vibration, joint position and motion, and pinprick were graded on 
the dorsal surface at the base of the nail of the terminal phalanx of the index finger 
and great toe as: 
 normal, 0; decreased, 1; or absent, 2 (Dyck et al. 1997).  
Pinprick was assessed with a straight pin, vibration was also using 128Hz tuning 
fork at the ankle and first metatarsal-phalangeal joints. The tuning fork was struck 
and then held to the skin. The examiner timed how long the vibration was perceived. 
Less than 10 seconds was considered impaired. Joint motion was tested by moving 
the terminal phalanx of the index finger and great toe, evaluated by the responses to 
ten questions. The neurological examination from which the NIS of the lower limbs 
(Dyck and Thomas 1999) was derived was used to calculate the neuropathy 
composite score for the Dyck’s score (Dyck et al. 1997; Dyck et al. 2003). 
 
Dyck’s score 
There is no reliable marker that could be used to test for CIPN. The Dyck’s 
neuropathy score, validated for diabetic peripheral neuropathy, provides an 
indication of neuropathic impairment in the form of a composite neuropathy score 
(Table 2.4). It looks at quantitative sensory testing including nerve conduction 
studies and autonomic nerve function together with clinical examination and 
reported symptoms (Dyck et al. 1997). The neuropathy impairment score for the 
lower limbs plus seven tests (NIS lower limbs+7) is considered to be the gold 
standard for the detection of diabetic neuropathy (Dyck and Thomas 1999). It 
measures muscle weakness, reflex loss, sensory loss and nerve conduction 
abnormalities in the lower limbs, and autonomic heart rate abnormalities during 
deep breathing. The Dyck’s staging criteria for scoring neuropathy is: ≥4.5 = clinical 
neuropathy; 1 – 4.5 (with experimental evidence of nerve dysfunction) = sub-clinical 
neuropathy and 0 = no neuropathy. 
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Table 2.4: Calculating Dyck’s neuropathy composite score 
(Dyck et al. 1997) 
 
1. Score items 17-24, 28-29 and 34-37 of NIS (lower limbs). The vibration score was 
substituted with percentile abnormality* of VDT for each great toe for the clinical 
vibration sensation point score (as calculated using CASE IV). 
2. Add the transformed points for percentile abnormality HRV of deep breathing 
3. Summate transformed points for the percentile abnormality* of five attributes of 
nerve conduction studies for lower limbs:  
- Peroneal nerve amplitude, velocity and latency 
- Tibial nerve latency 
- Sural nerve amplitude  
*Transformed points for percentile abnormality are defined as the values corresponding to 
confidence intervals using the standard deviation of normal value < 95th = 0; ≥ 95th – 99th = 1; 
≥ 99th – 99.9th = 2; ≥ 99.9th = 3 (≥5th = 0 to ≤0.1th = 3) (appendix 4). 
For point 3: Summate transformed points for percentile abnormality of the five attributes of 
nerve conduction of lower limb: divided by the number of attributes with obtainable values 
(*motor nerve conduction velocity and distal latency cannot be estimated when compound 
muscle action potential is 0), multiply by five (the number of attributes), and add this number 
to the global score. 
 
2.5.1.2 Qualitative measures: Questionnaires  
Health-related quality of life is an important assessment of the impact of disease or 
the related treatment on the patient’s physical, social and psychological functioning. 
Consistently, studies have reported reduced QoL in patients with neuropathic pain 
(Jensen et al. 2007). Ensuring accurate and reliable reporting of the health-related 
quality of life and pain, several assessments were used. 
 
2.5.1.2.1 EORTC	  QLQ-­‐C30	  and	  the	  myeloma	  module	  QLQ-­‐MY20	  
EORTC QLQ-C30 is a 30 item self-reporting questionnaire developed to assess the 
QoL of cancer patients. It contains five functional subscales (role, physical, 
cognitive, emotional and social functioning) as well as several symptom scales 
(Aaronson et al. 1993). The QLQ-MY20 module is used to gain extra information 
about health-related QoL in patients with MM, particularly issues around body image 
and future perspective. It is recommended that the QLQ-C30 and QLQ-MY20 are 
used together to measure QoL in trials in MM (Cocks et al. 2007). These health-
related quality of life assessments are important for evaluating the benefits against 
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the toxic effects of the treatment and this is especially important in relapsed MM 
patients whose survival is limited.  
 
2.5.1.2.2 Self-­‐report	  Leeds	  Assessment	  of	  Neuropathic	  Symptoms	  and	  Signs	  
(s-­‐LANSS)	  	  
This is a self-reporting screening tool that aims to identify pain of predominantly 
neuropathic origin, as distinct from nociceptive pain (Bennett et al. 2005). The 
domains assessed are: prickling/tingling, mottled/red/pink skin, sensitive skin, 
bursting/sudden pain, hot/burning, allodynia, and numbness/tenderness. If a patient 
registers 12 or more on this scale then there is a strongly indicative that neuropathic 
pain is present to some degree.  
 
2.5.1.2.3 Neuropathic	  Pain	  Scale	  (NPS)	  
This scale is designed to assess distinct pain qualities associated with neuropathic 
pain (Galer and Jensen 1997). The NPS is a self-report scale for measuring 
neuropathic pain. It consists of 10 distinct questions, which ask about the intensity 
and quality of the patient's pain: two global (intensity and unpleasantness) and eight 
specific ratings that assess both pain quality (sharp, dull, cold, hot, sensitive and 
itchy) and pain location (surface and deep). In validation studies, it has been found 
to have a good predictive power in discriminating between subgroups of patients 
with neuropathic pain (Jensen et al. 2006; Rog et al. 2007). The patient rates the 
dimensions on a numerical scale 0-10. The NPS has been used in several 
neuropathic pain double blind trials mainly as a secondary outcome, sometimes as a 
primary outcome and also used in reporting effects of treatments on specific items 
(Haanpaa et al. 2011). 
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2.5.1.2.4 Neuropathy	  Total	  Symptom	  Score	  (NTSS	  6)	  
The NTSS-6 was designed to evaluate individual neuropathy sensory symptoms in 
patients with diabetes mellitus and diabetic peripheral neuropathy. The NTSS-6 
showed internal consistency, test-retest reliability, and construct validity (Bastyr Iii et 
al. 2005). The dimensions are deep aching pain, burning pain, pickling/tingling 
sensation, numbness/dead feeling, lancinating/ electrical shock-like pain and 
allodynia. Each symptom is graded on intensity and frequency (Figure 2.12).  
 
Figure 2.12: NTSS-6 Scoring sheet 
The scores for the NTSS-6 range from 0 to 21.96. A score >0 indicates the presence of >1 
sensory symptom. Clinically significant symptoms are defined as an NTSS-6 total score >6 
points (either 6 symptoms with at least mild intensity and occasional frequency, or 3 
symptoms with at least moderate intensity and occasional frequency, or 2 symptoms with 
severe intensity and occasional frequency). We used the NTSS-6 in our study to try and 
identify descriptions of sensory symptoms experienced by myeloma patients. 
 
2.5.1.2.5 Chronic	  Pain	  Acceptance	  Questionnaire	  (CPAQ)	  
The CPAQ provides information on how chronic pain affects patients. It shows the 
level of acceptance of their chronic pain and their focus on participation in activities, 
the pursuit of personally relevant goals and the relative absence of attempts to 
control or avoid pain, respectively. The CPAQ was originally constructed as part of 
the development of an acceptance oriented treatment approach for pain patients. A 
revised 20-item version of the instrument with two subscales has shown 
adequate reliability and validity (Vowles et al. 2008). Data regarding the CPAQ 
indicated fully adequate internal consistency with Cronbach’s alpha of 0:85. 
(McCracken et al. 2004). The two subscales describe: the degree to which one 
engages in life activities regardless of pain (activity engagement, 11 items), and 
willingness to experience pain, which is the inverse of engaging in behaviours to 
limit contact with pain (pain willingness, 9 items). A single total score was calculated 
on the basis of the nine reverse-keyed items and the remaining 11 items measuring 
activities engagement. The CPAQ is rated on a 0 (never true) to 6 (always true). The 
Page | 127  
 
CPAQ total score ranges from 0 to 120, with a higher score indicating higher 
acceptance of pain. Two components were derived for scoring: activities 
engagement and pain willingness. A single total score was calculated on the basis 
of the nine reverse-keyed items and the remaining 11 items measuring activities 
engagement. 
Activity engagement (pursuit of life activities regardless of pain). Items – 1, 2, 3,5, 6, 
8, 9, 10, 12, 15, 19.(2) 
Pain willingness (recognition that avoidance and control are often unworkable 
methods of adapting to chronic pain) reverse score items – 4, 7, 11, 13, 14, 16, 17, 
18, 20 
 
2.5.1.2.6 Pain	  Catastrophizing	  Scale	  (PCS)	  
This is a 13-item self-report scale whose items are rated on a 5-point Likert-type 
scale ranging from 0 (not at all) to 4 (always) the degree to which they experienced 
each of 13 thoughts or feelings when in pain. This has three different categories to 
assess negative thinking styles related to pain: rumination, magnification, and 
helplessness. Coefficient alphas were .87, .60, and .79 for the rumination, 
magnification, and helplessness subscales, respectively and for the total PCS was 
.87(Sullivan and Bishop 1995). The PCS total score is computed by summing 
responses to all 13 items. The PCS total scores range from 0 – 52. The PCS 
subscales are computed by summing the responses to the following items:  
Rumination: Sum of items 8, 9, 10, 11 
Magnification: Sum of items 6, 7, 13 
Helplessness: Sum of items 1, 2, 3, 4, 5, 12 
The PCS proves to be a useful research instrument in efforts to understand the 
psychological processes that lead to heightened physical and emotional distress in 
response to aversive stimulation and it is a reliable and valid measure of 
catastrophising. 
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2.5.1.2.7 Hospital	  Anxiety	  and	  Depression	  Score	  (HADS)	  
To determine the presence of depression and anxiety, the HADS is frequently used 
(Zigmond and Snaith 1983). It is a validated 14-item questionnaire measuring 
anxiety and depression in two separate subscales. This provides a simple yet 
reliable tool and measures levels of psychological functions using two subscales, 
which can be added together to give a measure of overall psychological distress. 
Cronbach’s alpha has ranged from 0.80 to 0.93 for the anxiety subscale and 0.81 to 
0.90 for the depression subscale (Herrmann 1997).  
 
Neurophysiological testing, total neuropathy scoring and qualitative assessment was 
performed to be able to grade, score and report neuropathic dysfunction, impairment 
and symptoms using standard and reproducible approaches so that results were 
consistent, quantitative and useful. 
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2.6 Study visit for functional Magnetic Resonance 
Imaging  
 
Prior to imaging, the intensity of dynamic heat stimulus necessary to generate pain 
response of at least 7cm on a 10cm numerical rating scale (Figure 2.13) was 
identified at two anatomical sites: the dorsum of the foot and upper anterior aspect 
of the thigh. This was done due the high inter-individual differences of skin thickness 
and susceptibility to pain. Patients were asked to verbally rate their level of 
perceived pain intensity on a graphical numerical scale from 0 to 10. 
 
 
Figure 2.13: Graphical numerical rating scale 
 
The foot was chosen as this was the area where the patients with chemotherapy-
induced neuropathy had the pain; whilst the thigh was an area where patients had 
no pain as shown in figure 2.14, so this will be causing purely acute pain. 
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a)
 
b) 
 
Figure 2.14: CHEPS thermode application to right foot and right thigh 
 
All heat-pain stimulation was applied to the right hand side of the body for each 
participant. The experimental thermal stimulus was delivered using a contact heat 
evoked potential device (CHEPS), which rapidly delivers heat pulses with adjustable 
peak temperatures. This stimulus was applied using an MR-compatible, 
commercially available computer controlled peltier-type thermode (Medoc Pathway 
System, Medoc Ltd, Ramat Yishai, Israel). The foot was chosen as the primary 
stimulation area as this is the anatomical location where patients with CIPN develop 
pain-related symptomatology. The thigh was the secondary stimulation site. As this 
site was not being associated with neuropathic pain, this area was chosen as a 
potential control site. 
Prior to each subject entering the MR scanner, pain thresholds were ascertained at 
both thermode placement sites. At these and subsequent temperature iterations, 
each subject reported their subjective pain status with reference to a 0-10 point 
numeric rating (Likert) scale (where 0 represented no pain and 10 represented the 
most extreme pain). The temperature was increased or decreased by 0.5-2ºC until a 
pain score of 7/10 was identified. The maximum temperature at either site was set at 
47.9ºC (Figure 2.15). 
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Figure 2.15: Heat pain rating score 
 
 
All MR imaging was performed in the Academic Unit of Radiology, Royal 
Hallamshire Hospital. Data was acquired at 3 Tesla (Achieva 3.0T, Phillips Medical 
Systems, Holland). The scanning protocol included acquisition of standard T1-
weighted, 3-dimesional and T2-weighted, 2-dimensional anatomical images to 
screen for overt pathology prior to two fMRI runs. Whole-brain fMRI datasets were 
acquired on each subject using standard technique. This comprised the use of a 
single-shot, T2*-weighted, gradient-recalled, echo-planar imaging sequence: time to 
echo (TE)=35ms; time to repeat (TR)=3000ms; SENSE-encoding factor=1.5 to 
acquire 35 contiguous, trans-axial slices of thickness 4mm, having an in-plane 
resolution of 1.8mm x 1.8mm at every functional imaging ‘time-point’ or dynamic. All 
the subjects were instructed to lie motionless throughout the scanning procedure, 
aside from the requested finger tapping task. Additional foam pads within the head 
coil helped secure head fixation and prevent motion of the head (Figure 2.16). 
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Figure 2.16: fMRI and pain stimulator setup 
Reproduced with permission from Professor I.D.Wilkinson 
 
Each subject underwent heat-pain stimulation and finger tapping task whilst in the 
fMRI.  
 
2.6.1 Heat-pain stimulation 
The fMRI response to heat-pain stimulation was determined independently at the 2 
anatomical levels on the right side detailed above. One fMRI run was performed at 
each of these anatomical sites. Each run comprised the presentation of 7 blocks of 
heat-pain stimuli (duration 30 seconds) at the pre-determined 7/10 pain-inducing 
temperature, interspersed with 7 blocks of baseline temperature 32ºC (each 
baseline block duration was pseudo-randomised to 55, 60 or 65 seconds). The pre-
programmed thermode-device computer controlled the timing of the applied 
temperature protocol. For each anatomic site a 600 second (10 minute) long 
protocol was used (Figure 2.17). The onsets of the heat pain stimuli were at: 30, 
125, 205, 330, 390, 475, 570 seconds whilst the onsets of the baseline temperature 
were at 60, 145, 235, 330, 420, 505 seconds. Each stimulus was applied via an MR-
compatible thermode and the temperature used to provide a heat-pain stimulus was 
determined prior to imaging, as detailed above. The radiographer and a member of 
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the team operating the CHEPS thermode verified synchronisation between the start 
of the heat-pain stimulation and fMRI acquisition. 
 
Figure 2.17: Experimental setup for heat-pain stimulation 
A 30-second thermal stimulation followed by a random pain free interval (32ºC) of 50, 55 or 
60 seconds, this was performed 7 times first on the right foot and repeated on the right thigh  
At the end of the imaging session, all participants rated their overall pain when the 
heat-pain stimulus was delivered to the foot and to the thigh. 
 
2.6.2 Auditory-motor finger tapping task 
Inter-individual variation in non-pain related BOLD response was assessed and 
controlled for by the addition of a functional run assessing the brain’s response to an 
auditory-motor finger tapping task. A 180 second/60 dynamic scanning sequence 
was used. Patients were asked to touch their thumbs against the tips of the other 
four fingers consecutively on both hands in time with an audio cue which sounded 
every 2 seconds. This single-finger opposition task was explained to the subjects 
before the scanning, and subjects were allowed a brief practice session. A steady 
rate was chosen to eliminate the effects of varying motor rate. The subjects were 
instructed to maintain the pace during the activation periods. The task was 
monitored visually by the researcher (myself) during these periods. During the rest 
period, subjects were asked to relax their hands at their sides. The task began with 
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a rest period of 30 seconds (10 dynamics) then finger tapping for 30 seconds and 
this was repeated three times.  
 
2.6.3 Scanning Protocol 
A fixed scanning protocol (Table 2.5) was used on every subject for consistency. 
Table 2.5: fMRI scanning protocol 
TASK Description 
1) Survey Scan Provides anatomical survey images and sets up MRI for all 
subsequent sequences. 
2) SENSE Ref Scan  This is a set up scan, which prepares the coil.  
3) T2 Weighted/Turbo Spin 
Echo Scan 
An axial anatomical scan using T2 weighted imaging which 
is good for detecting pathologies in the brain and used for 
screening patients. 
4) Functional-Quality Analysis 
(F-QA) 
A short 1 dynamic long functional sequence which checks 
the quality of functional images before proceeding. 
5) Functional-Baseline 
(F-BASE) 
A functional scan which images brain activity at baseline (no 
stimulus/task). Patients are instructed to look at red cross 
(this is to ensure fixation of attention) for a total of 100 
dynamics.  
6) Functional imaging with audio 
cue initiated finger tapping 
 
A functional scan to collect information about inter-individual 
non-pain related BOLD variation. 
Patients are instructed to finger tap to an auditory cue for a 
total of 60 dynamics (toggling between 10 dynamics at rest 
followed by 10 dynamics of finger tapping).  
7) Functional imaging with heat 
pain stimulation to foot  
Functional scan. During this sequence heat pain stimulus is 
applied to the dorsum of right foot (see heat pain protocol 
below). 
8) Functional imaging with heat 
pain stimulation to thigh.  
Functional scan. During this sequence heat pain stimulus is 
applied to the thigh as in Task 7. 
9) T1 MPRAGE  A sagittal anatomical scan used to produce high quality 
anatomical images of the brain. 
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2.6.4 Data Storage 
Data collected from assessments for each subject was stored in a secure room. A 
unique scan number and an MRI screening form were stored in the MRI department. 
Imaging data for each subject was transferred and stored on a secure analysing 
computer in the imaging laboratory.  
 
2.6.5 Data analysis & statistical assessments 
Non-imaging data collected were converted into numerical scores and entered into 
Microsoft Excel for subsequent analysis. This was then entered into the Statistical 
Package PASW 18.0 for Windows and statistical analyses were performed (SPSS 
2009). 
The analysis of imaging data was carried out using statistical parametric mapping 
software (SPM5 - www.fil.ion.ucl.ac.uk/spm). Following spatial pre-processing (as 
described above in section 1.4.6), images were analysed. Blood Oxygen Level 
Dependent response was modelled using a box-car waveform convolved with a 
canonical haemodynamic response function.  
 
2.6.5.1 Individual images analysis 
Blood oxygen level dependent response was modelled using a box-car waveform 
convolved with a canonical haemodynamic response function. Following spatial pre-
processing, which included realignment, spatial normalisation and spatial 
smoothing, images were analysed using the General Linear Model. All activation 
results are displayed in the anatomical space as defined by the Montreal 
neurological institute (MNI); however the convention in the neuroscience community 
is to report brain locations in the standard space of the Talairach and Tournoux atlas 
(Talairach and Tournoux 1988). The location of regions with BOLD activity was 
determined by converting MNI (x,y,z) co-ordinates as provided by SPM5 into 
Talairach co-ordinates, which were then interpreted using the Talairach and 
Tournoux atlas (Talairach and Tournoux 1988). 
First-level functional images were produced comparing the BOLD response under 
the heat pain condition with the baseline BOLD signal. Images were produced for 
every functional run at each of the two anatomical stimulation sites (foot and thigh) 
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for each subject. Therefore, the first-level analysis yielded 2 contrast images per 
subject, comparing BOLD response under the heat-pain condition with baseline at 
the foot and thigh stimulation sites. 
 
2.6.5.2 Comparing groups analysis 
These resultant first-level contrast images were combined at the group level in a 
flexible factorial model with factors of subject, group (CIPN-myeloma and healthy 
volunteers) and site (foot and thigh). This appropriately modelled the independence 
of observations between subjects and groups, and the inequality of variance across 
all factors. The exception was the finger tapping analysis where 2-sample t-test was 
used. 
Within-group images of all pain (foot and thigh) response versus baseline were 
produced for each of the CIPN-myeloma and healthy volunteer groups. The 
statistical threshold for reporting within-group pain contrast activation was p<0.05, 
family-wise error (FWE) corrected across the whole brain volume. 
A functional anatomical mask of voxels activated in response to all heat-pain stimuli 
(compared with baseline) in both groups of subjects (CIPN-myeloma and healthy 
volunteers) was created at voxel-level statistical threshold p<0.001, uncorrected. 
This mask was used as a volume-of-interest for correction for multiple comparisons 
in subsequent between-group contrasts. 
The results were evaluated using contrast analysis where a contrast was specified 
in terms of weights for each condition. As an example, in the experiment of finger 
tapping comparing healthy volunteers to CIPN-myeloma patients; the design matrix 
had two columns and a contrast vector (e.g: 1 0, 0 1, 1 -1, -1,1) was added to 
observe what happened at the voxel level and whether there was any significant 
difference between the two groups (Figure 2.18).  
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Contrast: 1   0  0   1        1   -1            -1    1 
Figure 2.18: Design matrix for finger tapping showing contrast analysis 
There are 2 groups in each figure: Columns 1 are collated images from HV and columns 2 
are collated images from CIPN-myeloma patients. The contrast 1 0 means that the analysis 
is only looking at brain activation in HV whilst tapping their fingers; 0 1 looking at brain 
activation only in CIPN-myeloma patients whilst tapping their fingers; 1 -1 is looking whether 
there was significant different activation of voxels (brain activity) in HV compared to CIPN-
myeloma patients whilst tapping their fingers and -1 1 is vice versa of 1 -1.  
 
The statistical threshold for reporting between-group differences in pain-evoked 
activation was p<0.05 family-wise error corrected (voxel-level) or p<0.05 corrected 
for extent of activation (cluster level) in either the whole brain volume or functionally 
defined region-of-interest (above). All activation results were displayed in the 
anatomical space as defined by the Montreal Neurological Institute (MNI) 
(Ashburner and Friston 2005), with stereotactic co-ordinates converted to the 
standard space of Talairach and Tournoux (Talairach and Tournoux 1988) for the 
purposes of neuroanatomical labelling. BOLD response maps for painful stimulation 
versus baseline were correlated with single covariates of interest: TNSr, CPAQ and 
PCS in multiple regression analysis. In a GLM using SPM, the model assumes a 
linear relationship between regional cerebral blood flow and the covariate.  
 
!Column	  2  
 
Column	  1 
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2.6.5.3 Test for habituation 
In the first level analysis, the first 80 images and the last 80 images (out of 203 
images) for each subject were analysed individually as this included the first 3 heat-
pain stimuli and the last 3 heat-pain stimuli both for the foot and for the thigh. In the 
second level analysis, habituation was looked for comparing the 1st 3 stimuli vs the 
last 3 stimuli in:  
- healthy volunteers when the heat-pain stimuli was delivered to the foot and 
secondly to the thigh; 
- CIPN-myeloma patients when the heat-pain stimuli was delivered to the foot and 
secondly to the thigh; 
- comparing healthy volunteers and CIPN-myeloma patients when the heat-pain 
stimuli was delivered to the foot and secondly to the thigh 
The conditions specified in the second-level analysis were: 
The onset (seconds) of timing for the first three heat-pain stimuli:  
30 115 145 
The duration of each heat-pain stimuli was 30 seconds. 
 
The onset (seconds) of the timing for the last three heat-pain stimuli:  
21 106 201 
The duration of each heat-pain stimuli was 30 seconds. 
 
2.6.6 Power calculation 
In fMRI experiments, it is estimated that the inclusion of 12 subjects per study cell 
allows for between-groups comparisons with inter-subject variability properly 
modelled as a random effect in the statistical analysis (Friston et al. 1999). A pilot 
study carried out in Sheffield looking at diabetic neuropathy has shown significant 
differences when comparing painless and painful diabetic neuropathy in a limited 
sample size (n=6 in each group). 
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2.6.7 Statistical analysis 
Standardised measures were scored as directed in manuals and published reports. 
Descriptive statistics were calculated. Quantitative data were analysed using PASW 
version 18 (SPSS 2009). Cronbach's alpha is a psychometric statistic measuring the 
coefficient of reliability and internal consistency of a multi-item scale and a score 
>0.8 is regarded as good. This was used for the questionnaires used.  
 
To check if the data was normally distributed or not, the skewness and the 
histogram plot with normal curve overlay were performed. The age of the CIPN-
myeloma patients and the healthy volunteers’ age were tested for normal distribution 
(Table 2.6, Figure 2.19, 2.20) and results show that the data was not normally 
distributed. Skewness is a measure of the degree of asymmetry of a distribution. If 
the left tail (tail at small end of the distribution) is more pronounced than the right tail 
(tail at the large end of the distribution), the function is said to 
have negative skewness. If the reverse is true, it has a positive skewness (Weisstein 
2012). If the two are equal, it has zero skewness. The histogram is a representation 
of a frequency distribution. Therefore non-parametric tests were used for descriptive 
statistics. 
 
Table 2.6: The mean, median, skewness of the data 
Statistics CIPN-MM Age Healthy volunteers 
Age 
Mean 61.25 47.25 
Median 63.00 50.50 
Skewness -.421 -0.02 
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Figure 2.19: Histogram plot with overlay for CIPN-MM age 
The data is moderately skewed to the left: the left tail is slightly longer and more data of the 
distribution is at the right. 
 
 
Figure 2.20: Histogram plot with overlay for healthy volunteers age 
The data is very slightly skewed to the left: the left tail is very slightly longer. 
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2.7 Results 
2.7.1 Baseline characteristics 
 
The demographic details and disease characteristics of the MM patients and healthy 
volunteers are shown in Table 2.7. Ten MM patients (83%) had undergone 
autologous haemopoietic stem cell transplantation (HSCT) as part of their treatment 
and 4 (33%) received a second more recent autologous HSCT. Other anti-myeloma 
therapies that these patients received which are known to cause peripheral 
neuropathy varied between patients:  
5 (42%) vincristine, 9 (75%) thalidomide and 8 (67%) bortezomib.  
 
Table 2.7: Baseline characteristics (median [IQR]) of the subjects recruited 
 Multiple Myeloma 
patients 
Healthy Volunteers 
Group Size 12 12 
Age (Years) 63 [56-67] 53 [35-58] 
Sex 8 Males; 4 Females 6 Males; 6 Females 
Duration of MM (Years)  4.1 [2.0-7.7] Not relevant 
Duration of neuropathic 
pain (Years)  
2 [0.9-3.2] Not relevant 
 
A Mann-Whitney's U test was performed to evaluate the differences in the age 
between the two groups and a statistically significant difference was found (p=0.04).  
These CIPN-myeloma patients have had neuropathic pain for a median of 2 years 
and all patients were on a variety of analgesics. Seven patients (58%) were on a 
stable dose of opioids ranging from one (14.25%) being on tramadol and codeine, 
one (14.25%) being on fentanyl patch, three (43%) being on buprenorphine patches, 
one being on morphine slow release tablets (14.25%) and one (14.25%) being on 
OxyContin slow release tablets. Out of the 12 patients, 10 (83%) were on calcium 
channel blockers as a form of analgesia namely, three being on gabapentin (30%) 
and seven being on pregabalin (70%). The opioid doses had been stable for at least 
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one month and were not stopped, whilst the anticonvulsants were stopped 48hours 
prior to scanning. 
 
2.7.2 Quantitative results for multiple myeloma patients 
2.7.2.1 Quantitative Sensory Testing 
Quantitative sensory testing was conducted for cooling detection threshold (CDT) 
and vibration detection thresholds (VDT). The median [IQR] CDT was 19.2 [4.73] 
and VDT was 23.1 [15.3-21.0] as shown Table 2.8.  
 
Table 2.8: Cooling detection threshold and Vibration detection thresholds 
 Median IQR Minimum Maximum 
Cooling Detection 
Threshold JND  
19.20 15.3-21.0 5.44 22.20 
Vibration Detection 
Threshold JND  
23.10 21.2-24.2 14.83 25.00 
JND – Just noticeable differences 
 
2.7.2.2 Nerve Conduction Studies 
The nerve conduction studies were not elicited in all MM patients; in those patients 
where the nerve could not be stimulated and no recording measured, it was 
assumed that the nerve conduction was abnormal (Table 2.9). In those elicited the 
results below show that they varied from the norm. Normal ranges adjusted for age 
were derived from a nerve conduction study reference text (Liveson 1992).  
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Table 2.9: Nerve Conduction Study Results 
Nerves studied Mean Standard 
Deviation 
Minimum Median IQR Maximum 
Sural Amplitude 
(µV) 
5.49 9.39 0.00 0.00 0 -11.70 30.00 
Common 
Peroneal Nerve 
Velocity (m/secs) 
42.20 5.45 37.30 39.40 37.80 -
48.05 
49.30 
Common 
Peroneal Nerve 
Amplitude (µV) 
1.5 2.09 0.00 0.95 0 - 2.52 5.60 
Common 
Peroneal Nerve 
Latency (msecs) 
3.12 2.46 0.00 3.6 0 - 5.30 5.80 
Tibial Nerve 
Latency (msecs) 
4.06 3.86 0.00 4.12 0 - 8.09 9.25 
 
2.7.2.3 Autonomic testing 
From the heart rate variability values derived from the cardiac autonomic tests, 
patients’ age related reference ranges were calculated and displayed on graphs 
showing O’Brien normal ranges for their age. The median [IQR] for the R-R 
variability during deep inspiration was 1.24 [1.15 – 1.29]. In these patients, the 
autonomic cardiac studies were normal (three patients did not have this done: two 
patients had atrial fibrillation; one patient died prior to attending this test). 
 
2.7.2.4 Assessment tools 
2.7.2.4.1 Total	  Neuropathy	  Score	  (reduced	  version)	  
Motor and sensory symptoms and signs, pinprick and vibration perception threshold, 
and neurophysiological examination of the sural nerve amplitude and common 
peroneal nerve amplitude were used to obtain the TNSr. A higher score indicates 
worse peripheral neuropathy. Table 2.10 shows the score for the MM patients. 
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Table 2.10: Total Neuropathy Score, reduced version 
TNSr (0-32) 
Parameter Mean SD Median IQR 
Sensory symptoms 2.1 0.8 2 2-3 
Motor symptoms 0 0 0 0 
Pin sensibility 2.2 0.4 2 2-3 
Vibration sensibility 2.2 0.4 2 2-3 
Strength 0 0 0 0 
Tendon reflexes 0.3 1.1 0 0 
Sural nerve 
amplitude 
3.1 1.6 4 3-4 
Peroneal nerve 
amplitude 
3.4 0.69 3 3-4 
 
 
 
TNSr 
Median  IQR Mean SD Minimum Maximum 
14.00 11-17 13.6 3.6 9.00 21.00 
(1 missing data, patient passed away acutely prior to returning for nerve conduction studies).  
 
The peripheral neuropathy was graded on the basis of the TNSr the subjects were 
grouped according to: 
TNSr 2-8 = Grade 1; TNSr 9-16 = Grade 2; TNSr 17-24 = Grade 3; TNSr 25-32 = 
Grade 4 (Ware 1996).  
For the sample of patients, according to this grading system, the group comparison 
was: 
Grade 1 = 0 
Grade 2 = 67% (8 patients) 
Grade 3 = 25% (3 patients) 
Grade 4 = 0 
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2.7.2.4.2 Dyck’s	  Score	  
Assessment of neuropathy was also calculated using the Dyck’s composite score. 
The median [IQR] for Dyck’s Score (NIS - Lower limb) + 7) was found to be 12.3 [8-
20] (Table 2.11). 
 
Table 2.11: Dyck’s score 
Dyck’s score 
Mean  SD Median IQR Minimum Maximum 
13.7 6.5 12.3 8-20 5 24 
(1 missing data entry as the patient passed away acutely prior to returning for nerve 
conduction studies).  
 
According to the classification of Dyck’s, this cohort of patients would be classified 
as all having clinical neuropathy since the scores were ≥4.5. 
  
2.7.3 Qualitative results for multiple myeloma patients 
 
2.7.3.1 EORTC QLQ-C30 and the myeloma module QLQ-MY20 
From the EORTC QLQ-C30, the commonest symptoms were pain and fatigue; 
whilst in terms of the functioning scales the lowest mean score, indicating the most 
severe impairment was found in social functioning (Table 2.12).  
The individual item of the EORTC QOL scale that were reported as most 
bothersome by patients (>25% of patients reporting ‘very much’ or ‘quite a bit’ of 
bother) included the inability to do strenuous activities (58.4%) or take long walks 
(75%); patients felt limited in doing either their work or other daily activities (41.6%) 
and in pursuing their hobbies or other leisure time activities (41.6%) and they felt 
this interfered with their family life (50%) and with their social activities (41.7%). 
Over three-quarters of the patients had pain (83.4%), and felt fatigued (41.7%). 
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Table 2.12: EORTC-QLQ-C30 
A high score (maximum =100) in the functional scales indicates better health-related quality 
of life but a high score (maximum = 100) in the symptom scales indicate a high level of 
symptomatology / problems.  
 
From the EORTC QLQ-MY20, patients reported tingling in hands or feet as the most 
troublesome symptom (66.7%) followed by feeling drowsy (50%). From the 
subscales of the EORTC QLQ-MY20, patients were mainly worried about future 
perspectives (such as worrying about their illness, about their health in the future). 
Interestingly, 58% were not worried at all about dying (Table 2.13). 
 
 
 
 
EORTC QLQ-C30 Median [IQR] Mean [SD] 
Functional Scales   
Physical Functioning 63.5 [28.5-85.25] 59.5 [27.3] 
Role Functioning 67.0 [33.0-83.0] 61.0 [31.3] 
Emotional Functioning 83.5 [69.0-100] 78.6 [28.1] 
Cognitive Functioning 67.0 [21.0-79.0] 57.1 [32.9] 
Social Functioning 58.5 [33.0-67.0] 51.4 [28.9] 
Global Health Status/QoL   
Global Health Status/QoL 67.0 [50.0-73.0] 60.6 [18.9] 
Symptom Scales/Items   
Pain 50.0 [33.0-79.0] 54.1 [24.7] 
Fatigue 44.0 [24.75-75.35] 51.7 [28.7] 
Dyspnoea 0.0 [0.0-33.0] 19.4 [26.5] 
Insomnia 33.0 [33.0-58.5] 36.0 [22.4] 
Appetite loss 33.0 [0.0-33.0] 27.7 [31.3] 
Nausea & vomiting 0.0 [0.0-17.0] 7.0 [11.1] 
Constipation 0.0 [0.0-58.5] 19.5 [30.1] 
Diarrhoea 0.0 [0.0-33.0] 19.4 [26.5] 
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Table 2.13: EORTC QLQ-C20 myeloma module 
EORTC QLQ-C20 Median [IQR] Mean [SD] Range 
Subscales    
Disease specific a 43.0 [24.0-51.0] 38.6 [22.1] 0-100 
Have you had bone aches or pain? 2.0 [2.0-4.0] 2.58 [1.16] 1-4 
Have you had pain in your back? 2.0 [1.0-2.0] 1.92 [1.08] 1-4 
Have you had pain in your hip? 1.0 [1.0-3.0] 1.92 [1.24] 1-4 
Have you had pain in your arm or 
shoulder? 
1.0 [1.0-2.75] 1.67 [1.07] 1-4 
Have you had pain in your chest? 1.0 [1.0-1.0] 1.17 [0.39] 1-4 
If you had pain did it increase with 
activity? 
2.0 [1.0 – 3.0] 2.17 [1.19] 1-4 
Side effects of treatment a 26.0 [12.0-36.0] 25.3 [13.6] 0-100 
Do you feel drowsy? 2.5 [2.0-4.0] 2.75 [1.05] 1-4 
Do you feel thirsty? 1.5 [1.0-2.0] 1.67 [.078] 1-4 
Have you felt ill? 1.0 [1.0-2.0] 1.42 [0.67] 1-4 
Have you had a dry mouth? 2.0 [1.0-2.75] 1.92 [0.99] 1-4 
Have you lost any hair? 1.0 [1.0-1.0] 1.25 [0.87] 1-4 
Did you have any tingling hands or 
feet? 
3.0 [2.0-4.0] 3.0 [1.04] 1-4 
Did you feel restless or agitated? 2.0 [1.0-2.75] 2.0 [1.13] 1-4 
Have you had acid indigestion or 
heartburn? 
1.0 [1.0-2.75] 1.67 [1.07] 1-4 
Have you had burning or sore eyes? 1.0 [1.0-1.0] 1.08 [0.29] 1-4 
Body Image b 33.0 [0-67.0] 33.4 [33.5] 0-100 
Have you felt physically less attractive 
as a result of your disease or 
treatment? 
2.0 [1.0-3.0] 2.0 [1.0] 1-4 
Future Perspective b 67 [47.0-78.0] 62.2 [22.6] 0-100 
Have you been thinking about your 
illness? 
2.0 [2.0-3.0] 2.17 [0.72] 1-4 
Have you been worried about dying? 1.0 [1.0-2.0] 1.67 [0.98] 1-4 
Have you worried about your health in      
the future? 
2.5 [2.0-3.0] 2.58 [0.67] 1-4 
a) High scores indicate worse symptoms, b) High scores indicate better support/functioning. 
Individual items score: 1 = not at all, 2 = a little bit, 3 = quite a bit, 4 = very much 
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2.7.3.2 Self-report Leeds Assessment of Neuropathic 
Symptoms and Signs (s-LANSS) 
75 % (nine patients) scored >12 of the s-LANSS which suggests that their pain is 
predominantly of neuropathic origin. This was supported by the neurological 
examination, however examination showed all (n=12) patients had signs of sensory 
neuropathy in their feet. 
 
2.7.3.3 Neuropathic Pain Scale (NPS) 
From the NPS (range 0 – 10), MM patients scored itchy as the most troublesome 
and allodynia as the least symptom present. The different aspects of pain are 
reported in table 2.14. 
 
Table 2.14: Neuropathic Pain Score values for CIPN-myeloma group 
Neuropathic pain Mean [SD] Median [IQR] 
Itchy 6.0 [1.5] 6.0 [5.25-7.0] 
Intense 5.9 [1.7] 6.0 [4.5-7.0] 
Deep 5.8 [2.0] 6.0 [4.25-7.75] 
Dull 4.9 [2.5] 5.0 [3.25-7.5] 
Surface 4.8 [2.2] 5.5 [3.0-6.0] 
Hot 4.2 [3.0] 4.5 [0.75-6.75] 
Sensitive 4.2 [3.0] 5.0 [1.25-7.0] 
Cold 3.9 [2.8] 4.0 [1.25-6.5] 
Sharp 3.9 [2.9] 3.5 [1.25-6.75] 
Unpleasant 1.9 [2.5] 1.0 [0.0-3.0] 
 
Spearman’s rho correlation between each of the ten NPS descriptors for the twelve 
MM patients was calculated. The strongest positive correlation was between 
neuropathic pain that was described as cold and unpleasantness (r=0.801; p=0.002) 
followed by intensity and deep pain (r=0.765; p=0.004) and intensity and itchy 
(r=0.760; p=0.004). Another strong correlation was between sharp and cold feeling 
(r=0.715; p=0.009). 
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2.7.3.4 Neuropathy Total Symptom Score (NTSS-6) 
NTSS-6 total median [IQR] score was 7.8 [5.6-10.5]. Seventy-five percent of 
patients scored >6 points indicating clinically significant symptoms of neuropathy. 
The most frequently reported symptom (a symptom score of >1 on NTSS-6) was 
numbness (83%) followed by prickling (75%). Forty-one percent of patients reported 
lancinating and burning pain whilst 33% had aching pain. The least reported 
symptom was allodynia (16%). Eight-three percent of patients reported ≥3 
symptoms. 
 
2.7.3.5 Chronic Pain Assessment Questionnaire (CPAQ) 
In the CPAQ, a higher score indicates a higher acceptance of pain (range 0 – 120). 
Two components were derived for scoring: activities engagement and pain 
willingness as described in section 2.5.2.5. The median sum score for activities 
engagement was 45; pain willingness was 31. The total score for CPAQ was 75. 
The items pertained to activities engagements were correlated (alpha coefficient = 
0.775) as were items pertained to pain willingness (alpha coefficient =0.948).  
The more patients accepted their pain, the better their social functioning was 
(r=0.747; p=0.005) and the better their QoL (r=0.591; p=0.04) 
 
2.7.3.6 Pain catastrophizing scale (PCS) 
Higher scores indicate more pain catastrophizing. Table 2.15 contains the scoring 
from the MM patients. Alpha coefficients in this study were .80, .95, and .90 for the 
subscales magnification, rumination and helplessness respectively. For the total 
PCS, the alpha coefficient was .95. 
Table 2.15: PCS scores for CIPN-myeloma patients 
PCS Mean [SD] Median [IQR]  Range  
Total score 15.7 [13.1] 11.9 [4.75-27.5]  0-52  
Magnification 3.25 [3.1] 2.5 [1.0-6.25]  0-12  
Rumination 6.30 [4.9] 5.0 [1.5-11.75]  0-16  
Helplessness 6.08 [5.9] 4.5 [1.25-10.5]  0-24  
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2.7.3.7 Hospital Anxiety and Depression Scale (HADS) 
Fifty-eight percent of MM patients reported signs of anxiety, depression or a 
combination of both (Table 2.16). Those patients that reported anxiety were also 
depressed. 
Table 2.16: HADS results 
 CIPN- Myeloma patients 
No anxiety & depression 42% (5) 
Borderline for anxiety & depression 17% (2) 
Anxiety 25% (3) 
Depression 8% (1) 
 
2.7.4 Correlations between clinical demographics, 
questionnaires and quantitative data 
 
The EORTC MY20: 
Side effects of treatment were strongly correlated with cognitive functioning (r=-
0.0856; p<0.0001), social functioning (r=-0.784; p=003), fatigue (r=0.593; p=0.04) 
and insomnia (r=0.632; p=0.02) from the EORTC QLQ-c30.  
If the patient felt physically less attractive as a result of their disease or treatment, 
they were more likely to feel anxious (r=0.651; p=0.03); depressed (r=0.778; 
p=0.005); there was a negative significant correlation with emotional functioning 
from the EORTC QLQ-C30 (r=-0.765; p=0.006) and also this was strongly correlated 
with appetite loss (r=0.811; p=0.002).  
If the patient was worried about their future perspectives (such as thinking about 
their illness, been worried about dying and worried about their health in the future) 
then these patients scored higher on the pain catastrophizing questionnaire in the 
three domains of rumination, magnification and helplessness (r=-0.734; p=0.007).  
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The Chronic Pain assessment Questionnaire: 
The more the patients accepted their pain (total pain acceptance score) the better 
their QoL was (r=0.591; p=0.04) and the better their social functioning (r=0.747; 
p=0.005).  
The s-LANSS: 
Patients with neuropathy as indicated from the s-LANSS had lower levels of physical 
functioning (r=-0.591, p=0.04) and role functioning (r=-0.593; p=0.04).  
The Total Neuropathy Score, reduced version and Dyck’s score: 
There was a strong negative correlation with TNSr and role functioning (r=-0.801; 
p=0.003) from the EORTC QLQ-C30 and symptoms related to the disease from the 
EORTC myeloma module (r=-0.670; p=0.02). There was a strong correlation 
between TNSr and Dyck’s score (r=0.841; p=0.001). Dyck’s score was negatively 
correlated with physical functioning (r=-0.816; p=0.002) and role functioning (r=-
0.716; p=0.013) from the EORTC QLQ-c30. There was a strong correlation between 
NTSS-6 and Dyck’s score (r=0.719; p=0.013) but a weak correlation between 
NTSS-6 and TNSr (r=0.605; p=0.049).  
There was no correlation between S-LANSS and TNSr, Dyck’s score and NTSS-6.  
There were no statistically significant correlations between age, sex, and years 
since diagnosis and years since their neuropathic pain started. 
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2.7.5 fMRI analysis results 
2.7.5.1 Finger tapping 
 
All healthy volunteers and CIPN-myeloma patients underwent finger tapping fMRI 
assessment whilst in the scanner. Average group activation results for each cohort 
were calculated. In both cohorts the areas of significant activation included the 
primary motor cortex, the supplementary motor area and the cerebellum (PFWE-corr at 
voxel level p<0.0001) (Table 2.17 and Figure 2.21). 
 
Table 2.17: Areas of BOLD fMRI activation with finger tapping  
Neuroimaging Data 
HV + CIPN-myeloma finger tapping 
Talairach co-
ordinates (x,y,z) 
 t Statistic 
Rt primary motor cortex 42 -18 60 11.89 
Lt cerebellum -18 -52 -24 10.85 
Rt superior frontal gyrus 40 36 32 7.24 
 
 a) 
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 b) 
Figure 2.21: SPM generated brain images showing activation due to finger 
tapping 
a) SPM rendered to a generic 3D brain shown from six angles demonstrating areas of 
activation on finger tapping.  
b) Coronal and sagittal views of the brain superimposed on a normalized anatomical T1 image 
of subjects with activated regions shown in red for healthy volunteers, yellow for CIPN-
myeloma patients and orange for overlap. The activation is concentrated in the primary motor 
area (precentral gyrus), motor associated areas (frontal gyrus) and cerebellum. (Activation 
maps used threshold p<0.01 and extent threshold adjusted for illustrative purposes.)  
 
There were no significant differences in the brain activation between the healthy 
volunteers and the CIPN-myeloma patients during finger tapping.  
 
2.7.5.2 Pain stimulation 
All 24 subjects completed this part of the study.  
Pain rating and temperature used for pain stimulation 
A rating for pain intensity was taken before and after MRI scans (Table 2.18). 
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Table 2.18: Group median [IQR] temperature for pain stimulation and pain 
rating 
 Healthy 
Volunteers 
MM patients p-value 
Foot stimulation    
Temperature °C 46.7 [45.5-47.8] 47.2 [46.6-47.9] 0.23 
Pre-scan pain rating (0-10) 7.5 [6.6-8.0] 7.0 [7.0-8.0] 0.74 
Post-scan pain rating (0-10) 7.7 [6.6-8.7] 7.7 [7.0-8.0] 0.95 
Thigh stimulation    
Temperature °C 45.9 [45.6-47.9] 46.7 [45.5-47.9] 0.88 
Pre-scan pain rating (0-10) 7.7 [5.9-8.0] 8.0 [7.6-8.0] 0.28 
Post-scan pain rating (0-10) 8.0 [6.2-8.9] 8.0 [8.0-9.0] 0.29 
 
The median pain ratings are shown in Figure 2.22. 
 
Figure 2.22: Median pain rating pre and post scanning for foot and thigh 
stimulation.  
There were no significant differences (p>0.05) between the two groups. 
A Wilcoxon Signed Ranks Test showed that the pain ratings and the temperatures 
used as noxious stimulus for the foot and the thigh in both the healthy volunteers 
and MM patients were not statistically significant.  
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2.7.5.3 Brain activation in response to heat-pain stimulation 
in both healthy volunteers and CIPN-myeloma patients 
 
2.7.5.3.1 Individual	  group	  analysis	  	  
Statistical parametric activation maps were constructed for the CIPN-myeloma 
group and the healthy volunteers control group individually. Firstly, compared with 
baseline, thermal stimulation on the foot evoked brain activation in both healthy 
volunteers and CIPN-myeloma patients and the areas of significant brain activation 
are shown in figures 2.23 and 2.24. Tables 2.19, 2.20 show the areas of activation 
on painful stimulation on the foot in healthy volunteers and CIPN-myeloma patients. 
 
Figure 2.23: Regions of significant activation (yellow) following application of 
the thermal stimuli on the foot (painful versus baseline) for healthy volunteers 
 
 
Figure 2.24: Regions of significant activation (red) following application of the 
thermal stimuli on the foot (painful versus baseline) for CIPN-myeloma 
patients 
 
For both figures: Foci with a maximum exceeding statistical threshold p<0.05, FWE-
corrected in the whole brain, are shown at visualisation threshold p<0.001 uncorrected 
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Table 2.19: Areas of significant BOLD response in the Healthy volunteers: 
where Foot Pain response > Baseline signal 
Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels* 
Rt medial 
prefrontal lobe 
32 4 23 32 7.63 <0.001 1414 
Rt 
supramarginal 
gyrus 
40 63 -41 33 6.92 0.001 617 
Rt inferior 
frontal gyrus 
47 44 20 -9  6.72 0.001 1234 
Lt posterior 
cerebellar lobe 
- -30 -66 -16 6.37 0.003 2391 
Rt medial frontal 
gyrus 
8 5 39 42 6.32
  
0.004 325 
Lt anterior lobe 
of temporal 
gyrus 
38 -50 13 -8 6.16 0.006  679 
 
Table 2.20: Areas of significant BOLD response in the CIPN-myeloma patients: 
where Foot Pain response > Baseline signal  
Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels* 
Rt superior 
temporal gyrus 
22
  
55 4 0 6.04 0.009 490 
Lt precentral 
gyrus 
6 -52 2 12  5.48
  
0.044 648 
Lt middle 
frontal gyrus 
10 -34 40 20 5.37 0.05 163 
 
. 
Next, looking at brain activation by the application of the thermal stimuli on the thigh 
and compared with baseline, evoked significant brain activation in both healthy 
volunteers and CIPN-myeloma patients are shown in Figure 2.25 and 2.26 
respectively. Table 2.21 and 2.22 show the areas of activation on painful stimulation 
on the thigh in healthy volunteers and CIPN-myeloma patients. 
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Figure 2.25: Regions of significant activation following application of the 
thermal stimuli on the thigh (painful versus baseline) for healthy volunteers 
 
 
Figure 2.26: Regions of significant activation following application of the 
thermal stimuli on the thigh (painful versus baseline) for CIPN-myeloma 
patients 
For both figures: Foci with a maximum exceeding statistical threshold p<0.05, FWE-
corrected in the whole brain, are shown at visualisation threshold p<0.001 uncorrected 
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Table 2.21: Areas of significant BOLD response in the Healthy volunteers: 
where Thigh Pain response > Baseline signal  
Region BA 
 
Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels* 
Lt insula in 
lateral fissure 
- -40 6 2 6.16 0.006 1257 
Rt anterior lobe 
of temporal 
gyrus  
38 -55 13 -9 5.87 0.01 539 
Lt superior 
temporal gyrus 
42 -60 -32 20 5.43 0.05 432 
Rt middle 
frontal gyrus  
10 -32 48 20 5.42  0.05  260 
 
Table 2.22: Areas of significant BOLD response in the CIPN-myeloma patients: 
where Thigh Pain response > Baseline signal  
Region BA 
 
Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels* 
Rt 
supramarginal 
gyrus 
40 61 -41 35 7.23 <0.001 528 
Rt claustrum - 34 5 4  6.68 <0.001 936 
Lt posterior 
cerebellar lobe 
- -34 -58 -24 5.61 0.031 491 
 
Afterwards, statistical parametric activation maps were constructed for the healthy 
volunteers control group (foot + thigh) and the CIPN-myeloma group (foot + thigh) 
and shown in figure 2.27. 
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Figure 2.27: Regions of activation following application of the thermal stimuli 
(painful versus baseline) for CIPN-myeloma patients (red), healthy volunteers 
(yellow), and overlapping common regions of activation (orange).  
Foci with a maximum exceeding statistical threshold p<0.05, FWE-corrected in the whole 
brain, are shown at visualisation threshold p<0.001 uncorrected 
 
Table 2.23 and 2.24 show the areas of activation when the application of the thermal 
stimuli on the foot and thigh were applied in healthy volunteers and CIPN-myeloma 
patients respectively. 
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Table 2.23: Areas of significant BOLD response in the Healthy volunteers: 
where Foot + Thigh Pain response > Baseline signal  
Region BA 
 
Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Rt anterior 
cingulate gyrus 
32 4 24 23 7.47 <0.001 1643 
Lt superior 
temporal gyrus 
38 -50 13 -8 7.19 <0.001 1491 
Lt posterior 
cerebellar lobe 
- -30 -67 -20 6.56 0.002 2917 
Rt inferior 
frontal gyrus 
47
  
44 20 -9 6.52 0.002 1151 
Rt 
supramarginal 
gyrus 
40 64 -41 34 6.36 0.004 687 
Lt superior 
temporal gyrus 
42 -60 -30 18 6.13 0.007 709 
Lt superior 
frontal gyrus 
10 -32 48 20 5.80 0.018 469 
Rt middle 
frontal gyrus 
46
  
42 44 24 5.73 0.02 390 
Rt superior 
frontal gyrus 
8 6 39 48  5.68 0.025 216 
Lt postcentral 
gyrus 
7 -20 -41 68 5.66 0.026 212 
 
Table 2.24: Areas of significant BOLD response in the CIPN-myeloma patients: 
where Foot + Thigh Pain response > Baseline  
 Region BA 
 
Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Rt superior 
temporal gyrus 
22 56 4 0 8.10 <0.001 1356 
Rt 
supramarginal 
gyrus 
40 62 -41 35 7.65 <0.001 735 
Lt middle frontal 
gyrus 
46 -34 40 22 6.25 0.005 544 
Lt area 
opercularis 
44 -54 2 12 6.07 0.008 2228 
Lt posterior 
cerebellar lobe 
- -34 -58 -24 6.00 0.01 2535 
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2.7.5.3.2 Comparison	  between	  groups	  
The mean BOLD activation during the painful stimulus in healthy volunteers and 
CIPN-myeloma patients was compared and the differential cortical activation 
between the 2 groups during application of the thermal stimuli to the foot, to the 
thigh and to the foot + thigh together were observed. 
During application of the thermal stimuli to the foot, there was a significant activation 
in the right superior frontal gyrus (Talairach co-ordinates 5 41 47) in healthy 
volunteers compared to CIPN-myeloma patients (t=4.77; p=0.04 FWE corrected 
within the VOI (Figure 2.28).  
 
Figure 2.28: Functional image data (coronal and sagittal views) of the right 
superior frontal gyrus activation during application of the thermal stimuli to 
foot in healthy volunteers compared to CIPN-myeloma patients. 
Images are displayed against sections through a canonical single subject T1-weighted 
image. For display purposes, the voxel-level threshold is p<0.001, uncorrected at threshold 
level (kE) of 170.  
 
From the contrast estimates and 90% confidence interval (CI), it is suggested that 
CIPN-myeloma patients demonstrated hypo-activation at the superior frontal gyrus, 
brodmann area 8, whilst healthy volunteers showed activation (Figure 2.29).  
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Figure 2.29: Contrast estimates and 90% CI at superior frontal gyrus (co-
ordinate 5, 41, 47) depicted in Figure 2.28. 
Comparing activation at the superior frontal gyrus when applying thermal stimuli to the foot: 
in healthy volunteers (activation) and CIPN-myeloma patients (hypo-activation).  
 
An independent-sample t-test was conducted to compare the BOLD activation 
during thermal pain stimulation of the foot in CIPN-myeloma patients and healthy 
volunteers. There was a significant difference in the BOLD response for CIPN-
myeloma patients (mean = -0.12, SD = 0.38) and healthy volunteers (mean = 0.46, 
SD = 0.53) conditions; t(22) = -3.08, p = 0.005 as seen from the box plot in figure 
2.30.  
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Figure 2.30: Boxplot of contrast estimates of the superior frontal gyrus for 
CIPN-myeloma patients and healthy volunteers for the comparison results 
depicted in figure 2.29. 
Talairach coordinates (5 41 47) shown for this activation of increased BOLD response during 
application of thermal stimuli to the foot in CIPN-myeloma patients compared to healthy 
volunteers. 
 
During application of the thermal stimuli to the thigh, there was no significant brain 
activation when comparing healthy volunteers to CIPN-myeloma patients. 
 
When looking at the combined brain activation when applying the thermal stimuli to 
the foot + thigh, compared with CIPN-myeloma patients, healthy volunteers 
demonstrated significantly greater activation in the right superior frontal gyrus, close 
to the midline (Figure 2.31; Brodmann area 8; Talairach co-ordinates: 6, 39, 48; 
peak t = 4.87; p = 0.03, FWE-corrected within the volume-of-interest; 97 voxels 
exceeded height threshold p < 0.001, uncorrected).  
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Figure 2.31: CIPN-myeloma patients demonstrated hypoactivation of superior 
frontal gyrus during application of the thermal stimuli, compared with healthy 
controls.  
Functional imaging data are shown against axial (z=48mm) and sagittal (x=6mm) slices 
through a canonical single-subject T1-weighted image. For display purposes, the statistical 
threshold is p < 0.001, uncorrected, at the voxel-level. 
 
From the contrast estimates, it is suggested that CIPN-myeloma patients 
demonstrated hypo-activation at the superior frontal gyrus, whilst healthy volunteers 
(HV) showed activation (Figure 2.32).  
 
Figure 2.32: Contrast estimates and 90% CI at the superior frontal gyrus (co-
ordinate 6, 39, 48) when comparing healthy volunteers to CIPN-myeloma 
patients depicted in figure 2.31. 
Comparing activation at the superior frontal gyrus when applying thermal stimuli to the foot 
and to the thigh: in healthy volunteers (activation) and CIPN-myeloma patients (hypo-
activation).  
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When looking at the combined brain activation when applying the thermal stimuli to 
the foot + thigh, CIPN-myeloma patients demonstrated significantly greater 
activation in left precuneus when compared with healthy volunteers (Figure 2.33; 
Brodmann area 31; Talairach co-ordinates: -18, -61, 27; peak t = 4.82; 244 voxels 
exceeded height threshold p < 0.001, uncorrected; p = 0.01, corrected with respect 
to extent of activation). 
 
 
Figure 2.33: CIPN-myeloma patients demonstrated hyperactivation of 
precuneus during application of the thermal stimuli, compared with healthy 
controls.  
Functional imaging data are shown against axial (z=27mm) and sagittal (x=-18mm) slices 
through a canonical single-subject T1-weighted image. For display purposes, the statistical 
threshold is p < 0.001, uncorrected, at the voxel-level. 
 
From the contrast estimates, it is suggested that CIPN-myeloma patients 
demonstrated hyper-activation at the precuneus, whilst healthy volunteers showed 
de-activation (Figure 2.34).  
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Figure 2.34: Contrast estimates and 90% CI at the precuneus (co-ordinate -18, 
-61, 27) when comparing healthy volunteers to CIPN-myeloma patients 
depicted in figure 2.33.  
Comparing activation at the precuneus when applying thermal stimuli to the foot and to the 
thigh: in healthy volunteers (hypo-activation) and CIPN-myeloma patients (activation).  
 
There was a significant group-by-site interaction in the right prefrontal cortex, with 
CIPN-myeloma patients demonstrating significantly greater activation in response to 
thigh than foot pain thermal stimulation whereas healthy volunteers exhibited greater 
activation in response to foot than thigh thermal stimulation at this focus (Brodmann 
area 9; Talairach co-ordinates: 38, 37, 37; peak t = 6.21; p=0.005, FWE-corrected in 
the whole brain; 236 voxels exceeded height threshold p < 0.001, uncorrected), 
Figure 2.35 and this is also seen from the contrast estimates (figure 2.36).  
 
Figure 2.35: Right prefrontal gyrus activation in CIPN-myeloma group and in 
healthy volunteers.  
There was a significantly greater BOLD response with the application of the thermal stimuli 
to the thigh than foot in CIPN-myeloma patients whereas healthy volunteers exhibited 
greater activation in response to foot than to thigh stimulation. Functional imaging data are 
shown against axial (z=37mm) and sagittal (x=38mm) slices through a canonical single-
subject T1-weighted image. For display purposes, the statistical threshold is p < 0.001, 236 
voxels exceeded, uncorrected, at the voxel-level. 
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Figure 2.36: Contrast estimates and 90% CI at the right prefrontal gyrus (co-
ordinate 38, 37, 37) when comparing healthy volunteers to CIPN-myeloma 
patients depicted in figure 2.35. 
 
The reverse interaction effect was significant at the right cuneus, with CIPN-
myeloma patients demonstrating significant greater activation in response to foot 
than thigh thermal stimulation whereas healthy volunteers exhibited greater 
activation in response to thigh than foot thermal stimulation at this focus (Brodmann 
area 17; Talairach co-ordinates: 2, -89, 8; peak t=4.78; p=0.04 FWE-corrected within 
the volume-of-interest), Figure 2.37. This is also seen from the contrast estimates, 
figure 2.38. 
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Figure 2.37: Right cuneus in CIPN-myeloma and healthy volunteers 
There was a significant greater BOLD response with the application of the thermal stimuli to 
the foot than thigh in CIPN-myeloma patients whereas healthy volunteers exhibited greater 
activation in response to thigh than to foot stimulation. Functional imaging data are shown 
against axial (z=8mm) and sagittal (x=2mm) slices through a canonical single-subject T1-
weighted image. For display purposes, the statistical threshold is p < 0.001, 62 voxels 
exceeded, uncorrected, at the voxel-level. 
 
 
Figure 2.38: Contrast estimates and 90% CI at the right cuneus (co-ordinate 2,  
-89, 8) when comparing healthy volunteers to CIPN-myeloma patients depicted 
in figure 2.37.  
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2.7.6 Correlation of brain activation in CIPN-myeloma 
patients 
 
Additionally, a multiple regression analysis of the brain activation (when the 
application of the thermal stimuli was applied to the foot) was performed with TNSr 
in CIPN-myeloma patients, which found significant activation in the left operculo-
insular cortex (Talairach co-ordinates: -58, 2 4; peak t=8.02; p=0.03 FWE-corrected 
in the volume-of-interest for CIPN-myeloma foot activation) (Figure 2.39). There was 
a strong correlation between the functional contrast in this area of brain activation 
and the TNSr (Figure 2.40).  
However, there was no correlation with Dyck’s score and the brain activation when 
the application of the thermal stimuli was applied to the foot) in CIPN-myeloma 
patients.  
There was also no significant correlation between brain activation levels in the 
CIPN-myeloma patients and the CPAQ and the PCS questionnaires when these 
were used as covariates. 
 
 
Figure 2.39: CIPN-myeloma patients 
demonstrated activation at 
operculo-insular cortex during the 
application of the thermal stimuli at 
the foot when correlated with TNSr 
 
Functional imaging data is shown against 
axial (z=4mm) slice through a canonical 
single-subject T1-weighted image. For 
display purposes, the statistical threshold 
is p < 0.001, uncorrected, at the voxel-
level  
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Figure 2.40: Scatter dot graph with a line to fit showing the r2 linear regression 
Significant positive correlation was present between activation in the operulo-insular cortex 
and scoring of the TNSr 
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2.7.7 fMRI measures in CIPN patients on opioids 
There were seven CIPN patients (58%) who were on regular opioids for pain mainly 
neuropathic in origin, ranging from tramadol and codeine, morphine and oxycodone 
tablets and fentanyl and buprenophrine patches. These patients were asked to 
continue the opioids as the doses had been stable for more than one month.  
 
2.7.7.1 Opioids: CIPN-myeloma group analysis  
Statistical parametric activation maps were constructed for the CIPN-myeloma 
group who were on opioids and those who were not on opioids individually.  
Firstly, compared with baseline, thermal stimulation to the foot and thigh (combined) 
evoked significant brain activation in both these groups as seen in Figure 2.41.  
 
Figure 2.41: Regions of activation following application of the thermal stimuli 
(painful versus baseline) for CIPN-myeloma patients on opioids (green), CIPN-
myeloma patients not on opioids (cyan), and overlapping common regions of 
activation 
Foci with a maximum exceeding statistical threshold p<0.05, FWE-corrected in the whole 
brain, are shown at visualisation threshold p<0.001 uncorrected 
 
Table 2.25 and 2.26 show the areas of activation on application of the thermal 
stimuli to the foot and thigh in CIPN-myeloma patients on opioids and those not on 
opioids. 
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Table 2.25: Significant brain activation on application of the thermal stimuli 
(foot + thigh) in CIPN-myeloma patients on opioids 
Region BA 
 
Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Lt posterior 
cerebellar lobe 
- -20 -64 -26 9.7 <0.001 3583 
Rt superior 
temporal gyrus 
22 56 4 2  8.37 0.005 521 
Lt postcentral 
gyrus 
43 -58 -20 21 7.08 0.039 4105 
Rt inferior 
parietal lobe 
40 61 -43 37 6.95 0.048 326 
 
Table 2.26: Significant brain activation on application of the thermal stimuli 
(foot + thigh) CIPN-myeloma patients not on opioids 
Region BA 
 
Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Rt superior 
temporal gyrus 
22 58 4 0 9.58 0.001 691 
Lt middle frontal 
gyrus 
46 -34 40 15 7.87 0.011 321 
Lt postcentral 
gyrus 
4 -20 -32 60 6.98 0.046 186 
 
2.7.7.2 Opioids: comparison between CIPN-myeloma patients  
The mean BOLD activation during the application of the thermal stimuli in CIPN-
myeloma patients on opioids and those not on opioids was compared and the 
differential cortical activation between the 2 groups during foot + thigh stimulations 
was observed. 
During the thermal stimulation, there was significant activation in the left posterior 
cerebellar lobe (Talairach co-ordinates -20 -64 -27) in CIPN-myeloma patients on 
opioids compared to those not on opioids (t=8.54; p=0.004 FWE-corrected (Figure 
2.42).  
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Figure 2.42: Activation of left posterior cerebellar lobe in CIPN-myeloma 
patients on opioids compared to those not on opioids 
Functional imaging data are shown against coronal (y=-64mm) and sagittal (x=-20mm) slices 
through a canonical single-subject T1-weighted image. For display purposes, the statistical 
threshold is p < 0.001, 546 voxels exceeded, uncorrected, at the voxel-level 
 
From the contrast estimates, it is suggested that CIPN-myeloma patients on opioids 
demonstrated significant activation at the cerebellum, whilst those not on opioids 
showed de-activation (Figure 2.43).  
 
Figure 2.43: Contrast estimates and 90% CI at left posterior cerebellar lobe 
(co-ordinate -20 -64 -27) when comparing CIPN-myeloma patients on opioids 
to those not on opioids depicted in figure 2.42. 
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2.7.8 Attenuation of fMRI signal with noxious thermal heat 
stimulus 
 
Statistical maps were constructed and analysed for the combination of the first three 
and the last three images when the thermal stimuli were applied in both healthy 
volunteers and CIPN-myeloma patients at the sites of the foot and the thigh. 
 
2.7.8.1 Habituation: Individual group analysis 
Firstly, compared with baseline, thermal stimulation of the foot for the first three 
stimuli evoked different brain activation in both healthy volunteers and CIPN-
myeloma patients as seen in Figure 2.44 and 2.45 respectively.  
 
 
Figure 2.44: Regions of signification brain activation following the first three 
thermal stimulations on the foot (painful versus baseline) for healthy 
volunteers 
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Figure 2.45: Regions of significant brain activation following the first three 
thermal stimulations on the foot (painful versus baseline) for CIPN-myeloma 
patients 
 
For figures 2.44 and 2.45: Foci with a maximum exceeding statistical threshold p<0.05, 
FWE-corrected in the whole brain, are shown at visualisation threshold p<0.001 uncorrected 
 
Table 2.27 and 2.28 show the areas of significant brain activation on first three 
painful stimulations on the foot in healthy volunteers and CIPN-myeloma patients. 
 
Table 2.27: Significant brain activation on application of the thermal stimuli to 
the foot in healthy volunteers: first three thermal stimuli > Baseline  
Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Lt claustrum - -32 -21 8 9.64 <0.001 40897 
Lt posterior 
cerebellum 
- -24 -59 -17 9.00 <0.001 40897 
Rt inferior 
parietal lobule 
40 62 -36 26 6.64 0.002 2302 
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Table 2.28: Significant brain activation on application of the thermal stimuli to 
the foot in CIPN-myeloma patients: first three painful stimuli > Baseline  
 Region BA 
 
Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Lt insula 13 -40 -14 -5 8.55 <0.001 3033 
Rt superior 
temporal gyrus 
22 57 6 0 6.37 0.004 1891 
Rt cuneus 17 4 -80 14 5.04 0.001 
(cluster) 
360 
 
Next, looking at brain activation at the first three thermal stimulations on the thigh 
and compared with baseline, evoked different significant brain activations in both the 
healthy volunteers and CIPN-myeloma patients as shown in Figure 2.46 and 2.47 
respectively.  
 
 
Figure 2.46: Regions of significant brain activation following the first three 
thermal stimulations on the thigh (painful versus baseline) for healthy 
volunteers 
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Figure 2.47: Regions of significant brain activation following the first three 
thermal stimulations on the thigh (painful versus baseline) for CIPN-myeloma 
patients 
 
Table 2.29 and 2.30 show the areas of activation on first three painful stimulations 
on the thigh in healthy volunteers and CIPN-myeloma patients respectively. 
 
Table 2.29: Significant brain activation on application of the thermal stimuli to 
the thigh in healthy volunteers: first three painful stimuli > Baseline  
Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Lt insula - -32 16 6 7.48 <0.001 2349 
Rt middle frontal 
gyrus 
10/47 44 43 -4 6.73 0.001 3249 
Lt occipital lobe - -30 -69 18 6.41 0.003 3965 
Lt superior parietal 
lobe (postcentral 
gyrus) 
7 -20 -41 65 5.77 0.021 364 
Rt inferior frontal 
gyrus 
44 46 5 31 4.89 0.027 300 
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Table 2.30: Significant brain activation on application of the thermal stimuli to 
the thigh in CIPN-myeloma patients: first three painful stimuli > Baseline  
Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Lt middle frontal 
gyrus 
46/9 -36 36 22 6.81 0.001 638 
Rt medial frontal 
gyrus 
6/8 8 18 45 6.77 0.001 929 
Rt superior 
temporal gyrus 
22 47 13 -2 6.49 0.003 1074 
Rt inferior parietal 
lobe 
40 60 -35 33 6.38 0.003 292 
Rt precuneus 7 8 -68 38 6.10 0.008 116 
Rt middle frontal 
gyrus 
46/9 40 36 28 6.01 0.010 463 
Lt middle temporal 
gyrus 
21 -58 -12 -3 5.69 0.026 208 
Rt posterior 
cerebellum  
- 44 -60 -35 5.50 0.044 14 
 
The next section will focus on the last three painful stimulations when compared with 
baseline at the foot and then at the thigh respectively. Figure 2.48 and 2.49 show 
the areas of significant brain activation for the last three thermal stimulations at the 
foot site and the thigh site respectively for healthy volunteers. There was no 
significant brain activation during the last three painful stimulations on the foot in 
CIPN-myeloma patients whilst there was an area of significant activation during the 
last three painful stimulations on the thigh when compared to the baseline in CIPN-
myeloma group (Figure 2.50).  
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Figure 2.48: Regions of significant brain activation following the last three 
thermal stimuli to the foot (painful versus baseline) for healthy volunteers 
 
 
 
Figure 2.49: Regions of significant brain activation following the last three 
thermal stimuli to the thigh (painful versus baseline) for healthy volunteers 
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Figure 2.50: Regions of significant brain activation following the last three 
thermal stimuli to the thigh (painful versus baseline) for CIPN-myeloma 
patients 
 
Table 2.31, 2.32 and 2.33 show the areas of activation on last three painful 
stimulations on the foot and thigh in healthy volunteers and CIPN-myeloma patients 
respectively. 
 
Table 2.31: Significant brain activation on application of the thermal stimuli to 
the foot in healthy volunteers: last three painful stimuli > Baseline  
Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Rt supramarginal 
gyrus 
40 59 -43 32 6.42 0.003 840 
Lt supramarginal 
gyrus 
40 -58 -43 28 6.10 0.009 461 
Rt inferior frontal 
gyrus  
44 53 10 11 5.77 0.023 1159 
Rt cingulate gyrus 32 6 19 30 5.70 0.027 978 
Lt posterior 
cerebellum 
- -30 -59 -19 5.61 0.035 1331 
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Table 2.32: Significant brain activation on application of the thermal stimuli to 
the thigh in healthy volunteers: last three painful stimuli > Baseline  
 Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Rt superior 
temproral gyrus 
22 63 -40 22 7.37 <0.001 698 
Lt lentiform nucleus - -26 -8 8 7.09 <0.001 3481 
Lt sub-lobar insula 13 -55 -32 20 6.44 0.003 697 
Rt cingulate gyrus 24 8 -16 34 5.57 0.036 165 
Rt inferior frontal 
gyrus 
47 46 19 -8 5.40 0.050 435 
 
Table 2.33: Significant brain activation on application of the thermal stimuli to 
the thigh in CIPN-myeloma: last three painful stimuli > Baseline  
Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Rt inferior frontal 
gyrus 
47 46 15 -4 5.77 0.020 531 
 
 
2.7.8.2 Habituation: comparison between first three thermal 
stimuli vs last three thermal stimuli 
The mean BOLD activation during the first three thermal stimuli and the last three 
thermal stimuli delivered to the foot and then to the thigh in both the healthy 
volunteers and CIPN-myeloma patients were compared.  
 
Healthy volunteers 
In healthy volunteers, comparing the first three thermal pain stimulations delivered to 
the foot with the last three, showed significant activation in the left anterior lobe of 
the cerebellum and in the right claustrum. (Figure 2.51, Table 2.34) There was no 
significant brain activation when comparing the last three thermal pain stimulations 
delivered to the foot with the first three.  
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Figure 2.51: Functional image data (coronal and sagittal views) of the 
cerebellum and right claustrum activation during the application of the first 
three thermal stimuli to foot compared to the last three thermal stimuli in 
healthy volunteers  
Images are displayed against sections through a canonical single subject T1-weighted 
image. For display purposes, the voxel-level threshold is p<0.001, uncorrected at threshold 
level (kE) of 1683.  
 
Table 2.34: Significant brain activation on application of the thermal stimuli to 
the foot in healthy volunteers: First three stimuli vs last three stimuli  
 Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Lt anterior lobe 
of cerebellum 
- -18 -48 -14 6.56 0.002 4504 
Rt claustrum - -32 -23 7 6.17 0.007 1683 
 
From the contrast estimates, it is suggested that healthy volunteers demonstrated 
significant signal changes at these regions of activations (left anterior lobe of 
cerebellum and right claustrum) when comparing the first three thermal stimulations 
to the last three stimuli delivered to the foot (Figure 2.52 and 2.53).  
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Figure 2.52: Contrast estimates and 90% CI at the cerebellum (co-ordinate -18 
-48 -14) when comparing the first three thermal stimuli to the last three stimuli 
deliverd to the foot in healthy volunteers 
 
Figure 2.53: Contrast estimates and 90% CI at the claustrum (co-ordinate -32 -
23 7) when comparing the first three thermal stimuli to the last three stimuli 
deliverd to the foot in healthy volunteers 
 
In healthy volunteers, comparing the first three thermal pain stimulations delivered to 
the thigh with the last three stimuli, showed no significant activation in the brain; 
again no significant activation was demonstrated when comparing the last three 
thermal pain stimulations delivered to the thigh with the first three stimuli. 
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CIPN-myeloma patients 
In CIPN-myeloma patients, comparing the first three thermal pain stimulations 
delivered to the foot with the last three, showed different significant areas of brain 
activations (Table 2.35, Figure 2.54). There was no significant brain activation when 
comparing the last three thermal pain stimulations delivered to the foot with the first 
three painful stimulations.  
 
 
Figure 2.54: Functional image data (coronal and sagittal views) of the temporal 
gyrus and precentral gyrus activation during the first three thermal stimuli to 
foot compared to the last three thermal stimuli in CIPN-myeloma patients  
Images are displayed against sections through a canonical single subject T1-weighted 
image. For display purposes, the voxel-level threshold is p<0.001, uncorrected at threshold 
level (kE) of 144. 
 
Table 2.35: Significant brain activation on application of the thermal stimuli to 
the foot in CIPN-myeloma patients: First three stimuli vs last three stimuli  
 Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Lt medial 
temporal gyrus 
21 -40 -15 -8 5.79 0.021 386 
Rt precentral 
gyrus 
4 53 -12 41 5.63 0.033 740 
Rt precentral 
gyrus 
6 36 -4 37 5.60 0.036 843 
Rt sub-lobar 
insula 
13 30 15 -6 5.59 0.038 144 
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From the contrast estimates, it is suggested that CIPN-myeloma patients 
demonstrated significant signal changes at the regions of activations comparing the 
first three thermal pain stimulations to the last three stimuli delivered to the foot 
(Figure 2.55 a,b,c,d).  
a) 
a) at co-ordinates -40 -15 -8 (medial temporal gyrus) 
 
b) 
b) at co-ordinates 53 -12 41 (precentral gyrus, Brodmann 4) 
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c) 
c) at co-ordinates 36 -4 37 (precentral gyrus, Brodmann 6) 
 
d) 
d) at co-ordinates 30 15 -6 (sub-lobar insula) 
Figure 2.55: Contrast estimates and 90% CI when comparing the first three 
thermal stimuli to the last three stimuli deliverd to the foot in CIPN-myeloma 
patients 
 
In CIPN-myeloma patients, comparing the first three thermal pain stimulations 
delivered to the thigh with the last three, showed no significant activation and vice 
versa.  
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2.7.8.3 Habituation: Comparison between healthy volunteers 
and CIPN-myeloma patients 
The mean BOLD activation during the first three painful stimuli in healthy volunteers 
and CIPN-myeloma patients was compared and the differential cortical activation 
shown between the 2 groups during foot thermal stimulation and the thigh 
stimulation. 
During first three thermal stimuli delivered to the foot, there was a significant 
activation in the right cingulate gyrus and right anterior cerebellar lobe in healthy 
volunteers compared to CIPN-myeloma patients (Figure 2.56 and Table 2.36).  
 
Figure 2.56: Healthy volunteers demonstrated significant activation of the 
cingulate gyrus and cerebellum during the first three thermal stimuli to the 
foot when compared with CIPN-myeloma patients.  
Images are displayed against sections through a canonical single subject T1-weighted 
image. For display purposes, the voxel-level threshold is p<0.001, uncorrected at threshold 
level (kE) of 689. 
 
Table 2.36: Significant brain activation on application of the thermal stimuli to 
the foot in healthy volunteers vs CIPN-myeloma patients: First three stimuli  
 Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Rt anterior 
cerebellar lobe 
- 4 -43 -13 6.14 0.008 3569 
Rt cingulate 
gyrus 
24 14 2 35 5.84 0.018 689 
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From the contrast estimates, it is suggested that CIPN-myeloma patients 
demonstrated hypo-activation at the cingulate gyrus and the cerebellum, whilst 
healthy volunteers showed activation (Figure 2.57 a,b).  
a) 
a) at co-ordinates 4 -43 -13 (right anterior cerebellum) 
b) 
b)  at co-ordinates 14 2 35 (right cingulate gyrus) 
Figure 2.57: Contrast estimates and 90% CI when comparing the first three 
thermal stimuli deliverd to the foot in healthy volunteers and CIPN-myeloma 
patients. 
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During last three thermal stimuli to the foot, there was a significant activation in the 
right cingulate and middle frontal gyrus in healthy volunteers compared to CIPN-
myeloma patients (Figure 2.58 and Table 2.37).  
 
Figure 2.58: Healthy volunteers demonstrated significant activation of the 
anterior cingulate and middle frontal gyrus during the last three thermal 
stimuli to the foot when compared with CIPN-myeloma patients.  
Images are displayed against sections through a canonical single subject T1-weighted 
image. For display purposes, the voxel-level threshold is p<0.001, uncorrected at threshold 
level (kE) of 621. 
 
Table 2.37: Significant brain activation on application of the thermal stimuli to 
the foot in healthy volunteers vs CIPN-myeloma patients: last three stimuli  
 Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Rt cingulate 
gyrus 
24 6 -6 39 5.73 0.025 2667 
Rt middle 
frontal gyrus 
6 50 4 42 5.57 0.039 621 
 
From the contrast estimates, it is suggested that CIPN-myeloma patients 
demonstrated hypo-activation at the right anterior cingulate gyrus and the middle 
frontal gyrus, whilst healthy volunteers showed activation (Figure 2.59 a,b).  
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a) 
a) at co-ordinates 6 -6 39 
 
b) 
b) at co-ordinates 50 4 42 
Figure 2.59: Contrast estimates and 90% CI when comparing the last three 
thermal stimuli deliverd to the foot in healthy volunteers and CIPN-myeloma 
patients 
 
During first three thermal stimuli to the thigh, there was a significant activation in the 
temporal lobe in healthy volunteers compared to CIPN-myeloma patients (Figure 
2.60 and Table 2.38).  
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Figure 2.60: Healthy volunteers demonstrated significant activation of the 
temporal lobe during the first three painful heat stimulations at the thigh when 
compared with CIPN-myeloma patients.  
Images are displayed against sections through a canonical single subject T1-weighted 
image. For display purposes, the voxel-level threshold is p<0.001, uncorrected at threshold 
level (kE) of 592. 
 
Table 2.38: Significant brain activation on application of the thermal stimuli to 
the thigh in healthy volunteers vs CIPN-myeloma patients: first three stimuli  
 Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Rt temporal 
lobe 
- 34 -31 7 6.03 0.010 592 
 
From the contrast estimates, it is suggested that CIPN-myeloma patients 
demonstrated hypo-activation at the temporal lobe, whilst healthy volunteers 
showed activation (Figure 2.61).  
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Figure 2.61: Contrast estimates and 90% CI when comparing the first three 
thermal stimuli delivered to the thigh in healthy volunteers and CIPN-myeloma 
patients at the right temporal lobe (co-ordinates 34 -31 7). 
 
During last three thermal stimuli to the thigh, there was a significant activation in the 
putamen in healthy volunteers compared to CIPN-myeloma patients (Figure 2.62 
and Table 2.39).  
 
Figure 2.62: Healthy volunteers demonstrated significant activation of the 
putamen during the last three thermal stimuli at the thigh when compared with 
CIPN-myeloma patients 
Images are displayed against sections through a canonical single subject T1-weighted 
image. For display purposes, the voxel-level threshold is p<0.001, uncorrected at threshold 
level (kE) of 192. 
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Table 2.39: Significant brain activation on application of the thermal stimuli to 
the thigh in healthy volunteers vs CIPN-myeloma patients: last three stimuli  
 Region BA Talairach co-
ordinates 
Peak t p (FWE-
corr) 
Voxels 
Lt putamen - -26 -7 8 6.09 0.008 192 
 
From the contrast estimates, it is suggested that CIPN-myeloma patients 
demonstrated hypo-activation at the putamen, whilst healthy volunteers showed 
activation (Figure 2.63).  
 
Figure 2.63: Contrast estimates and 90% CI when comparing the last three 
stimuli deliverd to the thigh in healthy volunteers and CIPN-myeloma patients 
at the left putamen (co-ordinates -26 -7 8) 
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2.7.9 Reproducibility 
Four healthy volunteers were re-scanned a year later to test for reproducibility. The 
thermal stimuli to the foot and the finger tapping were repeated. Statistical 
parametric activation maps were constructed for the individual healthy volunteers. 
The mean BOLD activation in the same healthy volunteers was obtained for the first 
scanning session and the second scanning session (a year later) for the thermal 
stimuli to the foot and the finger tapping. Afterwards, using a 2-sample t-test in SPM, 
the mean BOLD activations were compared. There were no areas of significantly 
different activations when comparing the first scans to the second scans in the 
healthy volunteers both during the painful stimulation (Figure 2.64) and during the 
finger tapping (Figure 2.65). 
 
Figure 2.64: Comparison of the fMRI images of the 2nd and 1st sessions of 
scanning 4 healthy volunteers during thermal stimuli at the foot 
The design matrix on the right is showing the contrast of MR images of the 4 HV when 
comparing the 2nd session with the 1st session scanning. The image on the left displays glass 
brains in a coronal, sagittal and axial view with no significant activations.  
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Figure 2.65: Comparison of the fMRI images of the 2nd and 1st sessions of 
scanning 4 healthy volunteers during finger tapping 
The design matrix on the right is showing the contrast of MR images of the 4 HV when 
comparing the 2nd session with the 1st session scanning. The image on the left displays glass 
brains in a coronal, sagittal and axial view with no significant activations.  
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2.8 Discussion  
Chemotherapy-induced peripheral neuropathy is thought to be caused by drug-
induced damage to components of the peripheral nervous system: including 
neurons in the dorsal nerve root ganglia, axons, and Schwann cells. It is 
characterised by abnormal spontaneous discharge in A-fibre and C-fibre primary 
afferent neurons (Balayssac et al. 2011). Neuropathic symptoms are usually more 
common and severe in the lower extremities than in the upper extremities as the 
longest nerves are first affected, with sensory changes affecting the toes and later 
the fingers, before potentially progressing proximally in a glove and stocking 
distribution (Wolf et al. 2011). The sample of patients used in this study, who were 
selected specifically with signs and symptoms of CIPN, reported that numbness and 
prickling sensations were the most common symptoms from the NTSS-6 
questionnaire. This is consistent with the published literature, where the use of the 
EORTC CIPN20 questionnaire, which is specific for CIPN including three subscales 
assessing sensory, motor and autonomic symptoms, demonstrated that patients 
reported ‘quite a bit’ to ‘very much’ numbness (57%) or tingling (63%) in the hands 
and similar results were observed in the feet; numbness was highly correlated with 
tingling in the hands (r=0.69) (Wolf et al. 2011). We have not used this tool in this 
study as this was being examined in a large, international clinical trial at the time. In 
another cross-sectional study of screened patients who were treated with vinca 
alkaloids, taxanes or platinum derivatives, and using the National Cancer Institute 
Common Toxicity Criteria, it was found that 71% reported tingling, 58% had 
numbness, 46% complained of impaired sensory function and 40% reported pain in 
their hands and feet whilst 37% of patients who developed neuropathic symptoms 
scored these as the most troublesome side effect (Kautio et al. 2011). 
Structural damage to the peripheral nervous system results in abnormal 
somatosensory processing in the central and peripheral nervous system (Bhagra 
and Rao 2007). Most of the current concepts regarding the pathophysiology of 
neuropathic pain originated from experimental work in animal models indicating 
peripheral and spinal cord reorganization of nociceptive pathways (Baliki et al. 
2007). Animal models of neuropathic injuries that result in persistent pain suggest 
that peripheral and spinal cord pathways transmitting nociceptive signals towards 
the cortex undergo major reorganization (Woolf 2006; Apkarian et al. 2009). A 
recent study on two different strains of rats showed variable expression of 
experimental neuropathic pain after an injury and changes in peripheral nerve injury 
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did not differ in the DRG or spinal cord, thus suggesting that the behavioural 
difference between the rat groups lay within the brain and ultimately being 
dependent on the descending modulation that controls the spinal outcome of 
peripheral nerve injury (De Felice et al. 2011). Diabetic neuropathy which is 
characterised peripherally by axonal loss and a reduction in myelinated fibre density 
has been shown to have central nervous system involvement; MRI data has shown 
spinal cord shrinkage, thalamic neuro-chemical abnormalities and regional 
alterations in brain activations reflecting the involvement of the CNS in abnormal 
sensory perception and pain (Selvarajah et al. 2011). 
Although the main symptoms expressed in this group of MM patients were arising 
from CIPN, these patients also were fatigued and had poor physical and social 
functioning as reported from the EORTC QLQ-C30. The EORTC MY20 also showed 
they had issues around body image and this has been previously reported where 
body image significantly decreased over time in MM patients (Cocks et al. 2007). It 
is well known that pain is subjective and influenced by emotions, mood, memories, 
genetic and behavioural stimuli (Tracey and Mantyh 2007). Studies have shown that 
sad mood, anticipation and visualisation of a painful event can lead to an intensified 
pain experience (Shimo et al. 2011; Seifert et al. 2012; Yang and Symonds 2012). 
We identified regions of activation in the pain matrix during painful stimulation in 
both the healthy volunteers and the CIPN-myeloma patients and this is comparable 
to other studies and pathologies (Becerra et al. 1999; Gelnar et al. 1999; Coghill et 
al. 2003; Albuquerque et al. 2006). Activation in the right superior frontal gyrus has 
been previously reported in studies using painful stimuli in healthy volunteers. 
Activation in this area is associated with the subjective experience of the painful 
stimuli and with negative affective or unpleasant experiences (Fulbright et al. 2001). 
In CIPN-myeloma patients, there was no activation in this region and the 
explanation behind this could be that these patients having had neuropathic pain for 
two years and scoring low in the chronic pain accepting questionnaire and they were 
not the catastrophizing type (low score in the PCS). Thus, it might imply that they 
had adapted to the pain over the long time-span. This is further consolidated by the 
group-by-site interaction where CIPN-myeloma patients demonstrated significantly 
greater activation at the prefrontal cortex in response to thigh compared with foot 
thermal stimulation. This has been shown in previous studies where there was 
deactivation of the prefrontal cortex in response to pain in cluster headaches (Hsieh 
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et al. 1996) and in repetitive transcranial magnetic stimulation on acute pain induced 
by capsaicin (Tamura et al. 2004).  
There was activation of the precuneus in the CIPN-myeloma group and it has been 
reported in patients with chronic neuropathic conditions (Hsieh et al. 1995; Witting et 
al. 2001; Albuquerque et al. 2006; Buvanendran et al. 2010). There was deactivation 
of the precuneus in the healthy volunteers during thermal stimulation and this is 
consistent with the literature in normal individuals (Koyama et al. 2005; Kong et al. 
2010) The precuneus, which lies on the posteromedial aspect of the parietal lobe, 
plays a role in conscious pain perception, and is involved in a broad range of higher 
order cognitive functions. Activation of the posterior precuneus exhibits the strongest 
correlation with successful retrieval of remembered episodes (Cavanna and Trimble 
2006). In CIPN-myeloma patients the resultant activation could suggest that the 
enhanced response to painful stimulation in the precuneus was driven by 
abnormally enhanced pain-induced activation at the neuropathic site. This could 
imply that it stimulated the episodic pain memory retrieval. Furthermore, when 
investigating the group by site interaction, the current work found that CIPN-
myeloma patients demonstrated significant activation at the cuneus (found on the 
medial surface of the occipital lobe), with greater activation in response to foot 
thermal stimuli than in response to thigh stimulation. Healthy volunteers exhibited 
greater activation in response to thigh than foot thermal stimuli at this focus. This 
may potentially be explained by delivering the thermal stimulation at the foot site first 
in all cases (not randomised) in this experiment. Therefore when the thigh was 
stimulated in healthy volunteers, a pain experience had already occurred and 
perhaps been learnt and thus the cuneus was involved in the anticipatory role of 
pain. Such an effect has previously been shown in a fMRI study where right cuneus 
activation was attributed to the anticipation and subjective experience of pain 
(Fulbright et al. 2001).  
In this study, cerebellar activation during noxious stimulation was also noted and this 
has been reported previously in the literature (Peyron et al. 2000; Apkarian et al. 
2005; Kong et al. 2010). The cerebellum comprises two hemispheres that are joined 
at the midline by the vermis, with an anterior, a posterior, and a flocculonodular lobe; 
the three lobes are further divided into ten lobules, designated I to X (Schmahmann 
2000). Noxious heat stimuli in healthy volunteers can produce increased activation 
in areas that are believed to be play a part in cognitive processing together with 
sensory-motor integration (Moulton et al. 2010). It was thought that cerebellar 
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activation during painful stimulation was due to the motor response of moving away 
from pain and this has been associated with contralateral primary motor cortex 
activation (Peyron et al. 2000). However, unconscious subjects (under general 
anesthesia) also showed cerebellar activation when noxious heat stimuli where 
delivered (Hofbauer et al. 2004). A fMRI study showed that noxious stimuli activated 
different areas in the cerebellum compared to non-noxious stimuli namely the deep 
cerebellar nuclei, anterior vermis and bilaterally the cerebellar hemispheric lobule VI. 
There was also activation in ipsilateral hemispheric lobule III–VI, deep cerebellar 
nuclei and in the anterior vermis (lobule III) depending on the perceived pain 
intensity and these were associated high pain intensity ratings, which reflects a 
potential relationship between nociceptive activity in the cerebellum with pain 
perception (Helmchen et al. 2003). A further fMRI study showed that the cerebellum 
seemed to be capable of distinguishing active from passive painful stimuli (the 
painful stimulus delivered by a thermode was fixed to a lever, controlled by two 
ropes which could either be pulled by the investigator’s or the volunteer’s left hand in 
order to apply active or passive stimuli to the volunteer’s right hand) (Helmchen et 
al. 2004). The cerebellum has also been activated during the anticipation of pain in 
humans and in pain empathy (Moulton et al. 2010). Thus the role of the cerebellum 
in pain states is potentially complex. 
In CIPN-myeloma patients, there was a positive correlation between increasing 
TNSr scores and BOLD response in the operculo-insular cortex. This region 
includes parts of the insula deep inside the lateral sulcus, and parts of the frontal 
and parietal lobes that cover the insula, called the opercula, and plays a part in the 
cortical processing of painful stimuli (Baumgartner et al. 2010). There is evidence to 
show that the intensity of activation of the operculo-insular cortex correlates with the 
perceived pain intensity in the human brain (Iannetti et al. 2005). On the other hand, 
there was no correlation between Dyck’s score and brain activation, even though all 
CIPN-myeloma patients scored ≥ 4.5, which indicates neuropathy. However, dyck’s 
score is specific to diabetic patients and has not been used and validated in CIPN. 
Dyck’s scoring system measures neuropathy using a detailed methodology, with 
each individual component measures only one aspect of peripheral nerve function. 
The development of a composite measure of peripheral nerve function, the Total 
Neuropathy Score, can provide an comprehensive and easily obtained measure of 
the detection and quantification of peripheral neuropathy due to chemotherapy 
(Cornblath et al. 1999). 
Page | 200  
 
Central nervous system inputs resulting from painful stimuli undergo substantive 
modulation through spinal cord and brain neuroplasticity as well as modification from 
descending pathways. The type of the stimulation and the subject’s condition play 
important determining factors for the development of habituation or sensitization to 
the noxious repetitive stimulus. In healthy volunteers, repetitive nociceptive 
stimulation usually lessens the pain perception over time by causing habituation and 
also changes to the structure of the brain in somatosensory areas and mid-cingulate 
area (Teutsch et al. 2008). A study investigating habituation of heat pain (48°C) over 
eight days in healthy controls, in patients suffering from major depression and in 
patients suffering from chronic low back pain showed that habituation to repetitive 
heat pain was comparable between the three groups. Chronic pain patients reported 
similar pain ratings to healthy controls on the first day, however these patients 
showed higher pain thresholds than healthy controls over the subsequent days 
whilst patients with depression demonstrated significantly higher pain thresholds 
and showed a trend towards higher pain ratings per session. Furthermore, within 
each daily session, it was noted that the intensity ratings were significantly 
increased indicating sensitisation in all three groups (May et al. 2011). Sensitisation 
to a repetitive noxious stimulus seems to put the sensory system on the alert thus 
leading to higher pain ratings upon repetition whilst habituation is thought to protect 
the sensory system from non-important information (May et al. 2011). From 
neuroimaging on healthy volunteers, habituation has been demonstrated in areas 
including the primary and secondary somatosensory cortices, the insula and the 
ACC (Mobascher et al. 2010). In our study, both healthy volunteers and CIPN-
myeloma patients showed patterns of habituation when comparing the first three 
stimuli with the last three stimuli at the foot site; fMRI BOLD habituation was found in 
the right claustrum and cerebellum in healthy volunteers and in the precentral gyrus, 
sub-lobar insula and right medial temporal gyrus in CIPN-myeloma patients. 
However, there was no significant brain activation when looking for habituation at 
the thigh stimulation site in both groups. This could be explained since the stimuli in 
both groups were first delivered to the foot and afterwards to the thigh and therefore 
when the stimuli to the thigh were delivered, the subjects were already habituated 
since they had the experience of pain on their foot prior to the thigh.  
It is known that opioid analgesia attenuates cerebral responses to painful stimulation 
(Wagner et al. 2007) and opioid exposure causes functional and structural changes 
in the affect-processing and the reward circuitry (Younger et al. 2011). In our sample 
of patients, 58% were on opioids, which included oral codeine, morphine and 
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oxycodone and transdermal buprenorphine and fentanyl patches. Despite being on 
opioids, the neuropathic pain was still not well controlled as these patients reported 
high scores for neuropathic pain suggesting that this class of analgesia was not 
being very effective on decreasing the brain activation due to pain. On dividing the 
CIPN-myeloma cohort into 2 groups depending on whether or not they were on a 
regular, stable dose of an opioid, fMRI data demonstrated significant activation in 
the cerebellum in those patients receiving opioids. There are mu-opioid receptors in 
the cortex, vermis, and dentate nuclei of the cerebellum (Schadrack et al. 1999). In 
previous neuroimaging studies, after opioid administration, there have been 
decreases (Firestone et al. 1996; Wagner et al. 2001) or increases (Petrovic et al. 
2002; Leppa et al. 2006) in regional cerebral blood flow within the cerebellum. 
Furthermore, the cerebellum is known to be involved in motor functions but also in 
emotional and cognitive processing and thus opiodergic activation in the cerebellum 
in the current study could have a range of causes that would need further 
experiments to elucidate (Schmahmann and Sherman 1998).  
Clinical assessment has demonstrated that around 20% of MM patients have 
neuropathy at diagnosis, and up to 75% may experience treatment-emergent 
neuropathy. (Richardson et al. 2011) It is vital to detect neuropathy early, exclude 
reversible causes such as spinal cord compression and identify any predisposing 
factors. The degree of neuropathy should be monitored using a recognised scale 
and include neurological assessment. Despite its clinical importance, there is no 
consensus as to the best way to assess CIPN and none of the available tools were 
developed specifically for MM (Osborne et al. 2012). Whilst common toxicity scales 
can rapidly give an indication of CIPN severity, they rarely provide useful information 
regarding the detailed clinical and pathological aspects of CIPN (Cavaletti et al. 
2007). The TNSr has been shown to be a reliable tool with a high sensitivity in the 
context of CIPN (Cavaletti et al. 2007) and was used to assess neuropathy in this 
current study. In a study of 27 MM patients who received bortezomib and 
thalidomide therapy the median TNSr was 10 and this is comparable with our cohort 
of CIPN-myeloma patients where the median of TNSr was 14 (Chaudhry et al. 
2008).  
Involvement of the CNS by MM is reported to be very rare (Nieuwenhuizen and 
Biesma 2008). Myeloma patients with CIPN who took part in this study had received 
different forms of anti-myeloma therapy: vincrisitine, thalidomide and bortezomib. 
Several chemotherapy-induced CNS disorders are well described and it is known 
Page | 202  
 
that vincristine is associated with encephalopathy, cortical blindness, seizures, 
ataxia and parkinsonian-like symptoms (Quant 2010). Most drugs used as an anti-
myeloma treatment cannot permeate the blood–brain barrier (Nieuwenhuizen and 
Biesma 2008), however Hattori and Iguchi showed that thalidomide penetrates the 
blood–brain barrier and that it has a transient effect (Hattori and Iguchi 2004). To our 
knowledge, there have been no studies, specifically looking at the neurotoxic effects 
on the brain with the anti-myeloma drugs used in this study. This difference of anti-
cancer drug sensitivity between the central and the peripheral nervous system is 
that the CNS has a less permeable blood-brain barrier compared to the blood-nerve 
barrier protecting the peripheral system and thus the peripheral nervous system is 
more readily affected by drug neurotoxicity than CNS structures (Balayssac et al. 
2005). The anti-myeloma treatment in our cohort was associated with a length-
dependent sensory axonal, large>small-fibre neuropathy. This type of neuropathy 
has also been shown in a study by Chaudhry et al in 2008, where bortezomib and 
thalidomide combination therapy induced a length-dependent sensory>motor, 
axonal, large>small-fibre polyneuropathy (Chaudhry et al. 2008).  
Multiple myeloma is increasingly being considered as a chronic disease state in 
which progressive damage from the disease is compounded by cumulative 
treatment related toxicities (Brenner et al. 2009; Bird et al. 2011; Snowden et al. 
2011). 
 
Limitations of the study 
This study was a cross sectional study in which CIPN-myeloma patients were 
selected who already had neuropathy thought to be caused by vincristine, 
thalidomide and bortezomib and this was done to facilitate patient recruitment. We 
tried to ensure that the cause of the neuropathic pain in the MM patients was due to 
chemotherapy as we excluded those with a history of any other known risk factors 
for peripheral neuropathy, including diabetes, acquired immunodeficiency syndrome, 
chronic alcoholism, amyloidosis or renal failure and included only those patients 
whose pain started after they received any of the anti-myeloma therapies described 
above. Another possible limitation was the duration of thermal stimulation used. For 
the purposes of this study, a 30 second long heat-pain protocol with seven 
stimulation epochs was employed. When compared to shorter stimulation periods, 
this longer stimulation is more natural and perhaps reflects a general real life 
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experience of pain. This design was based on a pilot study that was undertaken 
prior to the main study. Despite the efficacy of producing pain-related functional 
activation, the long stimulation duration also allowed the opportunity for non-pain 
related functional changes to be detected. All the stimuli were delivered first to the 
foot and then to the thigh in both groups, thus confirming that habituation develops, 
however the stimuli sites could have been randomised with half the group receiving 
the thermal stimuli first to the thigh and then to the foot. The active and control 
groups were different in at least four ways: diagnosis of MM, diagnosis of 
neuropathy, medications, and age. The healthy volunteers were younger as the 
recruitment was mostly from hospital and university staff although there were no 
significant differences between the temperatures that were delivered and their 
resultant pain rating. The age difference makes it difficult to confidently attribute 
fMRI group differences to CIPN. Also the MM group reported poor social and 
physical functioning, which might have attributed to the central pain processing. We 
compared the cohort of MM patients with neuropathy to healthy volunteers; a more 
relevant control might have consisted MM patients who are receiving the same anti-
myeloma therapy but did not develop neuropathy. This might have led to better 
groups to compare, as the two groups would be MM patients receiving the same 
treatments. Therefore, we cannot be certain that the fMRI differences are due to the 
CIPN, although it remains the most likely explanation. 
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Chapter 3 
Living	  with	   advanced	  but	   stable	  multiple	  myeloma:	   a	  
study	  of	   the	   symptom	  burden	  and	  cumulative	  effects	  
of	   disease	   and	   intensive	   treatment	   on	   health-­‐related	  
quality	  of	  life	  	  
 
3 Introduction 
 
In the large majority of patients, MM is an incurable disease, but treatment of 
episodes may result in repeated phases of control. The number of treatment 
modalities in MM has increased significantly over the last several decades, and has 
been associated with significant increases in life expectancy (Child et al. 2003; 
Klepin and Hurd 2006; Smith et al. 2006; Bird et al. 2011) with an extension of the 
median survival by 50% at all ages (Kumar et al. 2008) and more profound 
improvements in younger patients, with predicted 5-year and 10-year survival 
estimates of over 50% and 30% respectively in patients under 60 years. (Pulte et al. 
2011). 
 Prior to the widespread use of novel agents, patients with MM were recognised to 
have the highest level of symptoms and the lowest HRQoL among haematological 
cancers (Johnsen et al. 2009). Despite enhanced disease control, none of the 
current novel agents are free of significant toxicity, which frequently persists after 
completing treatment. Myeloma is thus increasingly being considered as a chronic 
disease state in which progressive damage from MM is potentially compounded by 
cumulative treatment related toxicities (Brenner et al. 2009; Johnsen et al. 2009; 
Bird et al. 2011; Snowden et al. 2011).  
Despite the advances in treatment, and increasing numbers of patients achieving 
prolonged survival, the state of living with advanced MM in the era of novel agents is 
still poorly characterised. Many patients with MM have irreversible physical 
symptoms from the outset, particularly pain and fatigue, and, in the course of the 
disease, this is increased by progressive damage directly from MM itself and 
indirectly by the toxicity of treatments. Research has shown that pro-inflammatory 
cytokines can signal the CNS to induce symptoms of fatigue and several 
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inflammatory mediators have been linked to altered CNS activity, including IL-1β, IL-
6, and TNF-α (Collado-Hidalgo et al. 2006). In a haematological cancer study, 34 
patients aged 50 or older with acute myeloid leukaemia within 1 year of diagnosis 
showed potentially clinically important correlations between global QoL and IL-2, IL-
5, IL-8 and TNF-α. A similar correlation was observed between IL-6 and fatigue 
(Panju et al. 2009). In particular, IL-6 has been shown to play an important role in 
the inflammatory process after a nerve injury and has been linked to the 
commencement and maintenance of neuropathic pain (De Jongh et al. 2003; Lee et 
al. 2004). 
Although some toxicities may be acute, reversible and short-lived, others, such as 
peripheral neuropathy, may be insidious in onset and result in permanent damage. 
Drug toxicities and side effects may be additive or synergistic with other cytotoxic 
and supportive agents used sequentially or in combination, and to tissue/organ 
damage occurring by other means (Klepin and Hurd 2006). None of the novel 
agents are free of significant toxicity, and, perhaps ironically, many agents used in 
symptom control have significant side effects.  
In addition to physical problems that accumulate in patients with MM, psychological 
and social factors impact on HRQoL (Larsen et al. 2003; Gulbrandsen et al. 2004; 
Sherman et al. 2004; Straus et al. 2006; Frodin et al. 2010; Molassiotis et al. 2011). 
Although HRQoL has been explored previously in relation to specific treatments in 
MM patients, including transplantation (Larsen et al. 2003; Sherman et al. 2004; 
Straus et al. 2006) or more generally (Gulbrandsen et al. 2004), there is little 
information relating to the overall impact of modern clinical management strategies 
in patients with MM, particularly in the context of co-morbidities of an ageing 
population (Klepin and Hurd 2006). However, compared with some other cancers 
with prolonged survival (Mols et al. 2005), relatively little is known in MM about 
patients’ psychosocial and broader holistic needs, particularly with modern clinical 
management strategies.  
Thus, perhaps due to the tempo of improvements in survival in recent years, living 
as a long term ‘survivor’ with MM is inadequately defined. In this study, we identified 
a cohort of patients with advanced heavily pre-treated MM. In order to exclude the 
effect of active disease, we identified patients with stable disease off active 
treatment or on only maintenance. The aim of this exploratory study was therefore to 
characterise HRQoL, symptom burden and the state of living in advanced, 
intensively treated MM and find relationships between HRQoL, pain and 
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demographic variables. In addition, based on correlations between serum cytokine 
levels including IL-1β, IL-6, TNF-α, and symptoms in other cancers, (Collado-
Hidalgo et al. 2006) we used the opportunity to investigate the relationship between 
symptoms using the EORTC QLQ-C30 and BPI-SF and cytokines relevant to MM. 
Defining the elements of compromised health status on QoL will inform 
interventional studies for supportive and palliative care needs in patients with 
advanced relapsed MM to be used alongside the evolving treatments in this 
population.  
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3.1 Overview of this study 
 
3.1.1 Hypothesis 
In the modern management of advanced MM, patients are living longer and their 
lives are compromised due to a complex set of complications related to the disease 
and its treatment and these involve mainly physical and psychosocial issues.  
 
3.1.2 Primary Aims 
 
1) To characterise late effects in patients with advanced but stable MM, 
clinically and in terms of health-related quality of life and specifically define 
the physical consequences of MM and its treatment, including pain, 
neuropathy and other symptoms. 
 
2) To investigate the relationship between symptoms and functioning using the 
EORTC QLQ-C30 and BPI-SF and cytokine levels including IL-6, and tumour 
necrosis factor (TNF)-α, relevant to MM. 
 
3.1.3 Secondary Aim 
1) Comparison of the symptoms and functioning using the EORTC QLQ-C30, 
EORTC MY20 and BPI-SF between MM patients with neuropathy and those 
without using s-LANSS. 
 
The study was conducted in accordance with International Conference on 
Harmonisation-Good Clinical Practice and formally approved by Sheffield Teaching 
Hospitals NHS Foundation Trust and the local NHS Research and Development 
following local research ethics committee review. 
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3.2 Methods and Materials 
3.2.1 Patient Selection 
A diagnosis of MM was made using the criteria proposed in 2003 by the 
International Myeloma Working Group (Table 3.1). These criteria distinguish 
between MM and monoclonal gammopathy of undetermined significance principally 
on the basis of M-protein concentration, percentage of bone marrow plasma cells 
and presence or absence of myeloma-related organ and tissue impairment which 
include increased calcium levels (corrected serum calcium >0.25 mmol/l above the 
upper limit of normal or >2.75 mmol/l), renal insufficiency (creatinine >173 µmol/l), 
anaemia (haemoglobin 2g/dl below the lower limit of normal or haemoglobin 
<10g/dl), bone lesions (lytic lesions or osteoporosis with compression fractures) and 
other features like symptomatic hyperviscosity, amyloidosis, recurrent bacterial 
infections (>2 episodes in 12 months) (Bird et al. 2011).  
 
Table 3.1: Diagnostic criteria for monoclonal gammopathy of undetermined 
significance, asymptomatic myeloma and symptomatic myeloma  
adapted from (International Myeloma Working Group 2003) 
Monoclonal gammopathy 
of undetermined 
significance 
Asymptomatic 
Myeloma 
Symptomatic 
Myeloma 
M protein in serum <30g/l M protein in serum ≥30g/l 
and/or 
M protein in serum 
and/or urine 
Bone marrow plasma 
cells <10% and if trephine 
biopsy done, low level of 
plasma cell infiltration 
Bone marrow clonal plasma 
cells ≥10% 
Bone marrow plasma 
cells or biopsy proven 
plasmacytoma 
No related tissue or organ 
impairment 
No related tissue or organ 
impairment 
Myeloma-related tissue 
or organ impairment 
 
Patients recruited had received initial treatment with induction chemotherapy 
consolidated by at least one transplant procedure, followed later by treatment with at 
least one additional line of treatment for progressive or relapsed disease. 
Importantly, in order to exclude the impact of active disease and acute toxicity of 
treatment, patients were in stable plateau phase defined as a <25% change in 
serum or urine M-protein or, in patients with low serum M-proteins (<5g/L), no 
evidence of progressive disease (i.e. a rise in M-protein >5g/L), and either off active 
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cytotoxic re-induction treatment or on maintenance treatment for at least 3 months. 
Exclusion criteria included uncontrolled disease, inability to give informed consent 
and lack of fluency in English. The haematology team approached patients meeting 
the inclusion criteria when they attended for their follow-up appointment, and 
informed them of the study. The research associate, research fellow or the 
haematologist carried out the assessments. Recruitment started in July 2008 and 
ended in November 2010. The STROBE guidelines were applied for the reporting of 
this study (Osborne et al. 2003). 
 
3.2.2 Assessments 
3.2.2.1 Demographic, clinical and employment data 
Patients self completed questionnaires describing demographic and employment 
information. Clinical history, treatment and current medications were obtained from 
medical case notes. Neurological and medical examination was performed by 
myself or by another haematology doctor who was available to also recruit the 
patients.  
Serum tumour necrosis TNF-α was assayed by Immunotech TNF-α enzyme 
immunoassay whilst serum IL-6 was assayed using the electrochemilluminescence 
immunoassay (ECLIA). When blood was taken in the appropriate containers, these 
were stored immediately in freezing conditions until the samples were sent to the 
laboratory for testing. 
 
3.2.2.2 Health-related quality of life (HRQoL) 
For HRQoL measures, different questionnaires were used. A generic HRQoL 
measure was suitable for evaluating the impact of the common elements of health, 
well-being and functionality and also pain.  
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The generic Short Form-12 health survey v2 (SF-12) is a short health survey which 
is a subset of the SF-36 and utilises only 12 items drawn from each of the eight 
subscales of the SF36 (Ware et al. 1996; Jenkinson et al. 1997). SF-12 measures 
eight health domains and provides psychometrically-based physical component 
summary (PCS SF12) and mental component summary (MCS SF12) scores and 
therefore provides a glimpse into the overall HRQoL. It reflects sub-domains 
including general health perceptions, bodily pain, physical functioning, role physical, 
role emotional, social functioning (SF), mental health and energy/vitality. The PCS 
SF-12 and MCS SF-12 are computed using the scores of twelve questions and 
range from 0 to 100, where a zero score indicates the lowest level of health 
measured by the scales and 100 indicates the highest level of health (Detmar et al. 
2002). The PCS SF-12 and MCS SF-12 scores correlate 0.95 and 0.96 with the SF-
36 counterparts (Ware et al. 1996). Published reliability coefficients range from 0.73 
to 0.87 across all eight subscales of the SF-12 and test-retest reliability for PCS SF-
12 is 0.89 and for MCS SF-12 is 0.76 (Ware 2002). 
 
The European Organization for Research and Treatment of Cancer core quality of 
life questionnaire (EORTC QLQ-C30) (Aaronson et al. 1993) and the myeloma 
specific module EORTC QLQ-MY20 (Cocks et al. 2007) were used. The EORTC 
QLQ-C30 comprises nine multi-item scales: five functional scales (physical, role, 
cognitive, emotional and social); three symptom scales (fatigue, pain, and 
nausea/vomiting); and a global health and quality of life scale, three symptom 
scales, a global health and quality-of-life scale and single items assessing 
symptoms. Patients respond in a yes/no format and also a likert-scale and patients 
answer to items framed ‘the past week’. Scores for each scale were calculated as 
advised by the EORTC Study Group on QOL (Fayers et al. 2001) and linearly 
transformed.  
 
The principle for scoring these scales is the same in all cases: 
1) The average of the items that contribute to the scale is estimated and known 
as the raw score.  
The raw answers are transformed to a raw score by: 
RS= (answer 1+ answer 2+…+ answer n)/n 
n= number of questions within a scale 
2) Then a linear transformation is used to standardise the raw score to score, 
S, so that scores range from 0 to 100 
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For functional scales: S= (1- ((raw score-1)/range) *100 
Global quality of life and symptom scales/items: S= ((raw score -1)/range) *100 
 
Range is the difference between the maximum possible value of raw score and the 
minimum possible value. Therefore, the range of raw score equals the range of the 
item values. Most items are scored 1 to 4, giving range = 3. 
 
Higher scores on the functioning and global QOL scales represent better functioning 
and QOL whereas a high score for a symptom scale or item represents more 
symptoms/problems. The EORTC QLQ-C30 questionnaire has been shown to be a 
valid and reliable tool to measure QoL in research settings. The internal consistency 
of the items produced reliability coefficients of 0.52-0.89 with the exception of role 
function status (Aaronson et al. 1993). 
 
The EORTC MY20 has four scales (two symptom scales: disease symptoms, side-
effects of treatment; one function scale: future perspective, social support) and one 
single item: body image. All scores were linearly transformed to a 0–100 scale. A 
higher score on the symptom scales indicated a higher level of symptoms, whereas 
a higher score on future perspective, social support and body image indicated good 
functioning or good support. All scales except side-effects scales showed good 
convergence since the correlations between items and their hypothesised scale 
were greater than 0.4 and internal consistency was greater than 0.7 in all scales 
(Cocks et al. 2007). The EORTC MY20 is a good measure for additional aspects of 
QoL, especially issues around body image and future perspective and is a reliable 
and valid instrument for measuring QoL in MM patients. It is now recommended that 
the QLQ-C30 and QLQ-MY20 are used together to measure QoL in international 
clinical trials in MM.  
 
 
The Profile of Concerns questionnaire was adapted and used to assess concerns 
about MM (Spencer et al. 1999). This adapted version consisted of 21 items each 
naming a specific potential concern. The adapted version consisted of 21 items 
each naming a specific potential concern (range 0-5). Factor analysis restricted to 
items which were responded to by the majority of respondents, resulted in 
identification of three factors addressing 1) life and pain (8 items), 2) rejection (3 
items) looking at adverse reactions from family and friends and 3) sexuality looking 
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at dealing with being less attractive and less sexual (4 items). We included these 15 
items plus 7 additional ones thought relevant to MM patients. Each item named a 
specific potential concern and was rated on a series of 5-point Likert scales. In our 
study, Cronbach's alpha for items in pain and life issues was 0.86, for rejection 
issues was 0.89 and for sexuality issues was 0.89. 
 
3.2.2.3 Pain and peripheral neuropathy 
Pain was assessed with the Brief Pain Inventory short form (BPI-SF) (Cleeland and 
Ryan 1994) and peripheral neuropathy was assessed by using the self report Leeds 
Assessment of Neuropathic Symptoms and Signs (s-LANSS) (Bennett et al. 2005) 
and clinical neurological examination.  
The BPI-SF is a self-report measure of pain that measures the severity and location 
of pain and pain’s interference in domains of daily functioning and pain medications 
and amount of pain relief in the past 24 hours or the past week. This includes the 
three pain severity items (pain worst, pain average and pain now) and the seven 
interference items (how pain interferes with activity, mood, relations with others, 
walking ability, work, enjoyment of life and sleep). It uses simple numeric rating 
scales from 0 to 10. Pain varies considerably over a day and thus, the BPI-SF asks 
patients to rate their pain at the time of responding to the questionnaire. Also, the 
questionnaire asks the patient to specify the pain at its least, worst and average 
over the previous week. The reliability Cronbach’s alpha ranges from 0.77 to 0.91. 
BPI-SF has been shown to be psychometrically sound in its reliability and validity in 
pain and is also sensitive to changes in pain severity or pain interference resulting 
from pain treatment (Mendoza et al. 2006).  
The s-LANSS is a screening tool that aims to identify pain of predominantly 
neuropathic origin, as distinct from nociceptive pain (Bennett et al. 2005). The 
LANSS pain scale has been used widely, but as clinician examination is needed, 
this limits the instrument’s use in large-scale research. Therefore the s-LANSS is a 
modified version of the LANSS pain scale to make it capable of self-completion. The 
domains assessed are: prickling/tingling, mottled/red/pink skin, sensitive skin, 
bursting/sudden pain, hot/burning, allodynia, and numbness/tenderness. If a patient 
registers twelve or more on this scale then there is a strongly indicative that 
neuropathic pain is present to some degree. The S-LANSS has a Cronbach’s α of 
0.76 when completed unaided, rising to α =0.81 when completed at interview, 
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demonstrating a good level of internal consistency. S-LANSS score is a valid and 
reliable self-complete instrument for identifying neuropathic pain in clinic settings 
and research (Bennett et al. 2005).  
To minimise measurement error, research instruments should meet validity and 
reliability criteria. Validity is the degree to which a test measures what it claims to 
measure. It is important for a test to be valid in order for the results to be accurately 
applied and interpreted. There are three main types of validity. Content validity is 
based on the extent to which a measurement reflects the specific intended domain 
of content. Criterion related validity (instrumental validity) is used to demonstrate the 
accuracy of a measure or procedure by comparing it with another measure or 
procedure, which has been demonstrated to be valid. Construct validity is the extent 
to which a test measures the concept or construct that it is intended to measure. On 
the other hand, reliability refers to the consistency of a measure and it examines the 
amount of random error in the measurement technique, rather than random error. A 
test is considered reliable if the same result is obtained repeatedly. In group-level 
comparisons, the reliability coefficient should be 0.70, that is, 70% of the measured 
variance is reliable (Nunnally and Bernstein 2006). The reliability coefficient is the 
correlation coefficient between the two sets of scores. Measuring the reliability of 
tools occur in different ways.  
 
3.3 Statistical analysis 
Standardised measures were scored as directed in manuals and published reports.  
 
Two types of incorrect conclusions can be drawn when testing a statistical 
hypothesis. The null hypothesis is accepted or rejected on the basis of the value of 
the test-statistic. A type I error occurs when the null hypothesis is inappropriately 
rejected (false positive), indicating a test of poor specificity. A type II error occurs 
when the null hypothesis is falsely accepted (false negative), indicating a test of 
poor sensitivity (Table 3.2). Conventionally, it has been accepted that the probability 
of a type I error will be less than 5% and this is the reason for the threshold for P 
values: P must be less than 0.05 before we conclude that a study is positive. Type II 
errors are generally the result of a small sample size. To avoid the error, a sample 
size calculation is performed before beginning a study and as part of the calculation 
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asserts what a “true difference” is and accepts that this will miss it 10% to 20% of 
the time (i.e., type II error rate of 0.1 or 0.2) (American-College-of-Physicians 2001). 
 
Table 3.2: Type I and Type II errors 
 Null hypothesis (H0) is 
true 
Null hypothesis (H0) is 
false 
Reject null hypothesis Type I error 
False positive 
Correct outcome 
True Positive 
Fail to reject null 
hypothesis 
Correct outcome 
True Negative 
Type II error 
False negative 
 
 
To check if the data was normally distributed or not, the skewness and histogram 
plots with normal curve overlay were performed. The age of the patients, the years 
since diagnosis and the years since their first transplant were tested for normal 
distribution, as these characteristics are what define this cohort (Table 3.3, Figure 
3.1, 3.2, 3.3). The results show that the data was not normally distributed.  
 
 
Table 3.3: The mean, median and skewness of the MM cohort 
Statistics Age Years since 
diagnosis 
Years since 
transplant 
Mean 60.03 5.68 5.03 
Median 61.00 5.50 4.96 
Skewness -.457 .476 .663 
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Figure 3.1: Histogram plot with overlay for age of MM patients 
The data is moderately skewed to the left: the left tail is slightly longer and more data of the 
distribution is at the right. 
 
 
Figure 3.2: Histogram plot with overlay for years since the diagnosis of MM 
The data is moderately skewed to the right: the right tail is longer and more data of the 
distribution is at the left. 
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Figure 3.3: Histogram plot with overlay for years since the the first transplant 
The data is moderately skewed to the right: the right tail is longer and more data of the 
distribution is at the left. 
 
Non-parametric tests were used for descriptive statistics generally and correlation 
testing. One way t-tests were used to compare mean HRQoL scores with the 
general population (Oxford Healthy Lifestyles survey) based on published 
recommendations (Campbell et al. 2007; Walters 2009). A Mann-Whitney's U test 
was used to evaluate the symptoms and functioning using the EORTC QLQ-C30, 
EORTC MY20 and BPI-SF between MM patients with neuropathy and those without 
using the s-LANSS. A Mann-Whitney's U test counts the number of times an 
observation from sample 1 is greater than an observation from sample 2, this is 
denoted by U. Quantitative data were analysed using PASW version 18 (SPSS 
2009).  
Since the collected data had ordered categorical characteristics, the median and 
interquartile ranges were used. Nonparametric methods are most appropriate when 
the sample sizes are small and this test has the advantage of not requiring the 
assumption of normality or the assumption of homogeneity of variance. Non-
parametric tests are preferable when few assumptions can be made about the 
distribution of the data and if it is not normally distributed or contains outliers 
(Pappas and DePuy 2004). The median is a more robust measure of the centre of 
distribution, as it is not influenced by outliers and skewed data. The interquartile 
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range often represents the spread, which is simply the difference between the first 
and third quartiles. Spearman’s rank correlation coefficient was used for correlations 
between questionnaires and demographic and clinical data. Given the exploratory 
hypothesis-generating nature of the study, we used a Spearman’s rho (r) to test the 
direction and strength of the relationship between two variables and considered r of 
0.4 and below to be of low likelihood of clinical relationship, 0.4-0.6 moderate, and 
above 0.6 high clinical relationship (Swinscow and Campbell 2002). All tests were 
two-tailed and p<0.05 was used as significance level.  
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3.4 Results 
3.4.1 Demographic, clinical and employment data 
 
Basic demographic and clinical data are summarised in table 3.4. All patients were 
of Caucasian. Thirty-two patients (17 males, 15 females) were enrolled with a 
median age of 55 years (range 36-69) at diagnosis and 60 years (range 41-71) at 
assessment and a median 5.5 years from diagnosis (range 2-12) with a median 3 
lines (range 2-6) of previous treatment.  
Twenty-nine patients had been treated with high dose melphalan (140-200mg/m2) 
and autologous HSCT, and three patients had previous allogeneic HSCT, but all had 
disease progression post-transplant and none had evidence of graft-versus-host 
disease. In line with UK and local practice at the time of the study, none of the 
patients in this study had received a concurrent combination of drugs commonly 
considered to cause peripheral neuropathy i.e. bortezomib, thalidomide, or 
vincristine were never used concurrently, only sequentially, in combination with 
dexamethasone +/- other conventional chemotherapy agent (alkylating agent or 
anthracycline). At the time of assessment, twenty-nine (91%) patients were off all 
anti-myeloma treatment (except bisphosphonates) and three (9%) patients were 
receiving maintenance treatment with lenalidomide and one with interferon-alpha.  
All patients had received bisphosphonate treatment from diagnosis.  
At the time of diagnosis, 19 (59%) were employed whilst 4 (12%) were not working 
due to ill health, and 9 (28%) were retired or a home-maker. At the time of the 
assessment, 6 (19%) of this cohort were either actively employed whilst 7 (22%) 
were not working due to ill health and 16 (50%) were either retired or a home-maker 
(two (6%) missing data). The median hours worked per week had fallen from 39 at 
diagnosis (range 13-80) to 25.5 at assessment (range 11-40). Compared with when 
first diagnosed, 50% reported loss of earnings, 37% changed their job 
responsibilities and 44% felt they were less able to do their job well.  
Compared with when they were first diagnosed, 50% reported loss of earnings, 37% 
changed their job responsibilities and 44% became less able to do their job well. 
Those patients who had given-up paid work or were on long-term sick leave due to 
their illness, reported that they had been able to rethink what they wanted to do with 
their life (56%), fifty-nine percent reported that they now have a worse QoL whilst 
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30% were unsure. On the other hand, 76% were enjoying spending more time with 
their family. Forty-seven percent felt isolated at home and 72% missed their friends 
at work.  
 
Table 3.4: Demographics and clinical data of the cohort 
 
The majority of patients were married or living with a partner (87.5%). 25% of 
patients had a university or vocational degree. Patients were asked if they were 
informed of the benefits they were entitled to and 41% reported that hospital staff 
had informed them, only 9% were informed by the social worker, 16% were informed 
by their family and friends whilst 16% were not informed by anyone. Forty-two 
percent received no help in filling in the benefits form (24 patients answered, 75%) 
and 48% found it stressful completing the benefits claim.  
 
Median age at diagnosis 55 (range 36 - 69) 
Median age at assessment 60 (range 41 – 71) 
Median duration from diagnosis 5.5 years (range 2-12) 
Sex  17 males, 15 females 
Lines of treatment received  
(initial induction + HSCT counted as a single line) 
3 (range 2-6) 
 
HSCT  29 (91%) autologous HSCT  
3 (9%) allogeneic HSCT 
10 (31%) 2 HSCT procedures 
Other relevant anti-myeloma therapy  26 (81%) thalidomide (repeated 
courses) and/or lenalidomide  
27 (84%) vincristine  
22 (69%) bortezomib (all 
intravenous) 
21 (65%) doxorubicin  
32 (100%) high dose steroids 
4 (13%) interferon-alpha 
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3.4.2 Health-related QoL 
3.4.2.1 Generic QoL (SF-12)  
The sub-domains for the SF-12 are shown in Table 3.5.  
 
Table 3.5: SF-12 sub-domain health survey in the cohort of MM.  
SF 12; (n=32) Median (IQR) Mean (SD) 
Mental health 51.7 (50.5 – 52.4) 51.6 (1.3) 
Role emotional 49.2 (48.8 – 50.5) 49.6 (1.1) 
Social functioning 50.5 (49.4 – 50.5) 50.1 (0.5) 
Role physical 47.6 (45.9 – 49.0) 47.8 (2.3) 
General health 48.0 (46.8 – 48.5) 48.2 (1.4) 
Bodily pain 48.5 (48.2 – 49.4) 48.8 (1.1) 
Vitality 50.3 (49.5 – 51.0) 50.3 (0.7) 
Physical functioning 46.5 (45.8-48.8) 47.4 (2.5) 
Median, interquartile, mean and standard deviation for the SF-12 sub-domain 
A zero score indicates the lowest level of health measured by the scales and 100 indicates 
the highest level of health 
 
The main sub-domains reported as low by patients were physical functioning and 
the fatigue score in the vitality domain (Figure 3.4). 
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Figure 3.4: Sub-domain of the SF-12 looking specifically at fatigue 
 
Data from the SF-12 questionnaire was compared to the Oxford Healthy Lifestyles 
survey using a one sample t-test (Jenkinson and Layte 1997). The average score in 
the PCS SF-12 (47) of the advanced MM cohort patients were significantly lower 
than the population mean (p<0.001) but the average score for MCS SF-12 for our 
cohort (51) was similar to that of the population (50).  
 
 
3.4.2.2 Disease specific QOL 
EORTC QLQ-C30 and EORTC MY20 scores are summarised in Tables 3.6 and 3.7.  
From the EORTC QLQ-C30, All domains relating to functioning and global health 
were impaired, particularly social functioning. High levels of fatigue and pain were 
reported.  
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Table 3.6: Quality of life from the EORTC-QLQ-C30 
 
The median and interquartile range (IQR) and the mean and standard deviation (SD) 
reported. A high score (100) in the functional scales indicates better HRQoL but a high score 
(100) in the symptom scales indicate a high level of symptomatology / problems 
 
Individual items of the EORTC QLQ-C30 functioning scales reported as most 
bothersome (>25% of patients reporting ‘very much’ or ‘quite a bit’) included 24 
patients (75%) reporting inability to do strenuous activities and 21 patients (66%) 
reported having trouble taking long walks; 12 patients (37.5%) felt limited in doing 
either work or other daily activities and 15 patients (47%)felt limited in pursuing 
hobbies or other leisure time activities and 16 patients (50%) felt their physical 
function interfered with family life and 17 patients (53%) with social activities.  
From the EORTC QLQ-C30, over one-third of the patients reported that they had 
pain (‘quite a bit’ or ‘very much’; 40.7%), whilst from the EORTC QLQ-MY20 34.4% 
reported bone aches and pain and 28.1% reported back pain (‘very much’ or ‘quite a 
bit’; 28%). 
Functional Scales Median (IQR) Mean (SD) 
Physical Functioning 60 (41.7-80.0)  60.6 (25.4) 
Role Functioning 67 (33.0-79.0)  55.2 (31.2) 
Emotional Functioning 71 (44.0-92.0)  68.8 (23.9) 
Cognitive Functioning 83 (50.0-95.7)  71.8 (25.9) 
Social Functioning 50 (33.0-67.0)  46.9 (28.3) 
QoL/Global Health Status   
QoL/Global Health Status 57.5 (50.0-67.0) 58.8 (17.4) 
Symptom Scales/Items   
Pain 33 (17.0-67.0)  45.6 (31.9) 
Fatigue 44 (33.0-67.0)  48.9 (29.0) 
Insomnia 33 (0-67.0) 35.4 (36.5) 
Appetite loss 33 (0-33.0) 27.0 (31.0) 
Dyspnoea 33 (0-67.0) 33.3 (30.6) 
Nausea and vomiting 0 (0-17.0) 11.1 (17.3) 
Constipation 0 (0-33) 14.4 (24.2) 
Diarrhoea 0 (0-25) 10.4 (19.7) 
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Table 3.7: Quality of life from the EORTC MY20 
EORTC QLQ-C20 Median [IQR] Mean [SD] Range 
Subscales    
Disease specific a 22.0 [17.0-51.7] 29.0 [22.5] 0-100 
Have you had bone aches or pain? 2.0 [2.0-3.0] 2.38 [1.05] 1-4 
Have you had pain in your back? 2.0 [2.0-3.0] 2.03 [1.03] 1-4 
Have you had pain in your hip? 1.0 [1.0-2.0] 1.61 [1.05] 1-4 
Have you had pain in your arm or 
shoulder? 
1.0 [1.0-1.0] 1.16 [0.37] 1-4 
Have you had pain in your chest? 2.0 [1.0-3.0] 2.16 [0.97] 1-4 
If you had pain did it increase with 
activity? 
2.0 [1.0–3.0] 2.16 [0.97] 1-4 
Side effects of treatment a 22.0 [15.0-35.2] 25.0 [16.7] 0-100 
Do you feel drowsy? 2.0 [1.0-2.0] 1.87 [0.87] 1-4 
Do you feel thirsty? 2.0 [1.0-3.0] 2.03 [0.98] 1-4 
Have you felt ill? 1.0 [1.0-2.0] 1.56 [0.67] 1-4 
Have you had a dry mouth? 2.0 [1.0-3.0] 2.06 [1.06] 1-4 
Have you lost any hair? 1.0 [1.0-1.75] 1.37 [0.79] 1-4 
Did you have any tingling hands or 
feet? 
3.0 [1.0-3.75] 2.47 [1.19] 1-4 
Did you feel restless or agitated? 2.0 [1.0-2.75] 1.91 [0.86] 1-4 
Have you had acid indigestion or 
heartburn? 
1.0 [1.0-2.0] 1.41 [0.61] 1-4 
Have you had burning or sore eyes? 1.0 [1.0-2.0] 1.37 [0.61] 1-4 
Body Image b 33.0 [0-67.0] 41.0 [34.7] 0-100 
Have you felt physically less attractive 
as a result of your disease or 
treatment? 
2.0 [1.0-3.0] 2.15 [1.04] 1-4 
Future Perspective b 67 [44.0-78.0] 61.0 [21.7] 0-100 
Have you been thinking about your 
illness? 
2.0 [2.0-3.0] 2.31 [0.82] 1-4 
Have you been worried about dying? 2.0 [1.0-2.0] 1.72 [0.68] 1-4 
Have you worried about your health in      
the future? 
2.0 [2.0-3.0] 2.50 [0.84] 1-4 
a High scores indicate worse symptoms; b High scores indicate better support/functioning.  
Individual items score: 1 = not at all; 2 = a little; 3 = quite a bit; 4 = very much 
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Based on EORTC MY20, the most common symptom was reported by 17 patients 
as tingling in the hands and feet (53% reported quite a bit or very much). Thirteen 
patients also reported that they worried about their health in the future and 11 
patients thought about their illness (41% and 34% respectively reported quite a bit or 
very much). 
 
3.4.2.3 Pain and peripheral neuropathy  
Pain scores in the Brief Pain Inventory short form (BPI-SF) showed a median of 3 
(range 0 -10) for the cohort. The average pain was reported as mild (0-3) by 50% of 
patients, as moderate (4-6) by 38% and severe (>6) by 10% (1 missing data). As 
shown in Table 3.8, there were no significant differences between males and 
females in the pain scores in the BPI-SF.  
 
Table 3.8: BPI-SF for males and females  
 Males Females P-value 
Worse pain 4.0 (2-7.5) 4.0 (2-5) 0.29 
Least pain 1.0 (0-2.5) 1.0 (1-3) 0.65 
Average pain 3.0 (2-5) 4.0 (1-5) 0.35 
Pain right now 2.0 (1-5) 3.0 (1-4) 0.86 
Pain Interference 3.0 (1-5) 3.0 (2-4) 0.92 
 
The Mann-Whitney U Test to compare the medians (p-value); (Pain range 0 -10).  
 
There was no significant association between average pain severity scores and sex, 
years since diagnosis and years since the first transplant. 
On the s-LANSS, 16 patients (50%) scored ≥12 consistent with a predominantly 
neuropathic origin of pain. This was supported by the neurological examination, 
which showed signs of sensory neuropathy in 20 patients (67%).  
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Twenty-two (69%) patients were prescribed different types of analgesia for pain: 15 
out of the 22 (68%) patients were on opioids - six patients being on tramadol and 
codeine (40%), three being on fentanyl patches (20%), five on oxycodone (33%) 
and one on methadone (7%). Out of the 22 patients, 15 (68%) were on calcium 
channel blockers as a form of analgesia namely, six being on gabapentin (37%) and 
nine being on pregabalin (63%). 
 
3.4.2.4 Concerns  
Analysis from the adapted concerns questionnaire revealed that patients were 
worried that they will lose their independence and self-sufficiency, the cancer will 
come back and their life with their partner will be cut short (median 5; range 0-5). 
The least concerns for our group were that their family will be angry at them, they 
will argue more with their partner and they will be rejected by their friends or that 
their illness was contagious (median 1; range 0-5). The data was analysed for sex 
differences and there were no real correlations to factors for life and pain issues, 
sexuality issues and also for rejection issues. In older patients, their concerns of 
losing their independence increased (r=0.379, p=0.02). There was a positive 
correlation between concerns about life and pain issues and rejection issues 
(r=0.889, p<0.001) and a positive correlation between concerns about sexuality 
issues and rejection issues (r=0.436, p=0.01). Cronbach's alpha for items in pain 
and life issues was 0.86, for rejection issues was 0.89 and for sexuality issues was 
0.89. 
 
3.4.3 Correlations between clinical demographics, HRQoL, 
pain and cytokines 
There were significant correlations between QoL by EORTC QLQ-30 and the BFI-
SF scores for ‘pain on average’ (p=0.001) and pain interference with general 
activity, mood, walking, work, relations, sleep, and enjoyment of life (p<0.001). 
Physical functioning from EORTC QLQ-30 was significantly correlated with ‘pain on 
average’ based on the BPI-SF (p=0.006) and fatigue from the SF-12 (p=0.001). 
However, there were no correlations between HRQoL and age, sex, years from 
diagnosis and lines of treatment received.  
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Serum IL-6 was positively correlated with pain (p=0.03) and pain interference 
(p=0.003) based on the BPI-SF and inversely correlated with physical functioning 
(p=0.03) from the EORTC QLQ C30. Also serum IL-6 was positively correlated with 
insomnia (p=0.02) and appetite loss (p=0.02).  However, there were no significant 
relationships with TNF-α for these measures and no relationships were 
demonstrated between fatigue, overall HRQoL or other patient related factors and 
cytokine levels (Tables 3.9 and 3.10). 
Table 3.9: Correlations of cytokines with EORTC QLQ C30  
r = Spearman’s rho correlation coefficient 
 
Table 3.10: Correlations of cytokines with BPI-SF 
r = Spearman’s rho correlation coefficient 
Functional Scales IL-6 (p value; r) TNF-α (p value; r) 
Physical Functioning 0.03; -0.38 0.62; -0.91 
Role Functioning 0.07; -0.33 0.63; 0.09 
Emotional Functioning 0.85; 0.03 0.93; -0.02 
Cognitive Functioning 0.61; -0.09 0.39; 0.16 
Social Functioning 0.81; -0.04 0.22; 0.22 
QoL/Global Health Status   
QoL/Global Health Status 0.23; -0.22 0.63; -0.09 
Symptom Scales/Items   
Pain 0.02; 0.41 0.84; 0.04 
Fatigue 0.37; 0.16 0.89; 0.25 
Insomnia 0.02; 0.40 0.47; 0.13 
Appetite loss 0.02; 0.41 0.09; 0.30 
Dyspnoea 0.20; 0.23 0.66; 0.08 
Nausea and vomiting 0.28; 0.20 0.31; 0.18 
Constipation 0.57; 0.34 0.16; 0.26 
Diarrhoea 0.37; -0.16 0.51; -0.12 
BPI-SF IL-6 (p value; r) TNF-α (p value; r) 
Average pain 0.03; 0.38 0.15; 0.27 
Pain interference 0.003; 0.516 0.46; 0.14 
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3.4.4 Comparison between myeloma patients with 
neuropathy and myeloma patients without neuropathy  
 
Using s-LANSS, 16 patients (50%) scored ≥12 consistent with a predominantly 
neuropathic origin of pain (1 missing data) (Table 3.11). 
 
Table 3.11: Males and females with and without neuropathy according to s-
LANSS 
s-LANNS ≥12 
Neuropathy group 
s-LANNS ≤12 
Non-neuropathy group 
Males: 8 Males: 8 
Females: 8 Females: 7 
  
A Mann-Whitney's U test was performed to evaluate the differences in symptoms 
and functioning using the EORTC QLQ-C30, EORTC MY20 and BPI-SF between 
the two groups. It was found there was a significant difference (myeloma patients 
with neuropathy having worse symptoms) with regards to the physical, role and 
social functioning from the EORTC QLQ-C30 (Table 3.12); side-effects of treatment 
and future perspectives from the EORTC MY20 (Table 3.13) and average pain and 
pain interference from the BPI-SF (Table 3.14) between the 2 groups.  
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Table 3.12: Mann-Whitney's U test comparing neuropathy and non-neuropathy 
groups for the EORTC QLQ-C30 
 
Table 3.13: Mann-Whitney's U test comparing neuropathy and non-neuropathy 
groups for the EORTC QLQ-MY20 
EORTC QLQ-MY20 subscales Mann-Whitney U p value 
Disease specific  86.0 0.175 
Side effects of treatment  56.0 0.011 
Body Image  107.0 0.587 
Future Perspective  65.0 0.026 
 
Table 3.14: Mann-Whitney's U test comparing neuropathy and non-neuropathy 
groups for the BPI-SF 
BPI-SF Mann-Whitney U p value 
Average pain  58.5 0.024 
Pain interference  51.5 0.012 
 
Functional Scales Mann-Whitney U p value 
Physical Functioning 54.0 0.009 
Role Functioning 65.0 0.027 
Emotional Functioning 81.5 0.125 
Cognitive Functioning 97.0 0.35 
Social Functioning 78.0 0.09 
QoL/Global Health Status   
QoL/Global Health Status 90.5 0.232 
Symptom Scales/Items   
Pain 83.5 0.227 
Fatigue 111.5 0.734 
Insomnia 77.0 0.126 
Appetite loss 113.5 0.783 
Dyspnoea 116.5 0.884 
Nausea and vomiting 105.0 0.50 
Constipation 78.0 0.056 
Diarrhoea 107.5 0.518 
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The mean ranks for physical, role and social functioning from the EORTC QLQ-C30 
and future perspectives from the EORTC MY20 were higher in the non-neuropathy 
group (s-LANSS ≤12) meaning that this group had better functioning whilst the 
mean ranks for side-effects of treatment from the EORTC MY20 and average pain 
and pain interference were higher in the neuropathy group (s-LANNS ≥12) meaning 
that this group had more pain symptoms. However there was no significant 
difference between groups in age or sex, years since diagnosis, QoL, and emotional 
functioning (Table 3.15).  
 
Table 3.15: The mean ranks from the Mann-Whitney's U test  
 s-LANSS Mean Rank 
Physical functioning ≤12 
≥12 
20.40 
11.88 
Role functioning ≤12 
≥12 
19.67 
12.56 
Social functioning ≤12 
≥12 
18.80 
13.38 
Side effects of treatment ≤12 
≥12 
11.73 
20.00 
Future perspectives ≤12 
≥12 
19.67 
15.19 
Average pain ≤12 
≥12 
11.68 
18.84 
Pain interference  ≤12 
≥12	 
11.18 
19.28 
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3.5 Discussion  
In previous decades, when the average survival of patients with MM was relatively 
short and treatment options limited, the emphasis was on providing suppression of 
disease along with symptom relief and ultimately terminal care. In the modern 
management of advanced intensively treated MM, patients are living longer and are 
compromised due to a complex set of physical and psychosocial complications. 
Perhaps due to the tempo of improvements, QoL in long-term survivors of MM has 
been poorly characterised especially when compared to some other cancers where 
patients have prolonged survival.  
In this study we identified a cohort of patients with advanced, multiply relapsed and 
intensively pre-treated, but stable MM. Despite disease stability, the absence of 
acute treatment-related toxicity and standard use of supportive care measures (such 
as analgesics and bisphosphonates), our findings confirm significant compromise of 
physical and social functioning as well as QoL, which was closely related to a 
persistent and cumulative symptom burden. Although the influence of fatigue and 
pain on HRQoL has long been recognised in MM, (Gulbrandsen et al. 2004) the 
novel finding of this study is that on-going fatigue and pain are significant symptoms 
in longstanding MM patients, even in stable phase disease. Moreover, in our study, 
half of the patients had neuropathic pain. Clinical assessment has shown that up to 
20% of MM patients have clinical or sub-clinical evidence of neuropathy at diagnosis 
and as many as 75% may experience neuropathy during treatment (Richardson et 
al. 2011) but our study suggests continued suffering in patients with stable disease. 
Also our study showed that MM patients with neuropathy had a worse physical, role 
and social functioning; increased pain and pain interference when compared to MM 
patients who did not report neuropathy. In a study by Johnsen et al, patients with 
MM generally had the highest level of symptoms and problems compared to patients 
with other haematological diseases (Johnsen et al. 2009), and this was also 
supported by an earlier study in Nordic patients with MM six months of treatment 
had similar functioning and physical symptoms to our group of patients (Wisloff et al. 
1996). The influence of fatigue and pain on HRQoL has long been recognised in MM 
(Gulbrandsen et al. 2004).  
These findings in chronic stable MM cohort build on to other studies which have 
used broader more heterogeneous MM patients from all stages of disease, including 
those on acute treatment, where functioning is significantly impaired with fatigue, 
pain and peripheral neuropathy, insomnia and future health worries in around 30-
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40% of patients (Molassiotis et al. 2011). Compared with early stage disease 
assessed with EORTC QLQ C-30 and EORTC MY-20 (Cocks et al. 2007), our more 
advanced, heavily treated cohort had greater symptom burden, reduced body 
image, and more impairment of future perspectives. These are compounded by 
concerns of loss of independence, disease recurrence and death, despite control of 
their disease. Compared to a recent study, in which 25 MM patients were followed 
up 3 years after their autologous stem cell transplantation, our group of patients 
were five years post transplantation, and were found to have worse physical 
functioning, social functioning, emotional functioning and cognitive functioning whilst 
there was no difference in the QoL; also our group had worse pain and insomnia 
(Frodin et al. 2010). This might indicate that the longer these patients survive, the 
more troubled they are with symptoms thus follow-up at regular intervals is crucial to 
identify and manage these. In our study, overall mental functioning (measured by 
MCS SF-12) was preserved, suggesting effective coping mechanisms as these 
patients have been living with MM for a number of years. In a review by Pidala et al, 
it was suggested that patients who undergo autologous bone marrow transplantation 
return to their baseline emotional functioning by 3–6 months (Pidala et al. 2010). 
IL-6 is an important cytokine in the pathophysiology of MM, and is related to disease 
activity (Vito Michele 2001). Interestingly, correlations were detected between pain, 
physical functioning, insomnia and appetite loss and the cytokine IL-6, in this stable 
advanced cohort. However, as the correlation coefficients were generally low to 
moderate strength, we do not regard this as definitive data, but more a basis for 
future investigation as to whether a causative or other relationship (such as a 
biomarker) exists between IL-6 levels and these symptoms. A study investigating 
levels of pro-inflammatory cytokines IL-2 and TNF-α together with anti-inflammatory 
cytokines IL-4 and IL-10 in patients with painful and painless neuropathy and 
healthy volunteers showed that patients with painful neuropathy had increased 
levels of IL-2 and TNF-α, whilst patients with painless neuropathy had significantly 
higher levels of IL-4 and IL-10 (Uceyler et al. 2007). This indicates that interactions 
between these cytokines are vital for the pathophysiological changes associated 
with pain and additional cytokines may also be involved in the development of 
painful CIPN. We had specifically recruited patients with chronic stable MM and the 
relationship with pain and reduced physical functioning in this setting warrants 
further investigation. In other cancers inflammatory mediators have been linked to 
altered CNS activity, potentially influencing the perception of pain and other 
symptoms (Collado-Hidalgo et al. 2006).  
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As to whether novel strategies used in other cancers can improve HRQoL in the 
expanding population of long surviving myeloma patients requires further 
investigation. A randomised controlled trial of HRQoL assessments in general 
oncology practice demonstrated that these led to the encouragement of the 
discussion of QoL issues and increased the physicians’ awareness of their patients’ 
QoL together with greater patient satisfaction (Detmar et al. 2002). Other evidence 
suggests that cancer patients do not always report QoL problems during clinical 
appointments (due to time constraints, or sensitive nature of the problems) (Velikova 
et al. 2008) and compared to patients and their partners, physicians tend to 
overestimate patients’ QOL and underestimate symptoms (Hendriks and Schouten 
2002). Therefore, approaches to improve HRQoL may be economically beneficial, 
both individually and societally and have implications for a multi-disciplinary 
approach. Our study confirmed significant work disability and early retirement, along 
with restricted physical and social activities in patients with an average age of 
presentation of 55 years. In other settings, returning to or maintaining employment 
after cancer is important for survivors’ QoL, including mental and physical health 
(Aaronson et al. 1993). Furthermore, employment earnings can improve standards 
of living and a return to normal life activities (van der Wouden et al. 1992).  
Given the range of late-effects from MM treatment, management demands a multi-
faceted approach. Previously patients have been managed in a variety of settings, 
from general haematology clinics in a busy district general hospital to specialist 
clinics in tertiary referral centres, where, for example, there may be immediate 
availability of transplant services. Availability of specialist palliative and supportive 
care services also may vary considerably between units. However, there is a 
balance between local services, which might lack disease specific expertise but are 
convenient for the patient, versus centralised specialist services working alongside 
the haematologist, which may not always be desirable in terms of patient travelling. 
It might be better for patients with early diagnosis to be treated in centralised 
specialist services and localised services might be more appropriate for relapsed 
patients approaching end of life although this will depend on the patient and their 
carers’ preference and is locality dependent. 
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Limitations of this study 
We recognise that this exploratory, cross-sectional study has limitations, including 
relatively small numbers, and the fact that it included some patients who had 
previous allogeneic HSCT. However, all these patients had at least one episode of 
disease progression post transplant, and such patients would feature in specialised 
myeloma clinics in tertiary care centres. One further limitation is that our inclusion 
criteria also included patients on maintenance treatment. These included a minority 
who received maintenance treatment with lenalidomide or interferon-alpha, which 
have recognised side effects, and may have influenced the results of this analysis.  
This study was exploratory and was not designed to arrive at a firm conclusion 
regarding the issue of overlapping toxicities or the effect of cumulative dose from 
different chemotherapeutic agents. In line with UK and local practice at the time of 
the study, none of the patients in this study had received a combination of drugs 
commonly considered to cause peripheral neuropathy i.e. bortezomib, thalidomide, 
or vincristine were never used concurrently, and only sequentially, mainly in 
combination with dexamethasone +/- alkylating agent. We recognise the cumulative 
doses of individual agents may have varied between individuals, and that toxicities 
(such as peripheral neuropathy) from one drug may have persisted and then 
overlapped with later toxicities from other drugs, and a more complex analysis is 
desirable. We do not feel it is achievable with the present study, but future 
prospective studies designed to elucidate the impact of cumulative doses and 
overlapping toxicities are warranted.  
Furthermore, it is important to point out that this study selected younger, intensively 
treated myeloma patients, all of whom had at least one HSCT procedure and is not 
representative of all MM patients, particularly those in older age groups who have 
less intensive treatments.  
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Chapter	  4	  
4 Conclusions from both studies 
 
Chemotherapy-induced peripheral neuropathy is becoming increasingly common as 
patients are living longer and being exposed to more toxic treatment that will give 
them a longer life expectancy but with the deleterious consequences of side effects. 
Neurotoxicity can be so severe that it can limit the dose of chemotherapy or even 
potentially stop curative cancer treatment thus having an impact on survival. It has 
been well established that the incidence of CIPN can be variable, ranging from 0% 
to 70% of patients receiving chemotherapy, but generally occurring in 30–40% of 
patients. This variability is associated with several factors that can influence the 
development of CIPN especially, the patient’s age, dose intensity, cumulative dose 
and the duration of treatment, administration of other neurotoxic agents, and pre-
existing conditions such as diabetes (Barton et al. 2011) as well as the diagnostic 
criteria used and if neuropathy was measured using tools and neurophysiological 
testing. Once CIPN develops, especially with a subgroup of chemotherapy agents, it 
is usually long lasting and irreversible causing great suffering and disability to 
patients affecting their QoL as has been demonstrated in my studies. Unfortunately, 
clinical practice has shown that the current analgesics that are used for patients 
suffering from CIPN only provide pain relief in a small number of patients and this is 
sometimes only achieved at the expense of often, intolerable side effects. Although 
several therapies have been studied for the prophylaxis of CIPN; none have been 
effective and there are no clear guidelines regarding the use of prophylaxis. On the 
other hand, pharmacological treatment for neuropathic pain using various drugs, 
including antidepressants, calcium channel blockers, opioid agonists, and topical 
lidocaine, have been shown in randomised controlled clinical trials to be efficacious 
(Attal et al. 2010; Baron et al. 2010; Dworkin et al. 2010). However, to date, there 
have not been any trials of the use of opioids in patients with CIPN. Several of our 
patients in this fMRI study have been on opioids although their neuropathic pain 
linked to chemotherapy was not well controlled. There are concerns with the use of 
long-term opioids, such as physical dependency, misuse or abuse, and 
immunological changes; however if patients are selected properly, opioids may be a 
good option. As there is no effective prophylaxis for CIPN, the aim is to manage 
symptoms using drugs targeted at known chronic pain mechanisms including 
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calcium channel blockers and serotonin–norepinephrine reuptake inhibitors. The 
management of peripheral neuropathy should include symptom control, and dose 
adjustment of the anti-myeloma therapy alongside treatment of any potentially 
reversible causes. 
Due to the heterogeneity of neuropathic pain mechanisms and the coexisting 
psychological and emotional aspects of pain, treatment can be difficult and therefore 
needs a multidisciplinary therapeutic approach. This includes not only multimodal 
pharmacology, but also and non-pharmacological treatment regimens, such as 
psychological, physical, and occupational therapy. It is imperative in the 
development a holistic approach to neuropathic pain management that a correct 
diagnosis of the cause of pain is made, the type of pain is determined, and an 
appropriate treatment plan is made. Symptoms of neuropathy in the feet should be 
evaluated distinctly from those in the hands as they have been shown to differ and 
tend to be more severe in the lower extremities for individual patients. A better 
understanding of CIPN and its pathophysiological mechanisms into sensory signs 
will lead to a more effective and specific mechanism-based treatment approach 
(Baron et al. 2010). 
Structural damage to peripheral nerves causes abnormal somatosensory processing 
of the peripheral and possibly of the central nervous system (Windebank and 
Grisold 2008). When there is damage to the small nerve fibres this leads to burning 
and lancinating pain, cutaneous hyperesthesia, and loss of pain and temperature 
senses whilst involvement of large nerve fibres results in loss of vibration sense, 
loss of proprioception, loss of reflexes, muscle weakness, and slowed nerve 
conduction (Wolf et al. 2011). Chemotherapy-induced peripheral neuropathy has 
traditionally been considered a disease of the peripheral nerve only, with not much 
emphasis at how the brain interprets this pain and whether changes occur at the 
level of the central nervous system. Our results indicate that fMRI is capable of 
providing novel information with respect to the processing of pain within the CNS in 
CIPN. Our results also show that painful stimuli delivered to neuropathy-affected 
and symptom-free sites in CIPN evoke differential activation of distinct cortical 
regions and therefore we deduce that the nociceptive system undergoes plastic 
changes, which appear to reflect abnormal central pain processing. Functional MRI 
acquired in the context of pain stimuli and CIPN may thus help elucidate 
pathogenesis and development, stimulate treatment development and target and 
monitor future treatment to aid the successful survival of patients with treatable MM. 
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As well as reducing tumour load and prolonging life, it is important to take into 
account the cumulative burden of the disease and treatment-related symptoms (both 
acute and long-term), co-morbidities and the large range of associated 
psychological and social issues in patients with advanced MM (Ahmedzai and 
Walsh 2000). Stable disease after induction, after transplantation and after post-
transplant salvage therapy is quite different and patients have different symptom 
burdens depending on stage of the disease and the treatment they received (Kvam 
et al. 2009; Frodin et al. 2010). Supportive care plays an increasingly important part 
in the modern management of MM in maintaining a good QoL from the initial 
diagnosis through the different stages of active treatment and towards the end of 
life. Supportive care aims to maximise the benefits of treatment by ensuring the 
patients with MM maintain as high a QoL in spite of incurable disease and the 
cumulative effects of disease and treatment. Optimal comprehensive care in MM 
therefore requires an on-going multidisciplinary approach, including both nursing 
and supportive care, to improve an active awareness and appreciation of HRQoL, in 
both active and inactive disease (Bird et al. 2011). In the recently published British 
supportive care guidelines for MM, routine systematic assessments, such as holistic 
needs questionnaires and/or care plans, and specific interventions for fatigue, pain 
and rehabilitation have been recommended (Snowden et al. 2011). Further studies 
are needed to determine the benefit of such intervention with respect to HRQoL and 
functioning in patients at all stages of MM. 
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Chapter	  5	  
5 Final discussion and future work 
 
The principal aims of this work were to investigate the involvement of the CNS in 
MM patients with CIPN and to have a better understanding of what living with MM 
means to these patients clinically and in terms of health-related quality of life. 
In the first study (Chapter 2), the fMRI data reported suggests that painful stimuli 
delivered to myeloma patients with CIPN evoke differential activation of distinct 
cortical regions, reflecting different central pain processing when compared to 
healthy volunteers. In CIPN-myeloma patients, there is a possibility that neural 
adaptations have occurred secondary to sustained abnormal peripheral input. There 
was activation in the right superior frontal gyrus in healthy volunteers but not in 
CIPN-myeloma patients during heat-pain stimulation whilst there was activation of 
the precuneus in the CIPN-myeloma group and deactivation in the healthy 
volunteers during this stimulation. In addition, significant correlations were also 
found between brain activation in the operculo-insular cortex and the reduced 
version of Total Neuropathy Score. These findings highlight anatomical-functional 
regions that have been previously shown to be involved in other pain studies; 
however, this is the first identification of pain function-neuroanatomical correlates in 
the context of CIPN in MM. This shows that fMRI is capable of providing novel 
information with respect to the processing of pain within the CNS in CIPN. It could 
be postulated that cerebral involvement may occur concomitantly with peripheral 
nerve damage and these findings demonstrate clearly that the neuropathic process 
associated with CIPN is not confined to the peripheral nerve only but does involve 
the functioning of the brain. The study was cross-sectional, where CIPN-myeloma 
patients already had developed neuropathy. Taking this work forward, a sample of 
MM patients who are on the same chemotherapeutic agents but who do not develop 
neuropathy is being studied and compared to CIPN-myeloma patients and healthy 
volunteers. Prospective longitudinal studies would help to determine the natural 
history of cerebral involvement in CIPN and whether CNS involvement precedes 
peripheral nerve involvement. Provision of an early objective CNS marker with 
regards to the development of neuropathy may guide the development and objective 
assessment of much-needed pharmacological interventions, which could improve 
therapeutic response with minimal toxicity. Characterisation of the pain matrix 
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activation in CIPN may also identify novel CNS targets that could drive the 
development of new pharmaceuticals, or new ways of using current drugs. 
Furthermore, as CIPN occurs in many other cancers because of cytotoxic drug 
effects and new biological agents, prospective studies in the future will be of 
potential benefit not only to MM patients but other cancer patients undergoing anti-
cancer treatment to improve and enhance their QoL. It has been suggested that 
combination of fMRI and drug administration may prove useful in the future 
development of new analgesic compounds (Schweinhardt et al. 2006).  
Recent advances in our understanding of human brain function have been driven by 
the introduction of fMRI (Boguslawska et al. 1999). The non-invasive, ionising-
radiation free aspect of fMRI is useful in studies investigating the perception and 
modulation of pain using experimental noxious stimuli. Functional MRI has been 
used to characterise a network of brain areas that activate in response to pain 
stimuli, identifying a ‘pain matrix’ (Melzack 1999). Both clinical and experimental 
studies have shown interactions between pain unpleasantness, pain intensity and 
emotions, and neuroimaging studies have unravelled structures transmitting pain 
including the ascending spinal pathways and a central network of brain structures. 
The spinal pathways converge onto the brain stem, thalamic nuclei, the 
sensorimotor cortices and the limbic system (amygdala, hypothalamus, insular 
cortex, ACC) (May 2007). However, the pain matrix cannot be viewed as a single, 
stand-alone entity, which is implicated in nociception. Instead, it should be seen as a 
flexible system which is actively modulated by a variety of brain regions depending 
on inter-individual variability (due to emotion, chronic illness, previous experiences) 
which influence the perception of pain (Bingel and Tracey 2008). Disruption of the 
pain matrix, and the pathways between them, are thought to have implications for 
the pathogenesis and persistence of neuropathic pain (Tracey 2005). Studies have 
begun to evaluate CNS changes that occur in patients with neuropathic pain but to 
our knowledge, there have been no fMRI studies in multiple MM patients who have 
developed treatment emergent CIPN in myeloma.  
 
In the second study (Chapter 3), despite disease stability and absence of acute 
treatment toxicity in this specific group of younger MM survivors, the results showed 
that patients were significantly compromised by physical symptoms and 
psychosocial interactions. Among the strengths of this study was the use of 
validated measures to assess a range of outcomes amongst a sample of MM 
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patients at a similar point in treatment. Although care was taken to select 
psychometrically good instruments, scores on these measures cannot substitute for 
clinical diagnoses such as major depression, adjustment disorders, and steroid-
induced mood disorder. Another important limitation was the cross-sectional design; 
however it was perceived that there was a strong practical need for information 
about symptom burden during this phase of treatment, but obviously in clinical care, 
it is important to assess changes in adjustment and QoL throughout the course of 
disease and thus future longitudinal evaluations are needed. Future studies should 
also determine whether interventions such as routine use of systematic evaluations 
including the use of HRQoL assessments, holistic needs questionnaires and/or care 
plans, and specific interventions for fatigue, pain and rehabilitation can lead to 
improvements in HRQoL and functioning at all the stages of MM.  
Many patients with MM have a significantly prolonged survival through modern 
treatments that have improved disease control to the extent that MM now has the 
potential to be a chronic disease. The majority of these patients are now living with 
the burden of MM together with the cumulative side effects of treatments. Thus 
optimal supportive and palliative care is necessary in parallel with disease control to 
maximise QoL at all stages of the disease. Preservation of a good QoL presents 
challenges from diagnosis through the multiple phases of active treatment to the end 
of life. One of the commonest symptoms MM patients experience is pain and this 
could be the reason for presentation or subsequent relapse and also could be due to 
the side effects of the treatment. As the National Institute for Health and Clinical 
Excellence guidance has suggested supportive care is ‘care that helps the patient 
and their family to cope with cancer and treatment of it – from pre-diagnosis and 
treatment, to cure, continuing illness or death and into bereavement. It helps the 
patient to maximize the benefits of treatment and to live as well as possible with the 
effects of the disease. It is given equal priority alongside diagnosis and treatment’ 
(NICE 2004). In recently published supportive care guidelines for MM, it has been 
recommended that all patients should be assessed for unmet holistic needs at key 
times (at diagnosis, after initial treatment, during follow-up) in the disease trajectory 
(Snowden et al. 2011). 
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• E. Cachia, D. Selvarajah, M. D. Hunter, J. Snowden, S. H. Ahmedzai, and I. 
D. Wilkinson. Central Pain Processing in Chemotherapy Induced Peripheral 
Neuropathy. European Journal of Palliative Care, (2011), Abstract number: 
FC6.3, Abstract type: Oral. 
• E. Cachia, D. Selvarajah, M. D. Hunter, J. Snowden, S. H. Ahmedzai, and I. 
D. Wilkinson. Intracranial pain processing on fMRI in chemotherapy-induced 
peripheral neuropathy. (2011). European Society for Magnetic Resonance in 
Medicine, Abstract number: 356, Abstract type: Oral. 
• E. Cachia, D. Selvarajah, M. D. Hunter, J. Snowden, S. H. Ahmedzai, and I. 
D. Wilkinson. Central pain processing in chemotherapy induced peripheral 
neuropathy. Proc. Intl. Soc. Mag. Reson. Med. 19 (2011); 4167; Abstract 
type: Electronic poster. 
• E.Cachia, D. Selvarajah, R. Gandhi, A, Sankar, J. Snowden, SH Ahmedzai, 
S.Tesfaye, ID Wilkinson. Investigating the neural basis of pain processing in 
diabetic peripheral neuropathy and chemotherapy-induced peripheral 
neuropathy. Palliat Med 24: S5 (2010); Abstract number: 362, Abstract type: 
Poster. 
 
Oral presentations:  
 
The data generated in this thesis has been presented at local, national and 
international meetings including: 
 
• The British Pain Society Annual General Meeting (April 2012) - Central pain 
processing in chemotherapy-induced peripheral neuropathy. 
• European Society for Magnetic Resonance in Medicine, Leipzig (October 
2011) - Intracranial pain processing on fMRI in chemotherapy-induced 
peripheral neuropathy.  
• The University of Sheffield Radiology Symposium (October 2011) - 
Chemotherapy & the 'pain matrix. 
• European Association of Palliative Care, Lisbon (May 2011) - Central pain 
processing in chemotherapy-induced peripheral neuropathy in myeloma.  
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• APM AGM Mini conference, Dublin (March 2011) - Central pain processing 
in chemotherapy-induced peripheral neuropathy in myeloma.  
• Advanced Course in Pain and Symptom Management, Nottingham and 
Oxford (June, July 2010) - Pain, Neuropathy & Imaging. 
• Specialised Medicine and Specialised Cancer Services Joint Research 
Symposium, Sheffield (January 2010) - A study of pain, peripheral 
neuropathy and psychosocial late effects in patients with intensively treated 
advanced multiple myeloma. 
 
Manuscripts in preparation:  
• Elaine Boland, Christine Eiser, Yousef Ezaydi, Diana M Greenfield, Sam H 
Ahmedzai, John A Snowden. Living with advanced but stable multiple 
myeloma: a study of the symptom burden and cumulative effects of disease 
and intensive treatment on health-related quality of life. Submitted to the 
Journal of Pain and Symptom Management. 
 
• Elaine Boland, Dinesh Selvarajah, Mike Hunter, Yousef Ezaydi, Sam H. 
Ahmedzai, John A. Snowden, Iain D. Wilkinson. Central pain processing in 
chemotherapy-induced peripheral neuropathy: a functional magnetic 
resonance imaging study. In preparation and planned for submission to the 
Journal of Clinical Oncology. 
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Appendix 2      
 
STUDY TITLE: Central Pain Processing in Diabetic Neuropathy, 
Chemotherapy-induced painful neuropathy subgroup 
Principal Investigator; Professor Solomon Tesfaye MD  
 
You are being asked to take part in an educational study. Before you decide to take 
part, it is important for you to understand why the research is being done and what it 
involves. Please take the time to read the information sheet carefully and discuss it 
with friends, relatives and if you feel it necessary your GP. Please ask us if there is 
anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part.   
Thank you for reading this. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
 
Peripheral neuropathy is a term used to describe damage to nerves that are outside 
of the brain and spinal cord (peripheral nerves). Chemotherapy-induced peripheral 
neuropathy describes damage caused by chemotherapy to the peripheral nervous 
system, the system that transmits information between the central nervous system 
(e.g. the brain and spinal cord) and the rest of the body. Some anti-cancer drugs 
can cause nerve damage. This is the most common cause of peripheral neuropathy 
in people with cancer. This can lead to a change in the sensation in the hands and 
feet with increased sensitivity and pain. In some patients this results in severe 
intractable pain. Despite lots of research, the exact cause of this damage is unclear. 
 
The diabetes research department in this hospital is carrying out a study looking at 
how nerves in the brain may be involved. One aspect of this study is looking at 
another group of patients, that is; multiple myeloma patients who have been treated 
with chemotherapy and developed this nerve damage (neuropathy). Functional 
Magnetic Resonance Imaging (fMRI) - (MRI brain scan) is being performed on these 
patients with nerve damage looking specifically for changes within the brain caused 
by neuropathy. In this study, we will apply heat (like running your hand over a 
candle) to the top of the foot, thigh and forearm. In addition, we also propose to 
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study nerve activation to a soft brush stroke stimulus to the top of your foot and to 
flashing lights. 
 
The aim of this study is to allow us to gain a better understanding of how the 
processing of pain signals is altered in this group of patients and also to compare 
the results with the diabetes group. This may ultimately lead to better treatments, 
which could alleviate the problem. 
 
 
WHY HAVE I BEEN CHOSEN TO TAKE PART IN THE STUDY? 
 
You have been chosen to take part in the study as you have the condition that fit the 
criteria, which we are studying: 
 
 - People who have been treated with one of the following chemotherapy agents 
(thalidomide, bortezomib-velcade, vincrisitine) for multiple myeloma and now has 
established neuropathy (numbness and painless nerve damage). 
 
DO I HAVE TO TAKE PART? 
  
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you do decide to take part you are still free to withdraw at any time and without 
having to give a reason. This will NOT affect any medical care you receive  
 
WHAT WILL HAPPEN IF I AGREE TO TAKE PART IN THE STUDY? 
 
All of these tests will be carried out at the Royal Hallamshire Hospital. It will involve 
coming for up to 2 visits: 
 
First Visit: 
At the first visit a Doctor will document your medical history and carry out some tests 
to examine your nerves. These will include standard clinical tests of your ability to 
feel different sensations (vibration, cold etc.) and also measurements of the speed 
at which your nerves transmit impulses. We will also perform the standard clinical 
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tests that are used to test autonomic nerve function. This will involve connecting you 
to a heart monitor and taking a heart tracing (ECG) and monitoring blood pressure 
at rest and whilst doing different breathing exercises and lying down and standing 
up. At this visit we will also apply a heat stimulus to the top of your right foot, thigh 
and forearm to demonstrate the stimulus that will be applied during your second MRI 
visit (detailed below) and to also determine the temperature necessary to delivery an 
acceptable level of pain necessary for the study. This sensation could be likened to 
heat experienced when running your hand over a candle. These tests will be carried 
out in the diabetes research room on M floor.  
This will take about 1.5 hours. 
 
Second Visit 
During this visit you will have a fMRI scan of your brain. The machine uses a 
magnet to look at water atoms in your body. The scan takes 60 minutes. This will be 
performed in the MRI department, and involves lying flat and very still on a bed and 
moving through a scanner. It can be very noisy as the magnets moving makes a 
sound rather like a washing machine, you can be provided with ear plugs to lessen 
the noise. Some patients can feel claustrophobic but the procedure can be stopped 
at any time should you wish.  
During the MRI scan we will apply the heat stimulus (previously demonstrated at the 
first visit) to the top of your foot and upper thigh. Part of this examination will be 
assessing how your brain responds to heat stimulus, which you may find 
uncomfortable. Altogether this visit will last 1.5 hours. 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
 
The study may allow us to learn more about the nature of nerve damage due to 
chemotherapy, and whether the nerves in the brain are involved and be able to 
compare this to the diabetes group.  At present early neuropathy is very difficult to 
diagnose and involves several time consuming tests. If it is shown that fMRI scan 
can detect a unique pattern of activation in painful chemotherapy induced 
neuropathy, then it may be a way forward to making diagnosis easier (more 
objective) and aid the development of novel new treatments. 
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WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING PART? 
 
The MRI scan is a safe procedure that is used frequently in normal medical practice. 
It does not use ionising radiation or X-rays. Some people find the scan 
claustrophobic but the test can be stopped if you wish at any time. If you know that 
you suffer from claustrophobia we request that you do not volunteer to take part in 
this study for your own comfort. Application of heat stimulus will cause discomfort 
but we intend to only apply this for a short duration during fMRI scanning, on and off. 
The nerve tests are safe, but some people may experience slight discomfort during 
the nerve conduction test.  
Patients with neuropathy will be asked to discontinue pain relieving medications for 
48 hours prior to fMRI scanning. This is an important requirement for the study, as it 
will allow us to accurately assess the brain’s response to the heat stimulus applied 
without attenuation by medication taken. Discontinuing your pain relieving 
medication may cause an exacerbation of your painful symptoms and if these were 
potentially intolerable, we would advise that you do not take part in this study. Once 
the fMRI scanning is complete you can continue taking you medications as 
prescribed. 
 
WHAT IF SOMETHING GOES WRONG? 
 
In the unlikely situation of something going wrong you may complain via the normal 
NHS complaints procedure. You will also be able to take legal action if there is any 
medical negligence on behalf of the doctors seeing you.  
Should you have any cause for concern about the running of the study please 
contact the Lead Investigator Professor Solomon Tesfaye on 0114 2712709 or 
contact Professor Welsh in writing.  
Professor C.L Welsh 
Medical Director 
Sheffield Teaching Hospitals NHS Foundation Trust 
8 Beech Hill Road 
Sheffield 
S10 2SB 
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CAN I WITHDRAW FROM THE STUDY AT ANY POINT? 
 
If you do consent to take part in the study, it will be purely on a voluntary basis, and 
you may withdraw from the study at any time if you wish. You do not have to give a 
reason for withdrawing, and it will NOT affect your future medical care with us. If you 
do withdraw, we will request permission to retain any data collected prior to 
withdrawal.  
 
  
WILL MY TAKING PART IN THE STUDY BE KEPT CONFIDENTIAL? 
 
All information that we obtain during the course of this study will be kept strictly 
confidential; the only people who will have access to your results will be the medical 
staff running the study. All the information form the MRI scan will be kept in the MRI 
department. We will be informing your GP that you are taking part. 
 
WHAT WILL HAPPEN TO THE RESULTS OF THIS STUDY 
 
The results of this study may be published in medical journals, and may be 
presented at medical conferences. 
We will be happy to provide you with a copy of the results when they are published, 
if you contact us. The results should be available early 2012. 
Any publication of the results of this study will not include any information, which 
may disclose the identity of anyone taking part. 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
 
The study is being carried out by the Diabetes Research Department at the Royal 
Hallamshire Hospital and is being funded.  
 
WHO HAS REVIEWED THE STUDY? 
 
This study has undergone a detailed scientific review, and it has also been reviewed 
by the South Sheffield Ethics Committee. 
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WHAT IF I WISH TO COMPLAIN ABOUT THE WAY THE STUDY HAS BEEN 
CONDUCTED? 
 
If you have any cause to complain about any aspect in which you have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms are available to you and are not compromised in 
any way because you have taken part in a research study. 
 
If you have any complaints or concerns, please contact either the project co-
ordinator: 
Name: Professor Solomon Tesfaye         Tel: 0114 2711900 
 
Otherwise, you can use the normal hospital complaints procedure and contact the 
following person: 
Name: Andrew Cash Chief Executive        Tel: 0114 2712358 
 
WHO DO I CONTACT FOR FURTHER INFORMATION?  
 
If you would like to find out more information please contact: 
Professor Solomon Tesfaye 
Royal Hallamshire Hospital 
Glossop Road 
Sheffield, S10 2JF 
 
0114 2712709 
 
Thank you very much for taking the time to read this information sheet. If you agree 
to participate in the study, you will be asked to sign a consent form to confirm that 
you are satisfied with the information provided and have had adequate opportunity 
to discuss the information provided.  
If you do kindly agree to take part in this study you will be obliged not to take part in 
any other study nor for the 3 months following the completion of your participation.  
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Central Pain Processing in Diabetic Neuropathy 
 
Name of Researcher: Prof. Solomon Tesfaye 
 
CONSENT FORM 
                                     
       Please initial box  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I confirm that I have read and understand the information sheet dated 12 Aug 2009 
(version 1.0) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.  
I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected. 
I understand that sections of any of my medical notes may be looked at by 
responsible individuals from regulatory authorities or from the NHS Trust, where it 
is relevant to my taking part in this research. I give permission for these individuals 
to have access to my records.  
I agree to take part in the above study.  
 1. 
 
2. 
 
 
3. 
 
 
4 
 
5. 
 
   
 
_________________________ ______________         _______________________ 
Name of Patient Date Signature 
 
 
 
_________________________ ______________ _______________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
I give permission for my GP to be informed of my participation in this study  
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Appendix 3     
 
STUDY TITLE: Central Nervous System Involvement in Diabetic 
Neuropathy 
Principal Investigator; Professor Solomon Tesfaye MD  
 
You are being asked to take part in an educational study. Before you decide to take 
part, it is important for you to understand why the research is being done and what it 
involves. Please take the time to read the information sheet carefully and discuss it 
with friends, relatives and if you feel it necessary your GP. Please ask us if there is 
anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part.   
Thank you for reading this. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
 
Diabetes can produce nerve damage, leading to loss of sensation in the feet and 
legs. In some patients this results in severe intractable pain. Despite lots of 
research, the exact cause of this damage is unclear. 
 
The diabetes research department in this hospital is carrying out a study looking at 
how nerves in the brain may be involved. Functional Magnetic Resonance Imaging 
(fMRI)- (MRI brain scan) is being performed on volunteers with diabetes and healthy 
non-diabetic volunteers looking specifically for changes within the brain caused by 
diabetes. In this study, we will apply heat (like running your hand over a candle) to 
the top of the foot, thigh and forearm. In addition, we also propose to study nerve 
activation to a soft brush stroke stimulus to the top of your foot and to flashing lights. 
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If differences are found then it will allow us to gain a better understanding of how the 
processing of pain signals is altered by diabetes. This may ultimately lead to better 
treatments, which could alleviate the problem. 
 
WHY HAVE I BEEN CHOSEN TO TAKE PART IN THE STUDY? 
 
You have been chosen to take part in the study as you are a healthy volunteer 
without diabetes. 
 
DO I HAVE TO TAKE PART? 
  
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you do decide to take part you are still free to withdraw at any time and without 
having to give a reason. This will NOT affect any medical care you receive  
 
WHAT WILL HAPPEN IF I AGREE TO TAKE PART IN THE STUDY? 
 
All of these tests will be carried out at the Royal Hallamshire Hospital. It will involve 
coming for up to 2 visits: 
 
First Visit 
At the first visit a Doctor will document your medical history and carry out some tests 
to examine your nerves. These will include standard clinical tests of your ability to 
feel different sensations (vibration, cold etc.) and also measurements of the speed 
at which your nerves transmit impulses. We will also perform the standard clinical 
tests that are used to test autonomic nerve function. This will involve connecting you 
to a heart monitor and taking a heart tracing (ECG) and monitoring blood pressure 
at rest and whilst doing different breathing exercises and lying down and standing 
up. At this visit we will also apply a heat stimulus to the top of your right foot, thigh 
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and forearm to demonstrate the stimulus that will be applied during your second MRI 
visit (detailed below) and to also determine the temperature necessary to delivery an 
acceptable level of pain necessary for the study. This sensation could be likened to 
heat experienced when running your hand over a candle. These tests will be carried 
out in the diabetes research room on M floor.  
This will take about 1.5 hours. 
 
Second Visit 
During this visit you will have a fMRI scan of your brain. The machine uses a 
magnet to look at water atoms in your body. The scan takes 60 minutes. This will be 
performed in the MRI department, and involves lying flat and very still on a bed and 
moving through a scanner. It can be very noisy as the magnets moving makes a 
sound rather like a washing machine, you can be provided with ear plugs to lessen 
the noise. Some patients can feel claustrophobic but the procedure can be stopped 
at any time should you wish.  
During the MRI scan we will apply the heat stimulus (previously demonstrated at the 
first visit) to the top of your foot, upper thigh and forearm. Part of this examination 
will be assessing how your brain responds to heat stimulus, which you may find 
uncomfortable. Following heat stimulation we will stimulate the top of your foot with 
a soft brush, and finally stimulate your eyes with a sequence of flashing lights. 
Altogether this visit will last 2 hours. 
 
Follow Up Visit 
You may be invited to come back for a third visit (6-12 months later) for a second 
MRI scan when we will be assessing the reproducibility of the technique used. This 
part of the study is optional and does not stop you taking part in the main study. 
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WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
 
The study may allow us to learn more about the nature of nerve damage in diabetes, 
and whether the nerves in the brain are involved.  At present early neuropathy is 
very difficult to diagnose and involves several time consuming tests. If it is shown 
that fMRI scan can detect a unique pattern of activation in painful diabetic 
neuropathy, then it may be a way forward to making diagnosis easier (more 
objective) and aid the development of novel new treatments. 
 
WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING PART? 
 
The MRI scan is a safe procedure that is used frequently in normal medical practice. 
It does not use ionising radiation or X-rays. Some people find the scan 
claustrophobic but the test can be stopped if you wish at any time. If you know that 
you suffer from claustrophobia we request that you do not volunteer to take part in 
this study for your own comfort. Application of heat stimulus will cause discomfort 
but we intend to only apply this for a short duration during fMRI scanning, on and off 
for approximately 2 minutes each for the 3 areas. Those of you who have contact 
hypersensitivity will experience some discomfort when your foot are lightly brushed. 
However, this will only be on and off for approximately 2 minutes. The nerve tests 
are safe, but some people may experience slight discomfort during the nerve 
conduction test.  
There is a chance of less than one in a 100 that your MR scan will show a significant 
abnormality of which you are unaware. In such circumstances you will be referred to 
the appropriate specialist in consultation with your general practitioner, if that is what 
you like. Such detection has the benefit of starting treatment early but in a small 
number of cases may have implications for future employment and insurance. 
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WHAT IF SOMETHING GOES WRONG? 
 
In the unlikely situation of something going wrong you may complain via the normal 
NHS complaints procedure. You will also be able to take legal action if there is any 
medical negligence on behalf of the doctors seeing you.  
Should you have any cause for concern about the running of the study please 
contact the Lead Investigator Professor Solomon Tesfaye on 0114 2712709 or 
contact Professor Welsh in writing.  
Professor C.L Welsh 
Medical Director 
Sheffield Teaching Hospitals NHS Foundation Trust 
8 Beech Hill Road 
Sheffield 
S10 2SB 
 
CAN I WITHDRAW FROM THE STUDY AT ANY POINT? 
 
If you do consent to take part in the study, it will be purely on a voluntary basis, and 
you may withdraw from the study at any time if you wish. You do not have to give a 
reason for withdrawing, and it will NOT affect your future medical care with us. If you 
do withdraw, we will request permission to retain any data collected prior to 
withdrawal.  
  
WILL MY TAKING PART IN THE STUDY BE KEPT CONFIDENTIAL? 
 
All information that we obtain during the course of this study will be kept strictly 
confidential; the only people who will have access to your results will be the medical 
staff running the study. All the information form the MRI scan will be kept in the MRI 
department. We will be informing your GP that you are taking part. 
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WHAT WILL HAPPEN TO THE RESULTS OF THIS STUDY? 
 
The results of this study may be published in medical journals, and may be 
presented at medical conferences. 
We will be happy to provide you with a copy of the results when they are published, 
if you contact us. The results should be available early 2011. 
Any publication of the results of this study will not include any information, which 
may disclose the identity of anyone taking part. 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
 
The study is being carried out by the Diabetes Research Department at the Royal 
Hallamshire Hospital and is being funded by a grant from xxx. Travel expenses for 
travel to and from the hospital will be re-enumerated. 
 
WHO HAS REVIEWED THE STUDY? 
 
This study has undergone a detailed scientific review, and it has also been reviewed 
by the South Sheffield Ethics Committee. 
 
 
WHAT IF I WISH TO COMPLAIN ABOUT THE WAY THE STUDY HAS BEEN 
CONDUCTED? 
 
If you have any cause to complain about any aspect in which you have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms are available to you and are not compromised in 
any way because you have taken part in a research study. 
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If you have any complaints or concerns, please contact either the project co-
ordinator: 
Name: Professor Solomon Tesfaye         Tel: 0114 2711900 
 
Otherwise, you can use the normal hospital complaints procedure and contact the 
following person: 
Name: Andrew Cash Chief Executive        Tel: 0114 2712358 
 
WHO DO I CONTACT FOR FURTHER INFORMATION?  
 
If you would like to find out more information please contact: 
Professor Solomon Tesfaye 
Royal Hallamshire Hospital 
Glossop Road 
Sheffield, S10 2JF 
 
0114 2712709 
 
Thank you very much for taking the time to read this information sheet. If you agree 
to participate in the study, you will be asked to sign a consent form to confirm that 
you are satisfied with the information provided and have had adequate opportunity 
to discuss the information provided.  
If you do kindly agree to take part in this study you will be obliged not to take part in 
any other study nor for the 3 months following the completion of your participation.  
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Appendix 4          
Functional Pain Imaging Study: Case Report Form 
Study Code:   _______________ 
Date:   _______________ 
Handedness  _______________ 
Employment  _______________ 
(1= Yes, 2= Unemployed, 3= Retired on health grounds, 4= Retired other reasons) 
If answer above is 3 give the main medical diagnosis: _______________ 
Date of Birth:  _______________ 
Age:   _______________ 
Sex:    _______________ 
Onset of Pain:   _______________ 
 
 
Myeloma History 
 
(please list conditioning therapy 
and doses, cycle length, number of 
cycles, start and end date of 
cycles) 
(date of first diagnosis) 
(date and type of transplants) 
 
Date diagnosed 
 
 
Date/type of transplant (please state auto/allo) 
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Radiotherapy (site & year): _______________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditioning 
therapy/doses 
Cycle 
length(day
s/Months) 
Number 
of cycles 
Date/firs
t cycle 
Date of last 
cycle 
     
     
     
 
 
    
 
 
    
 
 
    
     
  
 
    
 
 
    
Page | 276  
 
Painful CIPN: NTSS-6  
1. A more or less continuous “dead feeling” like anaesthetised without tingling/ pins 
and needles:     Yes   No     
Symptom present at onset:  _____  _____   
If Yes,        
       
 
 
 
 
 
 
 
 
Persists Resolved 
Current nature of symptom:    ______        ______ 
If persists, 
  
 
 
  
 
 
 
 
 
If no/resolved (when): _______ 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
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2. A more or less continuous prickling/ pins and needles feeling with or without a 
dead leg.     Yes   No     
Symptom present at onset:  _____  _____   
 
 If Yes,     
   
       
 
 
 
 
 
 
 
 
Persists Resolved 
Current nature of symptom:    ______        ______ 
If persists, 
  
 
 
  
 
 
 
 
If no/resolved (when): _________ 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
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3. Unusual sensitivity or tenderness when regions of body touched:       
      Yes   No     
Symptom present at onset:  _____  _____   
 
If Yes,        
       
 
 
 
 
 
 
 
 
Persists Resolved 
Current nature of symptom:    ______        ______ 
 If persists, 
  
 
 
  
 
 
 
 
If no/resolved (when): __________ 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
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4. Sharp jabbing needle like/electric shock (lasting seconds or a minute or two):  
      Yes   No     
Symptom present at onset:  _____  _____   
 
If Yes,    
    
       
 
 
 
 
 
 
 
 
Persists Resolved 
Current nature of symptom:    ______        ______ 
If persists, 
  
 
 
  
 
 
 
 
If no/resolved (when): ___________ 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
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5. Burning discomfort:         
      Yes   No     
Symptom present at onset:  _____  _____   
 
If Yes,        
       
 
 
 
 
 
 
 
 
Persists Resolved 
Current nature of symptom:    ______        ______ 
 If Persists, 
  
 
 
  
 
 
 
 
If no/resolved (when): __________ 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
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6. Deep aching pain:        
      Yes   No     
Symptom present at onset:  _____  _____   
 
If Yes,        
       
 
 
 
 
 
 
 
 
Persists Resolved 
Current nature of symptom:    ______        ______ 
 If persists, 
  
 
 
  
 
 
 
 
If no/resolved (when): __________ 
 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
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7. Other pain (describe): ______________________________________________ 
      Yes   No     
Symptom present at onset:  _____  _____   
 
If Yes,        
       
 
 
 
 
 
 
 
 
Persists Resolved 
Current nature of symptom:    ______        ______ 
If persists, 
  
 
 
  
 
 
 
 
If no/resolved (when): __________ 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ 
(<33%) 
0.00 1.00 2.00 3.00 
Often   
(<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
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8. Which of the seven descriptions of pain above troubles you most now:
 _________________ 
Present pain (type): _______________ 
 
 
 
 
 
 
 
 
 
Past medical history 
(1= Yes, 2= No, 3= Don’t Know)       If yes (Month, Year) 
Have you ever suffered a heart attack?    _________  
Have you had coronary bypass grafting?   _________  
Do you suffer with diabetes mellitus?    _________  
Have you ever had a stroke?     _________  
Have you been told you have high blood pressure?  _________  
Have you been told you suffer from kidney disease?  _________  
Have you had problems like spinal cord compression?  _________  
 
 
 Absent Mild Moderate Severe 
Never 0.00 0.00 0.00 0.00 
Occ (<33%) 0.00 1.00 2.00 3.00 
Often   (<33, 
>66%) 
0.00 1.33 2.33 3.33 
Continuous 
(>66%) 
0.00 1.66 2.66 3.66 
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Have you been admitted to hospital before? 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
____________________________________________________________________ 
Family History 
(Age, if passed away document cause of death) 
 
Father:  
 ________________________________________________________ 
Mother:  
 ________________________________________________________ 
Brothers/Sisters:  
 ________________________________________________________ 
 
Current Medications 
Chemotherapy (inc dexa): 
________________________________________________________ 
Immunosuppressive agents:  
________________________________________________________ 
Anti platelet agents:  
 ________________________________________________________ 
ACE inhibitors: 
 ________________________________________________________ 
Beta blockers:  
 ________________________________________________________ 
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Calcium Channel Antagonists: 
________________________________________________________ 
Diuretics:  
 ________________________________________________________ 
Statins:   
 ________________________________________________________ 
Analgesia: 
 ________________________________________________________ 
Others: 
________________________________________________________ 
________________________________________________________ 
 
Alcohol (Units/week):  _______________  
Have you ever consistently consumed more than 20 units/week: _______________ 
Comments: 
_________________________________________________________________________
_________________________________________________________________________ 
Smoking History 
Current Smoker:      _______________ 
(1= Yes, 2= No, 3= Don’t Know) 
If no, when did you give up (month, year)  _______________ 
How many cigarettes do/did you smoke per day:  _______________ 
How many ounces/week of tobacco do/did you smoke _______________ 
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Physical Activity 
Exercise physically impossible:    _______________ 
(1= >3x weekly, 2= 1-2x weekly, 3= 1-3x monthly, 4= hardly ever)    
Hours per week 
Minimal exercise (e.g. walking, household work)  _______________  
Light exercise (e.g. lawn mowing, swimming cycling) _______________  
Heavy exercise (e.g. running, competitive sport)  _______________  
Physical Examination 
Height (cm):      _______________ 
Weight (Kg):      _______________ 
Hip circumference (cm):     _______________ 
Waist circumference (cm):    _______________ 
Blood pressure (mm/Hg):    _______________ 
Questionnaires	   (1= Yes, 2= No)	  
NTSS-6      _______________ 
NIS       _______________ 
 
NPS       _______________ 
 
EORTC QLQ C30     _______________ 
 
EORTC MY20      _______________ 
 
Pain Catastrophising     _______________  
 
HADS       _______________ 
 
S-LANSS      _______________ 
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Quantitative Sensory Assessments 
 
      JND      Percentile    ND 
Cooling detection threshold       _________ ________ _________ 
Vibration detection threshold   _________ _________ _________ 
Heat pain     _________ _________ _________ 
 
Autonomic Function Tests 
       RR     SD     BP  
Resting supine        _________ _________ _________ 
Deep breathing        _________  
Valsalva        _________  
Standing        _________   _________ 
 
Nerve Conduction Studies 
           Velocity     DL       
SNAP/CMAP 
Radial         _________ _________ _________ 
Peroneal        _________ _________ _________ 
Sural         _________ _________ _________ 
Tibial         _________ _________ _________ 
Has the patient been given a pain diary:   _______________ 
 
Has the patient been instructed to stop meds:  _______________ 
 
Results 
Hb:    _______________ 
Creatinine:  _______________  Total Protein:  _______________ 
eGFR:   _______________  Immunoglobulin: ______________ 
 
Alb:Crt:   _______________  Plasma viscosity: ______________ 
 
T Chol:   _______________ 
Page | 288  
 
Appendix 5 
Normal ranges for nerve conduction study 
 
Normal values and ranges used to calculate the percentile abnormalities for Dyck’s 
neuropathy composite score 
 
Common Peroneal Nerve 
 
Velocity (m/s): 53.32 ± 5.6 
Amplitude (µV): 20.5 ± 6.1 
Latency (ms): 2.9 ± 0.3 
 
Tibial Nerve 
Latency at ankle (ms): 4.28 ± 0.74 
 
Sural Nerve 
Amplitude (µV): >15 years old: 23.7 ± 3.8 
 
Data shown as normal values ± standard deviation  
m/s=metre/second; µV=micro volts; ms=milliseconds 
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Appendix 6 
Definitions in context of this study 
 
Clinical definitions 
Nociception: processing and transmitting sensory information about noxious stimuli. 
Neuropathic pain: ‘pain arising as a direct consequence of a lesion or disease 
affecting the somatosensory system’ as defined by the Neuropathic Pain Special 
Interest Group of the International Association for the Study of Pain (IASP). 
Acute pain: Acute pain is short-term pain of less than twelve weeks duration that 
is temporarily related to injury and that resolves during the appropriate healing 
period. 
Chronic pain: Chronic pain is continuous, long-term pain of more than 12 weeks or 
after the time that healing would have been thought to have occurred.  
 
Neuroimaging 
Functional MRI: is a technique based on the increase in blood flow that 
accompanies neural activity in the brain and obtains physiologic information about 
different parts of the brain; thus providing very accurate static anatomical maps and 
adds on additional dimensions. 
Tesla (T): the unit of measurement quantifying the strength of a magnetic field.  
Blood-oxygen-level dependent (BOLD): regional blood flow is valuable in studying 
brain function as it is closely related to neural activity and depends on the blood 
oxygenation level. In simple terms, BOLD is used as a contrast mechanism, when a 
region of the brain is activated there is increased blood flow in a specific area as 
well as increased use of oxygen and the difference in magnetic susceptibility of 
deoxygenated and oxygenated haemoglobin is detected as the BOLD signal. 
T1-weighted magnetic resonance image: created typically by using short TE and TR 
times. T1-weighted images that appear dark are due to oedema, tumour, infarction, 
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inflammation, infection, hemorrhage (hyperacute or chronic) whilst those that appear 
bright are due to fat, paramagnetic substances such as gadolinium and copper. 
T2-weighted magnetic resonance image: created typically by using longer TE and 
TR times. T2-weighted images that appear dark are due to calcification, fibrous 
tissue, paramagnetic substances such as deoxyhemoglobin, iron, ferritin, 
hemosiderin whilst those that appear bright are due to oedema, tumour, infarction, 
inflammation, infection, subdural collection. 
The signal to noise ratio (SNR) is a measure of signal strength relative to 
background noise. The signal is the voxel brightness and the sources of noise in the 
image are the MR coils and the patient’s body due to thermal motion. Incoherent 
noise appears on the image as irregular grainy patterns, which can degrade image 
details.  
 
Axial: a plane, slice or section made by cutting the 
body or part of it at right angles to the long axis. If 
the body or part is upright, the cut would be parallel 
to the horizon.  
 
 
Coronal: a plane, slice or section made by cutting 
across the body from side to side and therefore 
parallel to the coronal suture of the skull. 
 
 
 
 
Sagittal: a plane, slice or section of the body 
cutting from front to back through the sagittal 
suture of the skull, and continued down through the 
body in the same direction, dividing it into two 
parts, then turning one half to view it from its cut 
surface. 
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Data analysis 
Statistical Parametric Maps (SPM): images or fields with values that are, under the 
null hypothesis, distributed according to a known probability density function, usually 
the Student's t distributions known as t –maps. 
Block design: paradigm based (in my study) on presenting the noxious stimuli 
sequentially within a condition, alternating this with a rest period. 
General linear model (GLM): 4 components – observed data, design matrix, 
parameters (representing how well it fits the model at that voxel) and error 
(difference between the observed data and that predicted by the model). The GLM 
analyses each voxel using any statistical parametric test (t-test paired or un-paired, 
ANOVA - one-way, two-way, main effect, factorial, simple regression, linear 
regression, multiple regression, multivariate regression) and the resulting statistics 
are assembled into an image.  
Spatial pre-processing: the aim is to reduce unwanted variance components in the 
voxel time-series that are induced by movement or shape differences among a 
series of scans. 
Glass brain: Differences in activity may be represented as a 'glass brain', a 
representation of three outline views of the brain as if it were transparent. Only the 
patches of activation are visible as areas of shading. 
Voxel: volume element represents a value (BOLD signal, density) and a location on 
a regular grid in 3D space. The MRI scanner produces a map of the brain area 
being scanned that is represented as voxels.  
Z score: Statistical parametric maps have a value for a certain statistic at each voxel 
in the brain, which is the result of the statistical test done on the scan data for that 
voxel, across scans. This statistic is a Z statistic. Z scores are a way that SPM uses 
to display and analyse the p values from the t statistics. The Z scores are the 
numbers from the unit normal distribution (mean 0 sd/variance 1) that would give the 
same p value as the t statistic. 
T statistic: tests the null hypothesis. The serial t-test defines a resting state baseline, 
and compares the images acquired at each time point before, during and after the 
stimulus (in this study heat-pain) with this baseline. For each time point following the 
heat-pain stimulus, a mean and standard deviation image is constructed, as is a 
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baseline mean and standard deviation image. Then a set of t-statistical parametric 
maps are produced by calculating, on a pixel-by-pixel basis, the t-score (difference 
between mean image one and the mean baseline image, mean image two and 
baseline, and so on). 
Family-wise error (FWE) correction: controlling the chance of any false positives 
(type 1 errors). The standard conventionally dictates a statistic is significant if it is 
less than 5% likely to occur by chance: a p-threshold of 0.05. In imaging, each voxel 
in the brain represents a separate test; therefore thousands of tests for a given 
subject are being performed. If the conventional p-threshold of 0.05 is applied on a 
voxelwise basis, then, just by chance hundreds of false-positive voxels will appear. 
In order to avoid any false positives, p-threshold is corrected to account for how 
many tests being performed. The standard approach to FWE correction is the 
Bonferroni correction - dividing the desired p-threshold by the number of tests, and 
maintaining correct control over the FWE rate. The Bonferroni correction needs all 
the tests to be independent from each other and assumes there are more spatial 
degrees of freedom than there really are. 
Degrees of freedom (df): the number of values in the final calculation of a statistic 
that are free to vary. It is the difference between the number of observations or 
sample size and the number of parameters estimated. 
Random-field theory (RFT): body of mathematics defining theoretical results for 
smooth statistical maps. It attempts to control the FWE rate by assuming that the 
data follow certain specified patterns of spatial variance; the distributions of statistics 
mimic a smoothly varying random field. RFT corrections work by calculating the 
smoothness of the data in a given statistic image and estimating how unlikely it is 
that voxels with particular statistic levels would appear by chance in data of that 
local smoothness. 
Talairach co-ordinates: based on definition by Talairach and Tournaeux atlas and is 
the most commonly used system for reporting coordinates in neuroimaging. 
Talairach brain is the brain dissected and photographed for the Talairach and 
Tournoux atlas (1988). Therefore, images obtained from SPM are described in MNI 
and so are then converted to Talairach co-ordinates. 
MNI: The Montreal Neurological Institute defined a new standard brain by using a 
large series of MRI scans on normal controls. The SPM programme uses standard 
brains from MNI. 
